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Abstract 
In Chronic Myeloid Leukaemia (CML) tyrosine kinase inhibitor (TKI) therapy 
has greatly prolonged survival for patients in the chronic phase of CML and is effective 
also in patients in the accelerated blast phase. However, primary and secondary 
resistance to TKI remains a significant clinical challenge. Similarly, while a number of 
additional genetic lesions accompany transformation to the advanced phase, no change 
provides a method of prospectively distinguishing those patients who will progress 
rapidly to blast crisis from those whose disease pursues a relatively indolent course. The 
precise genomic mechanisms of transformation are elusive. It is therefore important to 
identify new prognostic markers and new molecular alterations that, alone or combined, 
can predict a patient’s clinical course or provide additional therapeutic targets. The first 
part of this thesis describes the prognostic relevance of MECOM oncogene expression 
in imatinib resistance and post-stem cell transplantation in CML patients. Expression of 
MECOM, a gene previously shown to be commonly transcribed in CML blast crisis and 
to a lesser extent, in the chronic phase, predicted an adverse response to second line 
TKI therapy, but not following stem cell transplantation. The second part of this thesis 
details the use of high-resolution comparative genomic hybridization (CGH) on 
diagnostic samples from CML patients in an attempt to identify additional prognostic 
indicators or recurrent co-operating lesions. A number of regions of apparent genomic 
enrichment were identified that were recurrently targeted to specific genes. An 
extensive range of confirmatory molecular assays, however, failed to support a true 
change in gene copy number. Interestingly, the majority of these genes were 
differentially expressed in the CML samples, raising the possibility that changes in 
chromatin conformation had given rise to the aberrant CGH results. Nevertheless, many 
of the under-expressed genes were attractive candidate genes for a role in BCR-ABL1-
induced oncogenesis, therefore two further lines of investigation were taken: 1) An 
analysis of the prognostic impact of differential expression of these genes at diagnosis 
in CML, which revealed four genes in particular whose expression was significantly 
associated with outcome; and 2) Functional analysis of one of these genes, STK17B, in 
which an increase in apoptosis in the CML cell line K562 was observed in association 
with forced expression of this gene mediated by inhibition of COX-2. Thus this work 
has identified novel prognostic indicators with a potential role in CML patient 
management that are also worthy of further investigation as rational targets for therapy.  
  
8 
 
Table of Contents 
Declaration of Originality ................................................................................................. 2 
Acknowledgments............................................................................................................. 5 
Contributions from others ................................................................................................. 6 
Abstract ............................................................................................................................. 7 
Table of Contents .............................................................................................................. 8 
List of Figures ................................................................................................................. 12 
List of Tables .................................................................................................................. 15 
List of Abbreviations ...................................................................................................... 16 
CHAPTER 1 Introduction............................................................................................... 20 
1.1 Background ........................................................................................................................ 20 
1.2 CML clinical features .......................................................................................................... 21 
1.3 CML epidemiology and aetiology ....................................................................................... 21 
1.4 Molecular Biology of Ph chromosome and BCR-ABL1 ...................................................... 22 
1.5 BCR-ABL1-mediated mechanisms of oncogenesis ........................................................... 25 
1.6 Mechanisms of disease progression .................................................................................. 26 
1.6.1 Genomic instability ....................................................................................................... 27 
1.6.2 Differentiation arrest .................................................................................................... 28 
1.6.3 Deficiencies of DNA repair ........................................................................................... 28 
1.6.4 Loss of tumour suppressor function............................................................................. 29 
1.7 Management of patients with CML ..................................................................................... 30 
1.7.1 CML treatment before the Imatinib era ........................................................................ 30 
1.7.2 The imatinib era ........................................................................................................... 30 
1.7.3 Second generation tyrosine kinase inhibitors and beyond .......................................... 35 
1.7.4 Stem cell transplantation ............................................................................................. 36 
1.8 Mechanisms of tyrosine kinase inhibition resistance ......................................................... 37 
1.8.1 Tyrosine kinase domain mutations .............................................................................. 38 
1.8.2 BCR-ABL1 independent pathways of tyrosine kinase inhibition resistance ................ 39 
1.8.3 Clonal evolution and relationship with tyrosine kinase inhibition resistance ............... 40 
1.8.4 Persistance of imatinib-resistant leukaemia stem cells ............................................... 40 
1.9 Heterogeneity and prognostication in CML ........................................................................ 41 
1.9.1 Prognostication in practice ........................................................................................... 41 
1.9.2 Recent attempts to further define heterogeneity in CML ............................................. 42 
1.10 Aims .................................................................................................................................. 45 
  
9 
 
1.10.1 To investigate the prognostic relevance of MECOM oncogene expression in 
imatinib resistant and post transplant CML patients ............................................................. 45 
1.10.2 To investigation the role of genes previously identified by high resolution CGH 
array screening as prognostic factors in CML pathogenesis. ............................................... 46 
CHAPTER 2 : Prognostic relevance of MECOM expression in imatinib resistant and 
post-transplant CML patients .......................................................................................... 47 
2.1 Introduction ......................................................................................................................... 47 
2.2 Materials and methods ....................................................................................................... 51 
2.2.1 Patients ........................................................................................................................ 51 
2.2.2 RNA Extraction and Complementary DNA (cDNA) Preparation ................................. 52 
2.2.3 Generation and application of MECOM reference plasmid ......................................... 52 
2.2.4 MECOM expression and standard curve generation ................................................... 53 
2.2.5 Statistical Methods ....................................................................................................... 55 
2.3 Results ................................................................................................................................ 56 
2.3.1 MECOM Expression predicts EFS, PFS and OS imatinib resistant CML patients 
treated with 2G-TKI ............................................................................................................... 56 
2.3.2 Lack of early cytogenetic response to 2G-TKI and MECOM expression indentifies 
those patients with higher risk of progression ...................................................................... 60 
2.3.3 MECOM expression and stem cell transplant in CML: Absence of adverse 
prognostic association .......................................................................................................... 63 
2.4 Discussion .......................................................................................................................... 65 
2.5 Further investigation ........................................................................................................... 67 
CHAPTER 3 : Self referenced high resolution oligo-array CGH of chronic myeloid 
leukaemia ........................................................................................................................ 69 
3.1 Introduction ......................................................................................................................... 69 
3.2 Aims and research plan ...................................................................................................... 74 
3.3 Materials and methods ....................................................................................................... 75 
3.3.1 Patients and Controls .................................................................................................. 75 
3.3.2 Cell Separation ............................................................................................................ 76 
3.3.3 Purification of CD34+ cells........................................................................................... 76 
3.3.4 DNA Extraction ............................................................................................................ 77 
3.3.5 Comparative genomic hybridisation............................................................................. 77 
3.3.6 RNA Extraction and Complementary DNA (cDNA) Preparation ................................. 78 
3.3.7 RNA and DNA Concentration Measurements ............................................................. 79 
3.3.8 Gene Expression Assays ............................................................................................. 79 
3.3.9 TaqMan
®
 Low-Density Array (TLDA) design ............................................................... 80 
3.3.10 Data analysis of TLDA and Statistics ........................................................................ 81 
3.3.11 Copy Number Measurement Assay ........................................................................... 81 
3.3.12 Paralog Ratio Test ..................................................................................................... 82 
3.3.13 Allelic Imbalance PCR ............................................................................................... 83 
3.3.14 Nucleosome Density Assay ....................................................................................... 84 
  
10 
 
3.3.15 CD34+ Culture Media ................................................................................................ 89 
3.3.16 Demethylating Azacitidine-5 Assay ........................................................................... 89 
3.4 Results ................................................................................................................................ 91 
3.4.1 Frequency of CGH copy number “calls” in CML patients ............................................ 91 
3.4.2 Validation of recurrent copy number calls using targeted molecular assays .............. 96 
3.4.3 Expression analysis genes subject to recurrent copy number calls .......................... 102 
3.4.4 Investigation of chromatin condensation in NAMPT and PSTPIP1 using a nuclease 
sensitivity assay .................................................................................................................. 106 
3.4.5 Use of 5-AZA to investigate the role of methylation in modulating the expression of 
candidate genes in CML CD34+ cells ................................................................................ 109 
3.5 Discussion ........................................................................................................................ 113 
3.6 Summary .......................................................................................................................... 120 
3.7 Future investigation .......................................................................................................... 122 
CHAPTER 4 : Validation of candidate prognostic factors from differentially expressed 
genes identified by CGH on CML samples .................................................................. 123 
4.1 Introduction ....................................................................................................................... 123 
4.2 RQ-PCR identification of potential biomarkers ................................................................. 127 
4.3 Material and method ......................................................................................................... 128 
4.3.1 Patients ...................................................................................................................... 128 
4.3.2 RNA Concentration Measurements ........................................................................... 128 
4.3.3 Complementary DNA (cDNA) Preparation ................................................................ 128 
4.3.4 Gene Expression Assays for investigation of prognostic significance. ...................... 128 
4.3.5 Statistical analysis of the predictive value of expression level of candidate genes in 
unselected cohorts of CML patients ................................................................................... 129 
4.4 Results .............................................................................................................................. 131 
4.4.1 Identification of candidate genes with potential prognostic value by re-analysis of 
expression data from chapter 3 according to patients’ response to imatinib ...................... 131 
4.4.2 Investigation of predictive value of 9 genes of potential prognostic significance in a 
large unselected cohort of CML patients. ........................................................................... 133 
4.4.3 Validation of the predictive value of 6 genes which were significantly associated 
with outcome using a second independent unselected cohort. .......................................... 135 
4.4.4 Kaplan- Meier analysis of genes whose expression was associated with outcome 
when codified using ROC ................................................................................................... 139 
4.5 Discussion ........................................................................................................................ 143 
4.6 Summary .......................................................................................................................... 149 
CHAPTER 5 : The importance of down-regulation of the STK17B gene in CML 
pathogenesis .................................................................................................................. 150 
5.1 Introduction ....................................................................................................................... 150 
5.2 Aims of this chapter .......................................................................................................... 153 
5.3 Material & Methods ........................................................................................................... 154 
5.3.1 CD34+ Culture Media ................................................................................................ 154 
5.3.2 CML Cell lines Culture Media .................................................................................... 154 
  
11 
 
5.3.3 Measurement of Intracellular STK17B protein level using western blot .................... 154 
5.3.4 Measurement of Intracellular STK17B protein level using Flowcytometry ................ 155 
5.3.5 Determination of the best COX-2-I concentration in culture ...................................... 157 
5.3.6 Measurement of Apoptosis using Flowcytometry ...................................................... 158 
5.3.7 Gene Expression Assays ........................................................................................... 158 
5.3.8 siRNA Electroporation Transfection........................................................................... 158 
5.3.9 Statistical analysis...................................................................................................... 159 
5.4 Results .............................................................................................................................. 160 
5.4.1 Identification of an appropriate cell line model for the investigation of drug-induced 
upregulation of STK17B in CML ......................................................................................... 160 
5.4.2 Investigation of the expression of STK17B protein in K562 after inhibition of SC-
236 treatment ...................................................................................................................... 162 
5.4.3 Investigation of the effect of COX-2 inhibition with and without concomitant IM 
exposure on apoptosis in K562 .......................................................................................... 163 
5.4.4 Investigation the effects of SC-236 treatment on CML CD34+ cells ......................... 164 
5.4.5 Confirmation of inhibition by siRNA induces apoptosis in K562 ................................ 166 
5.5 Discussion ........................................................................................................................ 168 
5.6 Summary .......................................................................................................................... 170 
CHAPTER 6 : Discussion ............................................................................................. 171 
6.1 Achievements ................................................................................................................... 174 
Appendix ....................................................................................................................... 205 
7.1 MECOM plasmid primers insert ....................................................................................... 205 
7.2 MECOM and G6PD Primers and probes ......................................................................... 205 
7.3 TLDA gene assay list ........................................................................................................ 206 
7.4 Nucleosome Digestion Assay ........................................................................................... 206 
7.4.1 Buffer A ...................................................................................................................... 206 
7.4.2 MNase Buffer ............................................................................................................. 207 
7.4.3 MNase Stop Solution ................................................................................................. 207 
7.4.4 Digestion Buffer ......................................................................................................... 207 
7.4.5 NAMPT promoter region primers ............................................................................... 208 
7.4.6 PSTPIP1 promoter region primers............................................................................. 208 
7.4.7 ABL1 primers as housekeeping gene ........................................................................ 208 
7.5 GUSB house keeping control gene Real-time PCR ......................................................... 209 
7.6 Paralog Ratio Test ............................................................................................................ 209 
7.7 LD Mix............................................................................................................................... 209 
7.8 NAMPT Allelic Imbalance SNP Assay .............................................................................. 210 
7.9 NAMPT Allelic Imbalance Indel Assay ............................................................................. 210 
Publications and contribution from PhD work ............................................................. 211 
  
12 
 
List of Figures 
Figure  1.1 The Translocation t(9;22)(q34;q11) in CML.. .............................................. 23 
Figure  1.2 Signal transduction pathways involved in BCR-ABL1 oncoprotein. ........... 26 
Figure  1.3 Mechanism of action of imatinib. .................................................................. 31 
Figure  1.4 Mechanism of imatinib resistance. ................................................................ 38 
Figure  2.1 Structure of alternatively spliced forms of MECOM.. .................................. 49 
Figure  2.2 RT-qPCR standard curve for G6PD and MECOM. ...................................... 54 
Figure  2.3 Overall survival of imatinib resistant patients according to presence of 
MECOM gene expression at the onset of second generation tyrosine kinase 
inhibitor (2G-TKI) therapy. ............................................................................................ 59 
Figure  2.4 Eevent free survival (EFS) for imatinib resistant patients according to 
presence of MECOM gene expression at the onset of second generation tyrosine 
kinase inhibitor (2G-TKI) therapy.  ................................................................................ 59 
Figure  2.5 Progression free survival for imatinib resistant patients according to 
presence of MECOM gene expression at the onset of second generation tyrosine 
kinase inhibitor (2G-TKI) therapy. ................................................................................. 60 
Figure  2.6 Overall survival of CML patients receiving second generation tyrosine 
kinase inhibitor (2G-TKI) therapy according to the presence of at least a minor 
cytogenetic response(MiCyR) at three months. .............................................................. 61 
Figure  2.7 Survival of CML patients receiving second generation thyrosine 
inhibitor dasatinib therapy according to the presence of at least a major cytogenetic 
response (MCyR) at 12 months. ..................................................................................... 62 
Figure  2.8 Leukaemia free survival analysis (LFS) of imatinib resistant CML 
patients treated with allogeneic haematopoietic stem cell transplantation (allo-
HSCT) according to MECOM expression level. ............................................................ 64 
Figure  3.1 Schematic diagram showing the pronciple of oligo-array comparative 
genomic hybridization.  .................................................................................................. 71 
Figure  3.2 Agarose gel electrophoresis showing amplification of complete 
nucleosomes (Bands of approximately 147bp) following differential exposure to 
nuclease.. ......................................................................................................................... 86 
Figure  3.3 Schematic diagram of primer coverage used in the nucleosome density 
assay. ............................................................................................................................... 87 
  
13 
 
Figure  3.4 Relative increase in PCR amplification of 6 regions within the NAMPT 
promoter in a CML sample (blue bars) compared to cells from a normal individual 
(red bars) at different lengths of nucleae exposure.. ....................................................... 89 
Figure  3.5 Extent of apparent recurrent enrichment at the NAMPT locus in relation 
to the boundaries of the gene itself observed by oligo array CGH. ................................ 92 
Figure  3.6 Extent of apparent recurrent enrichment at the PSTPIP1 locus in relation 
to the boundaries of the gene itself observed by oligo array CGH.. ............................... 92 
Figure  3.7 Map showing the location of the common region of “amplification” 
compared to the location (Chr.7:105905756) of the copy number assay for NAMPT 
gene. ................................................................................................................................ 97 
Figure  3.8 Map showing the location of the common region of “amplification” 
compared to the location (Chr.15:77296626) of the copy number assay for PSTPIP1 
gene. ................................................................................................................................ 97 
Figure  3.9 NAMPT Copy number analysis by DNA real-time PCR of CML 
diagnostic samples, CML remission samples and non-CML individuals. ..................... 98 
Figure  3.10 : PSTPIP1 Copy number analysis by DNA real-time PCR of CML 
diagnostic samples, CML remission samples and non-CML individuals. ..................... 99 
Figure  3.11 Paralog Ratio Test (PRT) to explore over-representation of the NAMPT 
locus. ............................................................................................................................. 100 
Figure  3.12 Investigation of allelic imbalance within the NAMPT gene at the site of 
two single nucleotide polymporphisms and an insertion/deletion polymorphism ........ 101 
Figure  3.13 Comparison of expression of NAMPT and PSTPIP1 in granulocytes 
from CML patients at presentation. .............................................................................. 103 
Figure  3.14 Of 30 genes that showed aberrant copy number calls by CGH, 12 
showed significantly different expressions between CML (n=32) & Normal (n=8) 
samples .......................................................................................................................... 105 
Figure  3.15 Schematic diagram showing Nucleosome Density Assay......................... 107 
Figure  3.16  Real time qPCR amplification at the NAMPT promoter following 
MNase treatment in CML PMN cells from 6 patients compared to amplification in 
MNase treated non-CML cells. ..................................................................................... 108 
Figure  3.17 Real time qPCR amplification at the PSTPIP1 promoter following 
MNase treatment in CML PMN cells from 4 patients compared to amplification in 
MNase treated non-CML cells. ..................................................................................... 109 
Figure  3.18 Effect of 5-Azacytidine on expression of 7 genes previously shown to 
be down-regulated in CML  .......................................................................................... 111 
  
14 
 
Figure  3.19 Effect of 5-Azacytidine on combined expression of the same 7 genes 
shown in (Figure  3.18). ................................................................................................. 112 
Figure  3.20 Granulocyte colony-stimulating factor (G-CSF)-induced myeloid 
differentiation involves NAMPT. .................................................................................. 117 
Figure  4.1 Nine of the genes previously identified by CGH were found to be 
differentially expressed in patients who responded optimally to imatinib ................... 132 
Figure  4.2 Kaplan-Meier survival analysis of an unselected cohort of CML patients 
according to expression of NAMPT. ............................................................................ 140 
Figure  4.3 Kaplan-Meier survival analysis of an unselected cohort of CML patients 
according to expression of PTCH1, segregated according to ROC analysis. ............... 140 
Figure  4.4 Kaplan-Meier analysis of achievement of MMR in an unselected cohort 
of CML patients according to expression of STK17B.................................................. 142 
Figure  5.1 Western blot X-ray film showing the effect of 5µM SC-236 on STK17B 
and GAPDH (control) protein expression in K562 cells. ............................................. 155 
Figure  5.2 Histogram of Media Fluorescent Index (MFI) showing increased 
STK17B protein expression in K562 with COX-2 inhibition. ..................................... 157 
Figure  5.3 STK17B gene expression in BCR-ABL1 positive cell lines following 
inhibition of COX-2 by 5μM SC-236. .......................................................................... 160 
Figure  5.4 STK17B gene expression in polymorphic nucleic cells in CML and non-
CML samples  ............................................................................................................... 161 
Figure  5.5 A significantly higher level of STK17B protein in was observed in K562 
cells treated with 5μM SC-236. .................................................................................... 162 
Figure  5.6 Apoptotic effect of imatinib, 5μM SC-236 and these agents combined in 
K562 cells. .................................................................................................................... 163 
Figure  5.7 A significantly higher level of STK17B gene expression was observed in 
CML CD34+ cells treated with 5μM SC-236 ............................................................... 164 
Figure  5.8 Apoptosis of CD34+ cells following treatment with imatinib, 5μM SC-
236 and these agents combined..................................................................................... 165 
Figure  5.9 Inhibition of STK17B transcript by RNA interference counteracts the 
apoptotic effect of COX-2 inhibition in K562.. ............................................................ 167 
  
  
15 
 
List of Tables 
Table  1-1 Definition of optimal response to treatment with imatinib at different 
time points ....................................................................................................................... 33 
Table  1-2  Definition of haematologic, cytogenetic and molecular responses ............... 34 
Table  2-1 Patient characteristics at the time of starting 2G-TKI and 2.5-year 
probabilities of event-free survival (EFS), progression-free survival (PFS) and 
overall survival (OS)* ..................................................................................................... 57 
Table  3-1: Summary of genes involved in recurrent copy number calls detected by 
CGH in 4 or more CML samples .................................................................................... 93 
Table  4-1 Comparison of the Sokal and Hasford scoring systems, the main 
prognostic risk calculation systems for CML. .............................................................. 124 
Table  4-2 Statistical analysis of the association of expression of 9 genes in CML 
diagnostic samples with key outcome measurements ................................................... 134 
Table  4-3 Validation of potential prognostic markers in a second unselected cohort 
(n=41) ............................................................................................................................ 136 
Table  4-4 Comparison of the outcome analysis for test and validation cohorts ........... 138 
 
 
 
 
 
 
  
16 
List of Abbreviations 
µ-bcr Micro breakpoint cluster region  
18S Ribosomal 18S RNA 
2G-TKI Second generation tyrosine kinase inhibitors  
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 
ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2  
ABL Abelson murine leukaemia viral oncogene homolog 
ADAMTSL4 ADAMTS-like 4, ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs)-like gene family  
aka Also known as 
ALL Acute lymphoblastic leukaemia 
allo-HSCT Allogeneic hematopoietic stem cell transplantation  
AP Accelerated phase 
APS Adenosine-5‟-phosphosulfate 
ATR Ataxia telangiectasia and RAD3-related 
BACs Bacterial artificial chromosomes 
BC Blast crisis 
BCAR1 Breast cancer anti-estrogen resistance 1 
BCR Breakpoint cluster region 
BM Bone marrow 
BMI1 BMI1 polycomb ring finger oncogene 
C19orf2 Chromosome 19 open reading frame 2 
CABIN1 Calcineurin binding protein 1 
CC Coiled-coil 
CCyR Complete cytogenetic response (No Ph+ve metaphses) 
CDH11 Cadherin 11, type 2, OB-cadherin (osteoblast) 
cDNA  Complementary DNA  
CEBPA CCAAT/enhancer-binding protein alpha 
CGH Comparative genomic hybridization  
ChIP Chromatin immunoprecipitation  
CHK1 Checkpoint kinase 1  
CHR 
Complete haematological response (WBC < 10 x 109/L, no immature granulocytes, basophils < 5%, platelets < 
450 x 109/L, non palpable spleen) 
CML Chronic myeloid leukaemia 
CMR Complete molecular response (BCR-ABL1 transcripts undetectable by RQ-PCR) 
CNAs Copy number aberrations 
CNVs Copy number variants 
COMMD3 COMM domain containing 3 
CP Chronic Phase 
CSNK1D Csein kinase 1, delta 
CT Cycle threshold 
DMBT1 Deleted in malignant brain tumours 1 
  
17 
DNMT3A  DNA methyltransferase 3 alpha 
dPCR Digital polymerase chain reacion 
DUSP1 Dual specificity phosphatase 1 
EBMT European group for Blood and Marrow Transplantation  
EFS Event-free survival  
EVI-1 Ecotropic viral integration site 1 
FBLIM1 Filamin binding LIM protein 1 
FDR false detection rate  
FISH Fluorescent in situ hybridization 
FOXG1 Forkhead box G1  
G6PD  Glucose-6-phosphate dehydrogenase 
GAP Guanosine triphosphatase activating protein  
G-CSF Granulocyte colony-stimulating factor 
G-CSFR Granulocyte colony-stimulating factor receptor 
GDP Guanosine diphosphate  
GEF Guanosine triphosphate (GTP) exchange factor 
GLIPR2 GLI pathogenesis-related 2 
GTP Guanosine triphosphate  
GUSB Glucuronidase, beta 
HCL Hydrochloric acid 
Hh Hedgehog (Hh) signalling pathway  
HIST2H2BE Histone cluster 2, H2be 
HLA Human leukocyte antigen  
HNRNPE2 Heterogeneous nuclear rib nucleoprotein E2 
hOCT1 Human organic cation transporters member 1 
HRH1 Histamine receptor H1 
HSC Haematopoietic stem cell  
IBMTR International Bone Marrow Transplantation Registry 
IFN- α Interferon alpha  
IL-1b Interleukin-1b 
IRIS International Randomized Study of Interferon and STI 
Kb kilobase  
KCL Potassium chloride 
KD Kinase Domain 
kDa kilodalton  
KO Knockout 
LFS Leukaemia free survival  
LITAF Lipopolysaccharide-induced TNF factor 
MALAT1 Metastasis associated lung adenocarcinoma transcript 1 
MAPK Mitogen-activated protein [MAP] kinase 
MAPK8IP1 Mitogen-activated protein kinase 8 interacting protein 1 
M-bcr Major breakpoint cluster region 
  
18 
m-bcr Minor breakpoint cluster region 
MBD3L2 Methyl-CpG binding domain protein 3-like 2 
MCyR Major cytogenetic response  
MDR1 Multidrug resistance P-glycoprotein  
MECOM MDS1 and EVI1 complex locus 
MgCl2 Magnesium chloride 
MiCyR Minimal cytogenetic response (36 – 65 % Ph +ve metaphases) 
minCyR Minimal Cytogenetic Response (66–94% Ph+ metaphases) 
mirRNA MicroRNAs 
MLV-RT Moloney murine leukaemia virus reverse transcriptase 
MMR Major molecular response  
MNase Micrococcal nuclease  
MNCs Mononuclear cells 
mRNA Messenger RNA 
MYH11 Myosin, heavy chain 11, smooth muscle 
NAMPT Nicotinamide phosphoribosyltransferase 
NGS Next generation sequencing 
NoCyR No Cytogenetic Response (≥ 95% Ph+ metaphases) 
NSCLC Early stage non-small cell lung cancer 
NTC Non-template control 
OS Overall survival  
PB Peripheral blood  
PBMNC Peripheral blood Mononuclear cells 
PCR Polymerase chain reaction 
PCyR Partial cytogenetic response (1 – 35 % Ph +ve metaphases) 
PDGFR  Platelet-derived growth factors  
PFS Progression-free survival  
Ph Philadelphia chromosome 
PLEKHM2 Pleckstrin homology domain containing, family M (with RUN domain) member 2 
PLK3 Polo-like kinase 3 (Drosophila) 
PMN Polymorphonuclear 
PP2A Protein phosphatase 2A 
PR proline rich  
PRT Paralog ratio test 
PSTPIP1 Proline-serine-threonine phosphatase interacting Protein 1 
PTCH1 Patched homolog 1 (Drosophila) 
PTP Protein tyrosine phosphatase 
PTPRE Protein tyrosine phosphatase, receptor type, E 
QSC Quiescent stem cells  
RR Relative risk 
RT-PCR Real-time polymerase chain reaction 
SALL3 Sal-like 3 (Drosophila) 
  
19 
SCT Stem cell transplantation 
SCYL1 SCY1-like 1 (S. cerevisiae) 
SIRT1 Sirtuin 1 
SLC Solute carrier family 
SLC16A3 Solute carrier family 16, member 3  
SNPs Single nucleotide polymorphisms 
SRGN Serglycin 
STK17B Serine/threonine kinase 17b 
TLDA TaqMan
®
  Low Density Array 
TNFα Tumour necrosis factor-α 
VSIG4 V-set and immunoglobulin domain containing 4 
WHO World Health Organisation  
  
20 
CHAPTER 1  Introduction 
1.1 Background 
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder 
affecting the stem cell compartment. It is characterised by excessive proliferation of 
mature granulocytes. CML is probably the most extensively studied and best 
understood of all human cancers. The association of CML with the Philadelphia (Ph) 
chromosome – an apparently shortened chromosome 22 – was made by Nowell and 
Hungerford (1960) and was the first consistent chromosomal abnormality to be 
associated with malignancy (Nowell et al. 1960). In 1973, it was discovered that the Ph 
chromosome was in fact the product of a reciprocal translocation, t(9;22)(q34;q11) 
(Rowley 1973). In 1983, the Abelson murine leukaemia viral oncogene homolog 
(ABL1) gene was identified at the breakpoint on chromosome 9 while the breakpoint 
cluster region (BCR) gene was found to map to the chromosome 22 breakpoint, 
implying combination of these genes in CML patients to form a novel chimeric fusion 
gene (Bartram 1983;Groffen 1984). Subsequently, the novel fusion protein derived 
from the chimeric BCR-ABL1 gene was found to possess extraordinary tyrosine kinase 
activity compared to normal ABL1, thus activating the signal transduction pathways 
causing uncontrolled cell growth and malignant transformation (Lugo et al. 1990). In 
1990, the human BCR-ABL1 transcript was retro-virally inserted into murine 
hematopoietic stem cells inducing a convincing CML-like disease (Heisterkamp et al. 
1990;Pear et al. 1998). Confirmation of the Bcr-Abl1 protein as the major pathogenic 
determinant in CML allowed the development of targeted ABL-specific tyrosine kinase 
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inhibitors (Druker et al. 1996), providing a paradigm for the development of targeted 
therapies in other malignancies. 
1.2 CML clinical features 
CML patients present with an increased number of myeloid cells in the 
peripheral blood, and thrombocytosis. The majority of patients are identified 
accidentally in routine blood screening at the chronic phase which is asymptomatic. 
CML patients will progress from chronic phase (CP) through an ill-defined median 
stage known as an accelerated phase (AP), to a terminal phase called Blast Crisis (BC) 
in which immature myeloid or lymphoid blasts are present in the peripheral blood. Prior 
to the introduction of targeted therapy, the whole sequence took an average of five 
years (Sawyers 1999).  
1.3 CML epidemiology and aetiology 
CML affects a relatively wide range of age groups, but is most frequently seen 
in the middle aged. The incidence increases in the elderly with a higher frequency in 
men than in women. It comprises around 15-20 % of all leukaemia cases and has an 
incidence of around 1-2 patients per 100,000 inhabitants per year (Rohrbacher et al. 
2009). There is no main aetiological cause behind the disease. However, reports noted 
an increased frequency of the disease after 1945, following atomic bombing of Japan 
(Kato et al. 1982). On the other hand, reports showed that people expressing Human 
leukocyte antigen (HLA) classes HLA-B8, HLA-A3 and HLA-DR4 have a reduced risk 
of developing CML (Posthuma et al. 1999;Posthuma et al. 2000).  
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1.4  Molecular Biology of Ph chromosome and BCR-ABL1  
The Ph chromosome is a derivative chromosome 22, smaller in size than a 
normal chromosome 22 chromosome, resulting from a reciprocal translocation 
t(9;22)(q34;q11) between the long arms of chromosomes 9 and 22 (Nowell et al. 
1960;Rowley 1973). It is the hallmark of CML, found in 95 percent of patients. In the 
remaining 5 percent, the translocation either involves one or more chromosomes in 
addition to 9 and 22, or is cryptic at the level of G-banding. The Ph chromosome 
translocation is also found in newly diagnosed acute lymphoid leukaemia (ALL) with 
occurrence of 5 percent of children, 15 to 30 percent of adults, and in acute 
myeloblastic leukaemia in 2 percent of patients (Kurzrock et al. 1988). Underlying this 
translocation is the BCR-ABL1 fusion gene itself, formed via the addition of a small 3' 
piece of the ABL1 gene from
 
chromosome 9 to a 5' piece of the BCR gene on 
chromosome
 
22, which is transcribed
 
into a chimeric BCR–ABL1 messenger RNA 
(mRNA) (Figure  1.1)(Faderl et al. 1999).  
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Figure ‎1.1 The Translocation t(9;22)(q34;q11) in CML. The Philadelphia (Ph) chromosome is a 
shortened chromosome 22 that results from the translocation of 3' (toward the telomere) ABL1 segments 
on chromosome 9 to 5' BCR segments on chromosome 22. Breakpoints (arrowheads) on the ABL gene 
are located 5' (toward the centromere) of exon a2 in most cases. Various breakpoint locations have been 
identified along the BCR gene on chromosome 22. Depending on which breakpoints are involved, 
different-sized segments from BCR are fused with the 3' sequences of the ABL1 gene. This results in 
fusion messenger RNA molecules (e1a2, b2a2, b3a2, and e19a2) of different lengths that are transcribed 
into chimeric protein products (p190, p210, and p230) with variable molecular weights and presumably 
variable function. The abbreviation m-bcr denotes minor breakpoint cluster region, M-bcr major breakpoint 
cluster region, and μ-bcr a third breakpoint location in the BCR gene that is downstream from the M-bcr 
region between exons e19 and e20. [Adapted from (Faderl et al. 1999)]. 
The Normal ABL1 gene spans approximately 230 kilobase (Kb) and, due to 
alternative splicing, two forms of ABL1 messenger RNA are formed. The ABL1 gene 
encodes a 145 kilodalton (kDa) protein (p145
ABL1)
, a non-receptor tyrosine kinase with 
expression seen in most tissues in both the nucleus and cytoplasm (Goff et al. 1982). 
The ABL1 protein has several structural domains, each with specific biological and 
physiological functions. Structural domains include SRC homology domains SH1-SH3, 
of which SH1 is responsible for the tyrosine kinase activity of ABL1, while SH2 and 
SH3 are involved in protein interactions. Additional domains include myristoylation, 
actin-binding, and DNA-binding motifs (Faderl et al. 1999). The BCR gene of 130kb 
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encodes a protein of 160kDa and, like p145
ABL1
, it is ubiquitously expressed 
(Laneuville 1995). There are several structural motifs, and the N-terminal has a coiled-
coil domain that is essential for polymerization. The central domain contains a 
guanosine diphosphate
 
(GDP) and guanosine triphosphate (GTP) exchange factor 
(GEF) that serves as an important control element for members of the RAS family. The 
C- terminal holds the guanosine triphosphatase activating protein (GAP) domain, with 
activating function for RAS related protein like RAC and RHO (Deininger et al. 
2000;Faderl et al. 1999). 
In Ph-positive malignancy, breakpoints in ABL1 can occur over a large area of 
about 300kb towards the 5’ end of the gene while BCR breakpoints are limited to three 
smaller breakpoint-cluster regions. In spite of the variability of ABL1 sequences 
retained in the genomic fusion, the chimeric mRNA always results in BCR being fused 
to ABL1 exon a2 due to splicing out of exon 1a (Deininger et al. 2000). The ABL1 
exons 2
 
to 11 (also called a2 to a11) are most commonly transposed to the major
 
breakpoint cluster region (M-bcr) of the BCR gene on chromosome
 
22 between exons 
12 and 16 (recognized as b1 to b5). Often, the breakpoint locations within BCR fall at 
exons b2 or b3. A BCR–ABL1 fusion gene with a b2a2 or b3a2 junction is created and 
transcribed into mRNA. The fusion mRNA is translated into a chimeric protein
 
of 
210kDa called p210
BCR–ABL1
 (Kurzrock et al. 1988). In most cases, CML cells
 
have 
either b2a2 or b3a2 transcripts but both fusion
 
products are produced in 5 percent of 
cases via alternative spicing (Melo 1996). Both transcripts show the same clinical 
features, treatment response, and
 
prognosis, except that patients with b3a2 transcripts 
have a higher platelet count (Shepherd et al. 1995).
 
In two-thirds of patients with Ph 
positive acute lymphoblastic leukaemia (ALL) and in rare cases of CML, the BCR 
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breakpoint is restricted to a 54.4kb area between exons e2' and e2, termed the minor 
breakpoint cluster region (m-bcr), which generates an e1a2 transcript that is translated 
into p190
BCR–ABL1
. A third micro breakpoint cluster region (µ-bcr), generated from 
e19a2, gives rise to a 230kDa fusion protein, named p230
BCR–ABL1
, which has been 
associated with chronic neutrophilic leukaemia (Pane et al. 1996).  
1.5 BCR-ABL1-mediated mechanisms of oncogenesis 
In contrast to c-ABL, the BCR-ABL1 oncoprotein, has uncontrolled kinase activity 
affecting many key cellular pathways leading ultimately to the cancer phenotype. The key 
pathways with which BCR-ABL1 interacts are shown in Figure  1.2. Most of the 
interactions are mediated by tyrosine phosphorylation and require the binding of BCR-
ABL1 to adapter proteins such as growth factor receptor-bound protein 2 (GRB2), DOK, 
CRK, CRK-like proteins, SHC and casitas B lineage lymphoma protein. The end result of 
these interactions are altered cellular adhesion, mitogenic activation, inhibition of apoptosis 
and deregulation of critical proteins (Goldman et al. 2003;Mughal et al. 2006). 
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Figure ‎1.2 Signal transduction pathways involved in BCR-ABL1 oncoprotein. The uncontrolled 
kinase activity of the BCR-ABL1 oncoprotien targets numerous pathways including MYC, STAT5, PI3/AKT 
and RAS, resulting in the phenotypic features of CML (Mughal et al. 2006) 
 
1.6 Mechanisms of disease progression 
CML progress from CP into BC through AP, but the exact mechanism of 
disease progression is unknown. According to definitions devised prior to the advent of 
imatinib, AP is an intermediate stage where the disease starts to become noncompliant 
to therapy; however AP is not seen in all patients who progress to BC. In AP the spleen 
size and total white blood cells (WBC) count increases and blasts comprise 10-19% of 
WBC, >20% of circulating basophils, thrombocytopenia develops and/or new 
cytogenetic abnormalities may appear. BC is the terminal stage of the disease and is 
associated with aggressive thrombocytopenia, anaemia and larger spleen size. In order 
to diagnose patients with BC, the World Health Organisation (WHO) guidelines state 
that patients should have more than 20% blasts in the peripheral blood (PB) or bone 
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marrow (BM), and/or extramedullary blast proliferation, and/or clusters of blasts in the 
BM as seen in histological sections. Many mechanisms for disease progression to BC 
have been proposed; which include (I) genomic instability, (II) differentiation arrest, 
(III) deficiencies of DNA repair and (IV) loss of tumour-suppressor functions (Melo et 
al. 2007). 
1.6.1 Genomic instability  
The mechanisms for surveying the genome for DNA damage and repairing 
these lesions are compromised in CML, and it is likely that similar failures of genome 
surveillance and DNA repair may contribute to the genomic instability of all human 
cancers. BCR-ABL1 interacts with the ataxia telangiectasia and RAD3-related (ATR) 
gene product, resulting in decreased activation of checkpoint kinase 1 (CHK1) which 
functions as a DNA damage scanner, causing inhibition of the cell’s normal response to 
DNA damage (Michor et al. 2006). Inability to detect the DNA damage and accurately 
restore the DNA lesion increases the genetic instability, which leads to accumulation of 
genetic mutations that may suppress normal haemopoiesis. There is evidence for this in 
the identification of mutations of numerous known tumour suppressor genes. At the 
chromosomal level recurrent non-random abnormalities are detectable in 60-70% of 
patients in BC, in addition to the Philadelphia rearrangement. Examples of this “clonal 
evolution” include trisomy 8 (33%), an additional Ph chromosome (30%), 
isochromosome 17 (20%), trisomy 19 (12%), loss of the Y chromosome (8% of males), 
trisomy 21 (7%) and monosomy 7 (5%). Rearrangements of known oncogenes 
associated with BCR-ABL1 independent signal transduction pathways are also seen, 
including MECOM (3q26), MLL (11q23), and AML/ETO t(8;21) (Johansson et al. 
2002). 
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1.6.2 Differentiation arrest 
An important feature of progression into BC is the inhibition of cellular 
differentiation resulting in the expansion of immature blasts in the bone marrow. This 
may occur by suppression of transcription factor CEBPα by p210BCR–ABL1. An example 
of BCR-ABL1 interfering with signalling is through increased stability of the 
heterogenous nuclear ribonucleoprotein E2 (HNRNPE2) which binds to CEBPα leucine 
zipper transcription factor mRNA in leukaemic cells and inhibits translation (Smith et 
al. 1996). This interaction causes loss of CEBPα expression which plays a vital role in 
myeloid differentiation, and might be a critical aspect leading to differentiation arrest in 
CML (Perrotti 2002). Also other gene fusions, arising via an accumulation of mutations 
and translocations, such as AML1-EVI-1 or NUP98-HOX9, may play a role in 
differential arrest but the precise mechanisms are unknown (Melo et al. 2007).  
1.6.3 Deficiencies of DNA repair 
DNA repair is also compromised in CML due to the aberrant activation of 
RAD51 by BCR-ABL1, resulting in homologous recombination that is not as reliable 
as in untransformed cells (Dierov et al. 2004). A further impairment of DNA repair 
may be due to the up regulation of low fidelity DNA repair DNA polymerase β by 
BCR-ABL1, which, due to its increased expression, may cause faulty DNA repairs at 
the cost of other polymerases with higher precision (Hoeijmakers 2001). 
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1.6.4 Loss of tumour suppressor function 
Various tumour suppressor genes are also inhibited by BCR-ABL1 oncoprotien. 
One such example is protein phosphatase 2A (PP2A); an inhibitor of BCR-ABL1. The 
amount of BCR-ABL1 in CML cells generally increases throughout the course of the 
disease. As its concentration increases, so does the up regulation of SET; an inhibitor of 
PP2A. Consequently, increased amounts of BCR-ABL1 result in stronger inhibition of 
PP2A and thereby, weaker inhibition of BCR-ABL1 by PP2A (Neviani 2005). 
Thus, the BCR-ABL1 fusion oncoprotein interferes with signalling pathways in 
leukaemic cells and is involved in the cause and disease progression of CML through 
various mechanisms as explained. However, it is clear that BCR-ABL1 is not working 
alone, and not exclusively responsible for complete transformation to CML as low 
levels of BCR-ABL1 are expressed in a substantial proportion of normal individuals 
(Bose et al. 1998). Some plausible theories to explain the latter observation include that 
in non-CML individuals the translocation occurs in cells that are terminally 
differentiated and may undergo apoptosis or be eliminated by the immune system, or 
that additional genetic lesions are required to cause CML (Deininger et al. 2000). 
Moreover, the presence of BCR-ABL1 alone is not sufficient to explain the considerable 
clinical heterogeneity seen between individuals throughout the course of the disease. 
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1.7 Management of patients with CML 
1.7.1 CML treatment before the Imatinib era 
Prior to the introduction of imatinib, CML patients were treated based on their 
age and phase of the disease. The choice of stem cell transplantation (SCT) was then 
accepted as the only curative treatment for CML. However, several studies showed that 
interferon alpha (IFN-α) was superior to hydroxyurea and busulfan as it was associated 
with a significantly higher response rate and longer survival (Stone 2004). Therefore, it 
became the standard treatment. Therapy was limited to interferon alpha either alone or 
in combination with cytarabine for CML patients who were not eligible for stem cell 
transplantation. IFN-α and cytoreductive chemotherapies were both unsuccessful in 
achieving complete cytogenetic response (CCyR; i.e. no Ph-positive cells detectable in 
the bone marrow) in a significant number of patients (Garcia-Manero et al. 2002). 
1.7.2 The imatinib era 
Following the discovery and characterization of the role of BCR-ABL1 in 
CML, investigations into novel targeted CML treatments began in earnest (Figure  1.3) 
(Druker 2008). In 1993, Novartis Pharmaceuticals (Basel, Switzerland) began to 
develop an inhibitor of BCR-ABL1 and by 1996 a compound named STI571, a platelet-
derived growth factor receptor inhibitor that was also an effective ABL1 tyrosine 
kinase inhibitor, was created (Druker et al. 1996). The activation of BCR-ABL1 
tyrosine kinase occurs via the transfer of phosphate from ATP to tyrosine residues on 
various substrates. Imatinib binds to the BCR-ABL1 tyrosine kinase and blocks the 
ATP binding site thus preventing the phosphorylation of substrate and therefore the 
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kinase activity (Beran et al. 1998). This compound induced apoptosis specifically of 
ALL and CML cell lines due to inhibition of proliferation in vivo and in vitro. 
Modification of the compound to increase the strength of ABL1 tyrosine kinase 
inhibition (TKI) resulted in the development of imatinib mesylate (marketed by 
Novartis as Glivec
®
)(Druker et al. 1996). 
 
Figure ‎1.3 Mechanism of action of imatinib. The binding of imatinib to tyrosine residues on BCR-ABL1 
inhibits activation of tyrosine kinase activity by phosphorylation as well as blocking binding sites for 
substrates. Illustration by A. Y. Chen (Druker 2008). 
The largest clinical trial of imatinib therapy in newly diagnosed patients, the 
International Randomized Study of Interferon and STI571 (IRIS), enrolled over 1100 
patients and assessed hematologic and cytogenetic responses, tolerability, and the 
probability of progression to AP or BC CML (Druker et al. 1996). Imatinib was found 
to be superior to α-interferon plus low-dose cytarabine in first-line therapy, with the 
complete cytogenetic response at 18 months being 76% versus 15% respectively 
(Druker et al. 1996). Significant improvements in survival rates of patients diagnosed 
with CML with imatinib were also found at a 5 year update of this trial (Druker et al. 
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1996), with the tyrosine kinase inhibition (TKI) being currently recommended to be 
used as the first line therapy. A more recent update of the IRIS study, reported that the 
event free survival (EFS) at 8 years was 81% and freedom from progression to AP/BP 
was 92%. Estimated overall survival (OS) was 85% at 8 years and 93% when only 
CML related deaths and those prior to SCT were considered (Deininger et al. 2009). 
However the IRIS study considers only patients who continue to take imatinib. This 
gives a misleading impression of the efficacy of imatinib in the CML population as a 
whole, since patients who cease to receive imatinib for reasons of resistance or 
tolerability are excluded from the study. In fact closer analysis of the original patient 
cohort reveals that only 55% patients remained on imatinib at 8 years, while 45% had 
discontinued treatment for a variety of reasons: 17% for withdrawal or lack of renewal 
of consent; 6% for adverse events or safety; 16% unsatisfactory therapeutic outcome; 
3%  for stem cell transplantation; and 3% who died of non-CML related causes 
(Deininger et al. 2009). (Marin et al. 2010) established that adherence was critical for 
CML patients with who achieving a complete cytogenetic response with imatinib 
therapy. 
Primary and secondary resistance to imatinib in both CP and AP therefore 
remains a significant clinical challenge in CML treatment, despite the excellent 
outcome achieved by imatinib in the majority of patients. Therapeutic milestones used 
to determine optimal response are shown in Table 1-1, (Baccarani et al. 2009;Marin et 
al. 2005). The evaluation of response according to the current European Leukemianet 
(ELN) recommendations are based on blood counts and differential, on the examination 
of marrow cell metaphases and on a quantitative assessment of BCR-ABL1 transcripts 
level, that definitions of these responses are provided in Table 1-2 (Baccarani et al. 
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2009). Failure as determined by any of these criteria would indicate the need for 
therapy change. 
Table ‎1-1 Definition of optimal response to treatment with imatinib at different time points 
 Optimal response Suboptimal response Failure Warnings 
Baseline - - - 
High riskª 
CAᵇ/Ph + ve 
3 months At  least MiCyR No CyR  No CHR - 
6 months At least PCyR Less than PCyR No CyR  - 
12 months CCyR PCyR 
Less than 
PCyR  
Less than 
MMR 
18 months MMR Less than MMR 
Less than 
CCyR 
- 
Any Time, 
during 
treatment 
Stable or 
improving MMR 
Loss of MMR 
Mutations 
Loss of CHR 
Loss of CCyR 
Mutations 
CA/Ph +ve 
Rise in 
transcript 
levels CA/Ph-
ve 
a: Sokal et al., 1984 or Hasford et al., 1998.  
Key: CA, Chromosomal Abnormality; MiCyR, Minor Cytogenetic Response; CyR, Cytogenetic Response; CHR, 
Complete Hematologic Response; PCyR, Partial Cytogenetic Response; CCyR Complete Cytogenetic Response; 
MMR, Major Molecular Response. Definitions of responses are shown in Table 1-2. 
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Table ‎1-2  Definition of haematologic, cytogenetic and molecular responses 
Complete Hematologic Response 
(CHR) 
WBC <10×10
9
/L, 
Platelets< 450x10
9
/L, 
no immature granulocytes, 
less than 5% basophils 
Complete Cytogenetic Response 
(CCyR) 
No Ph+ metaphases 
Partial Cytogenetic Response 
(PCyR) 
1–35% Ph+ metaphases 
Minor Cytogenetic Response 
(MiCyR) 
36–65% Ph+ metaphases 
Minimal Cytogenetic Response 
(minCyR) 
66–94% Ph+ metaphases 
No Cytogenetic Response    
(NoCyR) 
≥ 95% Ph+ metaphases 
Major Molecular Response      
(MMR) 
BCR-ABL: ABL ≤ 0.1% on the 
International Scale 
Complete Molecular Response 
(CMR) 
BCR-ABL transcript undetectable by 
RT-qPCR 
 
The most extensively described mechanism of resistance is the emergence of 
point mutations within the BCR-ABL1 kinase domain (Branford et al. 2002). The 
resistant phenotype conferred by the majority of these mutations can be overcome by 
using second-line tyrosine kinase inhibitor therapies such as dasatinib or nilotinib 
(Apperley 2007). Other mechanisms of imatinib resistance include amplification and/or 
over expression of the BCR-ABL1 gene and abnormalities in drug influx and efflux. 
Aside from mechanisms of resistance, a population of quiescent stem cells insensitive 
to imatinib that persist in patients despite durable cytogenetic remission on imatinib has 
been identified (Milojkovic et al. 2008). Therefore, although imatinib has greatly 
improved the prognosis for the majority of individuals diagnosed with CML, there are 
still various limitations to current treatment options and progression to BC remains the 
obstacle to cure. 
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1.7.3 Second generation tyrosine kinase inhibitors and beyond 
Much like imatinib innovation, whereby an understanding of
 
the molecular 
pathogenesis of CML led to the development of
 
imatinib, the understanding of the 
mechanism of resistance to
 
imatinib led to the rapid development of new so-called 
“second generation” tyrosine kinase inhibitors. Presently, the two most widely used in 
the clinic are nilotinib and dasatinib. Nilotinib is a modified imatinib molecule which is 
30 times more potent than imatinib. Nilotinib maintains the kinase specificity profile of 
imatinib to ABL kinases, KIT, and PDGFR kinases (Weisberg et al. 2005). Dasatinib is 
structurally distinct to imatinib and has a dual effect on ABL1 and SRC–family kinases. 
Dasatinib is able to bind and inhibit both the active and inactive conformations of 
ABL1, and is 100-300 times more potent than imatinib (Shah et al. 2004;Tokarski et al. 
2006). Both dasatinib and nilotinib are active against the majority of BCR-ABL1 point 
mutations that confer imatinib resistance with the exception of T315I and, in the case of 
dasatinib, F317L. Both inhibitors have been approved for the treatment of patients who 
are resistant or intolerant to imatinib (Lombardo et al. 2004;Tokarski et al. 2006). 
Novel “third line” therapies being developed for CML therapy include ponatinib 
which is effective on CML cell lines which are sensitive and resistant to imatinib and 
also B cells carrying the T315I mutation in the tyrosine kinase domain (see below; 
(Cassuto et al. 2012)). In addition, a combination of Vismodegib, an inhibitor of the 
Hedgehog pathway, and nilotinib has been shown to eliminate CML stem and 
progenitor cells (Katagiri et al. 2013). A phase 1/2 trial of the JAK1 and JAK2 inhibitor 
INCB018424 showed that the drug produced an long term objective response in 
patients with myelofibrosis, a Ph chromosome negative myeloproliferative disorder 
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(Verstovsek et al. 2010). The drug may have a potential role in treating imatinib 
resistant patients with CML. 
1.7.4 Stem cell transplantation 
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) was considered 
as the only curative approach until the introduction of TKI therapy, and may still be the 
only means of eradicating all Ph+ stem cells. Often, however, HSCTs cannot be carried 
out due to relative transplant risk factors such as stage of disease, patient age, 
combination of male recipient/female donor as well as the problem of finding suitable 
related donors (Goldman et al. 2001). Indeed, these risk factors have helped to create a 
scoring system to evaluate the transplant risk for each patient. Currently, this 
assessment is still based on the data collected by the International Bone Marrow 
Transplantation Registry (IBMTR) and the European group for blood and marrow 
transplantation (EBMT) between 1978 and 1997 (Gratwohl et al. 1998;Gratwohl et al. 
2006). Outcome analysis over 15 years has found that the overall survival (OS) is 50%. 
A transplantation risk score was proposed by the European Blood and Bone Marrow 
Transplantation Group in 1998 (Gratwohl et al. 1998), and has been confirmed by the 
Centre for International Bone Marrow Transplant Research in 2004 (Passweg et al. 
2004). The EBMT risk score was based on 3,142 patients treated with allo-HSCT; 
patients with low risk score of (0-2) had a transplantation related mortality rate of 31% 
(Gratwohl et al. 1998). However, this percentage was reduced to 17% in a study 
performed between 2000 and 2003 (Gratwohl et al. 2006). For the patients defined as 
moderate risk score of (3-4), the transplantation related mortality was approximately 
50%, and about 70% for the patients with a high risk score of (5-6) (Gratwohl et al. 
1998). 
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1.8 Mechanisms of tyrosine kinase inhibition resistance 
The mechanisms of resistance to tyrosine kinase inhibition (TKI) therapy in 
CML are various and are only partially understood. Mechanisms of TKI resistance for 
which there exists empirical evidence can either be BCR-ABL1 dependent or BCR-
ABL1 independent. BCR-ABL1 dependent mechanisms of resistance include mutations 
in the BCR-ABL1 tyrosine kinase domain, BCR-ABL1 gene amplification leading to 
over expression of the BCR-ABL1 protein, and over expression of the multidrug 
resistance P-glycoprotein (MDR1). There are many proposed mechanisms for BCR-
ABL1 independent pathway of resistance, including patient related factors such as poor 
compliance, pharmacological factors which include poor intestinal absorption, drug 
interactions, binding with plasma components, and the activation of alternative signal 
transduction pathways that do not rely on BCR-ABL1 kinase activity Figure 1.4. 
(Apperley 2007). 
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Figure ‎1.4 Mechanism of imatinib resistance. Schematic diagnram showing various methods of 
imatinib resistance for which there exists direct or circumstantial evidence, namely drug compliance, 
absorption, kinase domain mutations, BCR-ABL1 gene amplification, clonal evolution and persistence of 
imatinib resistant leukaemia stem cells.[modified from (Apperley 2007)]. 
1.8.1 Tyrosine kinase domain mutations 
Point mutations in the BCR-ABL1 kinase domain are the best understood and 
most extensively described mechanism of imatinib resistance, and the only resistance 
mechanism with a current role in clinical management. Their frequency varies 
according to the method of detection, the disease phase, and the definition of resistance 
(Quintas-Cardama et al. 2009). In general they account for around 40% of patients with 
imatinib resistance (O'Brien et al. 2008). There are four categories of kinase domain 
mutation found to be associated with clinical resistance to imatinib affecting (I) the 
phosphate (P)-loop (II) the imatinib binding site, (III) the catalytic domain, and (IV) the 
activation loop. The first mutation described in association with imatinib resistance was 
the T315I mutation, located in the imatinib binding site. Presence of a T315I mutation 
prevents stable localisation of imatinib within the ATP binding pocket by stearic 
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obstruction and has been found to confer poor outcome. P-loop mutations have the 
effect of destabilizing the conformation of the BCR-ABL1 molecule required for 
imatinib binding, and have also been associated with poor prognosis (Branford et al. 
2003). Mutations found in the catalytic domain can also affect imatinib binding. The 
activation loop of the ABL1 kinase has different conformations, either open (active) or 
closed (inactive). Imatinib can only bind in the inactive (closed) configuration; 
resistance emerges when mutations in the activation loop cause a permanent open 
(active) configuration. Some resistance mechanisms may be overcome with imatinib 
dose escalation (Mahon et al. 2000;Soverini et al. 2006). Although over 50 different 
mutations have been reported, amino acid substitutions in less than ten residues 
[M244V, G250E, Y253F/H, E255K/V (P-loop), T315I (imatinib binding site), M351T, 
and F359V (catalytic domain)] account for 85% of all resistance-associated mutations 
(Soverini et al. 2006). 
1.8.2 BCR-ABL1 independent pathways of tyrosine kinase inhibition resistance 
The activation of BCR-ABL independent signal transduction pathways is also 
believed to be a cause of TKI resistance in some patients. In theory, activation of any 
signal transduction pathway capable of conferring a selective advantage to the cell 
independently of BCR-ABL1 would confer a degree of insensitivity to a TKI. Recently, 
up regulation of SRC-family kinases Lyn and HcK, which play a crucial role in 
hematopoietic cell signalling, has been demonstrated in CML cells exposed to imatinib. 
Importantly this alteration in the SRC-family kinase activity was shown to be adequate 
to induce imatinib resistance through a mechanism that may involve phosphorylation of 
BCR-ABL1.(Pene-Dumitrescu et al. 2010) The frequency of activation of other BCR-
ABL1 independent pathways is currently unknown. 
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1.8.3 Clonal evolution and relationship with tyrosine kinase inhibition resistance 
Clonal cytogenetic evolution refers to the acquisition of cytogenetic 
abnormalities in addition to the Ph chromosome after presentation. The most common 
anomalies are an additional Ph chromosome, trisomy 8, and isochromosome 17q 
(Johansson et al. 2002). This clonal evolution has been linked with poor response to 
imatinib and increased haematological relapse (O'Dwyer et al. 2004) with a subsequent 
reduction in overall survival (Cortes et al. 2003), and is likely to be associated with 
CML progression as it reflects the genetic instability of the CML proliferative 
progenitors (Cortes et al. 2004). It is unlikely that cytogenetic evolution is the primary 
cause of imatinib resistance in all cases, but the activation of BCR-ABL1 independent 
signal transduction pathways that underlie certain additional chromosome abnormalities 
(e.g. the MECOM gene at 3q26) is likely to be associated with the poor response to TKI 
seen in patients who acquire these aberrations in advanced phase disease. The frequent 
acquisition of point mutations in a range of cancer genes including RUNX1, AXL1 and 
WT1 (Grossmann et al. 2011) is also likely to have a negative effect on response to 
imatinib in advanced stage disease, although this has yet to be fully explored. 
1.8.4 Persistance of imatinib-resistant leukaemia stem cells 
In-vitro studies have confirmed that a population of quiescent stem cells exist 
that are insensitive to imatinib and accumulate with imatinib exposure (Graham et al. 
2002). These primitive leukaemic CD34+CD38− cells, account for less than 1% of total 
CD34+ cells present at diagnosis (Copland 2006). This minority of cells has the ability 
to sustain the disease with the constant potential for progression. These quiescent stem 
cells (QSC) have also been shown to persist despite achieving CCyR with imatinib 
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(Bhatia et al. 2003). Dasatinib significantly increases inhibition of CrKL 
phosphorylation (a downstream product of BCR-ABL1 kinase activity) in these QSC in 
comparison to imatinib, but is still ineffective in completely eradicating QSC (Copland 
2006;Konig et al. 2008). Correspondingly, the QSC show resistance to nilotinib, as 
results confirmed that, like imatinib the predominant effect of nilotinib is 
antiproliferative rather than proapoptotic. Furthermore, it was noted that the level of 
QSC increases if cells are treated with a combination of nilotinib and imatinib 
(Jorgensen et al. 2007). Evidence for the persistence of QSC following imatinib therapy 
is also provided by the stop imatinib trail (STIM) in which 61% of CML patients in 
complete molecular remission (CMR) relapsed after imatinib was withdrawn (Mahon et 
al. 2010). 
In summary, resistance to TKI therapy is considered to be multifactorial and 
further investigation of the core causes of TKI resistance remain mandatory in order to 
best direct appropriate therapy in this subset of patients (Milojkovic et al. 2009a). 
1.9 Heterogeneity and prognostication in CML 
1.9.1 Prognostication in practice  
Despite the uniform pathogenesis, CML demonstrates an unpredictable and 
poorly understood clinical heterogeneity particularly in the extent of time patients 
remain in chronic phase, which is proportionally correlated with survival. Although 
arguably more striking pre-TKI this heterogeneity persists even in the TKI era. Several 
groups have attempted to determine prognostic factors that could be used to predict 
outcome before the imatinib era. Two prognostic scoring systems for patients with 
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CML emerged: the Sokal and Hasford systems (Hasford et al. 1998;Sokal et al. 1984). 
The Sokal scoring system is the most widely used prognostic scoring method, and 
depends on a number of clinical and laboratory findings, including age, spleen size, 
platelet count and peripheral blood blasts (Sokal et al. 1984). The Hasford prognostic 
system includes the same factors, but takes account of two additional factors, namely 
the percentage of eosinophils and basophils in the peripheral blood (Hernandez-Boluda 
et al. 2009). 
In the imatinib era, the Sokal score maintains some clinically predictive value. 
Given the current availability of alternative therapies such as second and third 
generation TKIs and stem cell transplantation (SCT); it would be of great use to the 
clinician to identify new factors that prospectively differentiate patients at increased 
risk of TKI failure in early stage. In current practice, the most important prognostic 
information is provided by the degree of cytogenetic and molecular response obtained 
at different time points (Hernandez-Boluda et al. 2009), including notably, the 
molecular response at 3 months (Marin et al. 2012). 
1.9.2 Recent attempts to further define heterogeneity in CML 
Many studies have aimed to identify markers of heterogeneity in CML patients 
which may have a prognostic value. One of the first proposed markers of poor outcome 
with proven clinical value was the detection of large deletions of the derivative 
chromosome 9, which were associated with poor prognosis on interferon therapy at any 
stage of the disease (Huntly et al. 2001). However, Castagnetti et al. showed no 
prognostic impact of detection of der(9) deletions at diagnosis in CML patients who 
were treated with imatinib (Castagnetti et al. 2010), a finding corroborated by others 
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(Quintas-Cardama et al. 2011). A method has been proposed to measure one of the 
surrogate targets for phosphorylation of BCR-ABL1, P-Crkl, using flow cytometry at 
diagnosis to evaluate the response to imatinib (Hamilton et al. 2006). However, upon 
trail to validate the preliminary findings on CML patients at diagnosis no predictive 
value of measuring P-Crkl could be demonstrated (Khorashad et al. 2009). Other 
studies correlated the level of human organic cation transporter 1 (hOCT1) gene 
expression at diagnosis with response to imatinib (Wang et al. 2007b). However, a 
recent study on presentation samples collected from CML patients before starting 
imatinib failed to confirm any correlation between hOCT1 gene expression and 
imatinib  response (Zhang et al. 2009). A recent study of kinase domain mutations in 
over 300 CML patients correlated the occurrence of KD mutation with cytogenetic 
response after starting imatinib therapy (Khorashad et al. 2008). Presence of a KD 
mutation was found to be predictive of loss of CCyR, regardless of resistance-
conferring properties of individual mutations, or the size of the mutant clone. However 
the logistical challenge of regular screening for KD mutations in patients responding to 
imatinib has thus far precluded the adoption of routine monitoring to aid patient 
management. 
Gene expression microarrays have also been used as a tool to help understand 
mechanisms of resistance to imatinib by correlating global gene expression in 
responders and non-responders at diagnosis. Although gene expression signatures of 
CML patients who are responders or non-responders to imatinib are very similar 
(Crossman et al. 2005). De lavallade et al, (2010) showed a characteristic gene 
expression signature associated with primary resistance to imatinib. Eight 
markedly over-expressed genes e.g. DDX11 and TOPBP1, were involved in DNA 
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replication and repair by homologous recombination (HR); while a further 36 genes, 
including PTEN, were significantly down regulated (de Lavallade et al. 2010). 
Furthermore, several studies have reported genes differently expressed in advanced 
stage chronic myeloid leukaemia such as AML1, ETS2, CREBBP, GLI2, WT1,  MDFI,  
RRAS2, ITPR1, FOS, ARG, CD7, PR3, ELA2 CXCR4 and BMI1 (Yong et al. 
2006;Zheng et al. 2006); however few, if any, have been associated mechanistically 
with a particular feature of disease development or adopted into clinical practice (Melo 
et al. 2007). 
Comparative genomic hybridisation (CGH) studies of CML to detect regions of 
cryptic genetic imbalance began over a decade ago on CML cell lines (Drexler et al. 
1999;Gribble et al. 2000;Rodley et al. 1997). Recent high-resolution array based CGH 
studies have also been performed on CML (Brazma et al. 2007;Hosoya et al. 2006). In 
the latter studies, multiple genomic imbalances were described which were markedly 
more frequent in advanced stage patients, although no strong candidate genes for 
disease progression were identified within the aberrant loci. Both studies used reference 
DNA from a normal sex-matched individual, meaning that polymorphic copy number 
variations (CNVs) could not be excluded from the list of observed imbalances. In 
addition, the relatively low resolution of the array platforms meant that aberrations of 
less than 1Mb in size – potentially containing multiple genes – could not be detected. 
Use of single nucleotide polymorphism (SNP) arrays on CML and acute lymphoblastic 
leukaemia (ALL) samples found a deletion in the zinc finger transcription factor Ikaros 
(IKZF1) that distinguished Ph+ ALL and Lymphoid BC from Myeloid BC (Mullighan 
et al. 2008). This illustrates that biologically and clinically significant recurrent changes 
can be found using molecular arrays (Mullighan et al. 2008). There is, therefore, a need 
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for improved genomic characterisation of CML that focuses on specific clinical and 
biological questions. 
In summing up, no practical method of prospectively predicting outcome of 
CML patients at presentation or at the time of change of therapy has been identified. 
Further investigation of genes previously identified by global genome-wide studies may 
help to confirm the role of some of these genes in the pathogenesis of CML and/or in 
the mechanism of drug resistance or disease progression and aid clinical management. 
1.10 Aims 
The work included in this thesis involves further investigation of the aetiology, 
clinical impact and functional relevance of aberrations of genes originally detected by 
global cytogenetic or molecular cytogenetic analysis of CML. There were two broad 
aims: 
1.10.1 To investigate the prognostic relevance of MECOM oncogene expression in 
imatinib resistant and post transplant CML patients 
The MECOM gene at chromosome band 3q26 exhibits a number of properties 
consistent with its role as an oncogene, and is activated in a subset of most myeloid 
leukaemias, either via rearrangement of chromosome band 3q26, or by other as yet 
undetermined mechanisms (Vinatzer et al. 2003). MECOM activation has been 
described in CML blast crisis, and less commonly in CP (Ogawa et al. 1996a;Ogawa et 
al. 1996b) raising the question of whether this BCR-ABL1 independent mechanism of 
oncogenesis plays a role in suboptimal response to TKI therapy and/or represents an 
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early marker of disease progression. One aim of the work presented in this thesis was 
therefore to investigate 1) the frequency of detectable MECOM expression in imatinib-
resistant chronic CML patients and 2) the predictive value of this measurement on 
treatment response and likelihood of disease progression on subsequent second 
generation tyrosine kinase inhibitors (2G-TKIs) and/or post stem cell transplantation. 
1.10.2 To investigation the role of genes previously identified by high resolution 
CGH array screening as prognostic factors in CML pathogenesis. 
Recent work at the Hammersmith using a high resolution CGH platform 
revealed several targeted regions of genomic enrichment in DNA samples from CML 
patients. However, it is presently unclear whether these findings represent true gene 
copy number change or an alternative type of genomic aberration. The first aim is to 
investigate the gene expression of these genes in CML patients compared to normal 
subjects. The second aim of this thesis is to explore in more detail the integrity of these 
genes in CML, and their prognostic and biological importance. 
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CHAPTER 2 : Prognostic relevance of MECOM 
expression in imatinib resistant and post-transplant 
CML patients 
2.1 Introduction 
Second generation tyrosine kinase inhibitors (2G-TKI) such as dasatinib or 
nilotinib are effective therapies for chronic myeloid leukaemia (CML) patients who 
have failed imatinib, especially if the patient started treatment while in the chronic 
phase (CP) (Hochhaus et al. 2007;Kantarjian et al. 2007). However, more than 50% of 
patients fail to achieve major cytogenetic responses on 2G-TKI and a significant 
proportion of these eventually experience disease progression (Hochhaus et al. 
2007;Kantarjian et al. 2007;Milojkovic et al. 2009b). Very little is known about the 
mechanisms of resistance to TKI. Mutations in the kinase domain (KD) of the BCR-
ABL1 gene have been extensively described (Apperley 2007); however, while several 
other mechanisms have been proposed, including clonal evolution, plasma drug 
concentration, and variations in intracellular drug availability, a clear mechanism of 
resistance cannot be identified in the majority of the patients (Apperley 
2007;Milojkovic et al. 2009b). As 2G-TKI, third generation tyrosine kinase inhibitor 
(3G-TKI) and allogeneic stem cell transplantation are all possible therapies for patients 
failing imatinib there is an urgent need for additional factors present at the point of 
imatinib resistance that predict for response (or lack of response) to 2G-TKI and would 
therefore help in management decisions. 
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With the exception of some KD mutations, the precise role of proposed 
resistance causing mechanisms in lack of response or overt relapse is not completely 
understood. Clonal evolution, defined as the acquisition of additional cytogenetic 
changes to the t(9;22), is no exception to this. The term is relatively broad and, in 
addition to gain of the Ph chromosome, includes the acquisition of abnormalities with 
relatively ill-defined contributions to pathogenesis, such as chromosomal aneuploidy, 
as well as the emergence of rare abnormalities that give rise to well characterised 
oncogenic drivers. Examples of the latter include rearrangements of the MDS-1 and 
EVI-1 complex locus (MECOM) oncogene at 3q26 or the CBFB oncogene at 16q22.1. 
As with clonal evolution in malignancy in general, it is likely that a proportion of 
additional chromosome changes in CML are “passenger mutations” arising via 
progressive genomic instability and may therefore be an effect of TKI resistance rather 
than a cause. In contrast a proportion are likely to be genuine drivers of (BCR-ABL1 
independent) oncogenesis. Murine studies of the contribution of MECOM activation to 
AML, for example, have confirmed this abnormality as sufficient to induce acute 
leukaemia (Zhang et al. 2011). It is therefore plausible that, if acquired in an early CML 
stem cell, mutation in an established oncogene such as MECOM would give rise to 
progression to acute leukaemia (BC) while simultaneously conferring resistance to TKI 
due to the BCR-ABL-independent nature of the resulting signal transduction.  
While the contribution of MECOM oncogene activation via chromosomal 
translocation to the TKI-refractory advanced stage CML is relatively well established, 
the incidence of over-expression of the gene in the absence of overt chromosomal 
rearrangement, and the impact of this expression on TKI resistance has not been 
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investigated. The relationship between MECOM expression and TKI resistance will be 
the focus of this chapter. 
Previously, MECOM gene was referred to as ecotropic viral integration site-1 
(EVI-1) which was first identified as a common locus of retroviral integration in murine 
myeloid leukaemias (Mucenski et al. 1988). In humans, MECOM is located at 
chromosome 3 band q26. MECOM exhibits a number of properties consistent with its 
role as an oncogene, and is activated in a subset of most myeloid leukaemias, either via 
rearrangement of chromosomal band 3q26, or by other as yet undetermined 
mechanisms (Vinatzer et al. 2003). MECOM contains 16 exons, spans 60kb, with 
multiple alternative 5′ mRNA variants and several spliced transcripts (Wieser 2007), 
giving at least three distinct proteins: MECOM-E, MECOM-1Δ324, and MECOM-ME, 
latter contains a proline-rich (PR) domain (Figure 2.1) (Goyama et al. 2010;Roy et al. 
2012). 
 
Figure ‎2.1 Structure of alternatively spliced forms of MECOM. There are two sets of zinc-finger (ZF) 
domains. At the C-terminus, there is a highly acidic stretch (Ac), in between a repression domain (RD) of a 
proline-rich region. MECOM-ME contains a PR domain at the N-terminus [modified from (Roy et al. 
2012)]. 
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Both (PR) domain-positive and negative proteins have been found to act as 
oncogenic factors (Kay et al. 2000). MECOM is involved in the regulation of 
embryogenesis, including haematopoiesis, angiogenesis, and neural and heart 
development (Yuasa et al. 2005). Recently it was demonstrated that each pair of zinc 
finger domains of MECOM binds to DNA independently and regulates a different sets 
of target genes. These include a set of genes which are either tumourigenenic or genes 
associated with cancer. MECOM synergises with the AP1 family member FOS in 
invasive tumours (Bard-Chapeau et al. 2012). High MECOM expression in de novo 
AML patients had adverse prognostic impact even without 3q26 rearrangements (Haas 
et al. 2008;Lugthart et al. 2008). 
MECOM activation in the absence of overt 3q26 rearrangement has been 
described in CML blast crisis, and less commonly in CP (Ogawa et al. 1996a;Ogawa et 
al. 1996b). We therefore sought to investigate the frequency of detectable MECOM 
expression in imatinib-resistant CP CML patients and the predictive value of this 
measurement on treatment response and likelihood of disease progression on 1) a 
subsequent 2G-TKI or 2) after stem cell transplantation. 
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2.2 Materials and methods 
2.2.1 Patients 
 Between April 2005 and July 2008, 75 consecutive patients with 
Philadelphia (Ph) chromosome-positive CML in CP resistant to imatinib who were 
treated with dasatinib (n=61) or nilotinib (n=14) were studied. Written informed 
consent was obtained from all patients before enrolment. Patient characteristics were 
typical of those with imatinib-treated ‘late’ CP (Table  2-1). No patient harboured a 
3q26 rearrangement in the Ph-positive clone, as assessed by conventional cytogenetics. 
The median follow up from starting 2G-TKI was 30 months (range 6 to 53); 95% of the 
patients were followed for at least one year. Dasatinib and nilotinib were administered 
as previously described (Hochhaus et al. 2007;Kantarjian et al. 2007;Milojkovic et al. 
2009b). Bone marrow morphology and cytogenetics were assessed prior to 2G-TKI 
therapy and then every 3 months. Chronic phase (CP), complete haematological 
response (CHR), major cytogenetic response (MCyR), complete cytogenetic response 
(CCyR) and major molecular response (MMR) were defined by conventional criteria 
(Milojkovic et al. 2009b). During the follow up 45, 42 and 22 patients achieved MCyR, 
CCyR and MMR respectively. The 30-month cumulative incidences of MCyR, CCyR 
and MMR were 59.1%, 55.1% and 25.7% respectively. The 30-month probabilities of 
overall survival (OS), progression-free survival (PFS) and event-free survival (EFS) 
were 90.7%, 88.9% and 86% respectively. A further set of 48 patients were tested for 
MECOM expression after the first stem cell transplant, of which they fail imatinib 
therapy whom survived >28 days with leukaemia free survival (LFS). MECOM 
expression was measured in archived cDNA samples from 48 patients who 
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subsequently received SCT. The last disease-positive sample prior to transplant was 
used (BCR-ABL1:ABL1 >10%).  
2.2.2 RNA Extraction and Complementary DNA (cDNA) Preparation 
RNA extraction was carried out using the QIAcube machine (Qiagen, Hilden, 
Germany) and by following the standard protocol using the program RNeasy Mini 
(Qiagen). Reverse transcription of RNA was carried out using the Moloney murine 
leukaemia virus reverse transcriptase (MLV-RT) enzyme (Invitrogen, Carlsbad, USA) 
and the RNasin
®
 Ribonuclease Inhibitor (Promega, Madison, USA) to avoid RNA 
degradation. 2.4µL of MLV-RT (Invitrogen) and 1.2µL of RNasin (Promega) were 
added to 42µL of cDNA mix per reaction. The cDNA mix included 0.1M DTT 
(Biosynth, Staad, Switzerland), 25mM dNTPs (Bioline, London, UK), random primers 
at concentration 3ng/µL (Promega, Madison, USA), distilled water and a 5x buffer 
containing 0.25mol/L Tris hydrochloric acid (HCL), 0.375mmol/L potassium chloride 
(KCL) and 15mmol/L magnesium chloride (MgCl2) (Invitrogen, Carlsbad, USA).  The 
freshly extracted RNA was incubated at 65°C for ten minutes prior to adding the 
enzymes and cDNA mix to linearise the molecules. Following addition of the enzymes 
and mix, samples were incubated at 37°C for two hours. Lastly, the cDNA was placed 
at 65°C for ten minutes to inactivate the MLV-RT enzyme and cDNA was stored at -
20°C. 
2.2.3 Generation and application of MECOM reference plasmid 
Part of the MECOM cDNA including the fragment targeted by the real time PCR 
assay was amplified using primers (Appendix 7.1) and inserted into a plasmid 
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(pCR
®
2.1-TOPO
®
 Vector) using the TOPO TA Cloning Kit as recommended by the 
manufacturer (Invitrogen). The plasmid was extracted after growing the transformed E. 
Coli (One Shot
®
 Chemically Competent TOP10 E. coli) using a Qiagen midiprep kit 
(QIAGEN). The purified plasmid was measured using a NanoDrop ND-1000 
Spectrophotometer and the copy number of the plasmids was calculated. Serial 10-fold 
dilutions of plasmid in tRNA buffer were then prepared. These plasmid dilutions were 
used to generate a standard curve for real time PCR measurement using the ABI 7500 
platform. The housekeeping gene G6PD was used as a control for normalisation to 
ensure PCR efficiency equivalence. Serial dilution of the plasmid with inserted G6PD 
was prepared in the same way that it was described for MECOM. 
The probes for MECOM and G6PD were labelled with different fluorescent dyes 
(Appendix 7.2) and the real time PCR assay for these genes was performed in a 
multiplex TaqMan
®
 system with MECOM and G6PD primers (300nM) and probes 
(200nM) in the same reaction. The multiplex system reduced the variation, optimised 
the condition for comparable results from different plates and reduced the amount of 
cDNA needed for the experiment. The MECOM:G6PD ratio was calculated by dividing 
the mean quantity of MECOM  by the mean quantity G6PD for each sample. 
2.2.4 MECOM expression and standard curve generation 
Peripheral blood was collected from the 75 patients before starting treatment 
with the chosen 2G-TKI. Total RNA was extracted from cells using an automated 
QIAcube and a RNeasy kit (Qiagen), and was reverse transcribed to generate cDNA. 
MECOM expression was measured using a multiplex TaqMan
®
 assay using MECOM 
primers and probes described by Vinatzer et al (Vinatzer et al. 2003). A VIC
®
-MGB-
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labelled G6PD probe, designed in house, was used as an endogenous control. Six 
standards of known concentration were used, prepared by serial dilution of two 
plasmids containing part of the MECOM and G6PD genes, respectively. Prepared by 
serial dilution of cDNA from a CML patient in blast crisis with a t(3;21) translocation 
involving the MECOM locus, as assessed by FISH analysis. Standards were tested in 
triplicate while all patient samples were tested in duplicate. An example of a standard 
curve is shown in (Figure 2.2). A CT value of 40, the intercept of the standard curve 
slope, or lower, was used to indicate MECOM positivity. Patients with a CT value of 
greater than 40 were classified as negative for MECOM expression. As expected, 
cDNA extracted from the peripheral blood of twenty normal individuals produced a CT 
value greater than 40, consistent with absence of MECOM expression.
 
Figure ‎2.2 RT-qPCR standard curve for G6PD and MECOM. Each standard was tested in triplicate. 
Performance was as follows: G6PD: Slope=-3.3, Y-intercept=38.3, Correlation coefficient (R
2
)=0.998 and 
MECOM: Slope=-3.4, Y-intercept=40.3, R
2
=0.996. 
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2.2.5 Statistical Methods  
Probabilities of overall (OS), progression-free (PFS) and event-free survival 
(EFS) were calculated using the Kaplan-Meier method. PFS was defined as survival 
without evidence of accelerated or blastic phase disease: EFS relevant events were 
death from any cause, loss of MCyR, loss of CCyR, progression from CP and loss of 
CHR. The probabilities of cytogenetic and molecular responses were calculated using 
the cumulative incidence procedure, where cytogenetic or molecular response 
represented the events of interest and death and disease progression were the 
competitors. Univariate and multivariate analyses for the different outcomes were 
carried out using the log-rank test to identify prognostic factors for overall survival, 
PFS, EFS and cytogenetic response as previously described (Milojkovic et al. 2009b). 
The associations between MECOM expression and other pre-therapy characteristics 
were studied using the Fisher exact test. p values were 2-sided and 95% conﬁdence 
intervals (CI) computed. As reported previously by others (Tam et al. 2008), no 
significant difference was found between the dasatinib and nilotinib cohorts with regard 
to any of the parameters examined, which allowed us to consider the patients on 2G-
TKI as a single cohort. 
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2.3 Results  
2.3.1 MECOM Expression predicts EFS, PFS and OS imatinib resistant CML 
patients treated with 2G-TKI 
MECOM expression was detected by real-time PCR in 8 (10.7%) of the 75 
patients enrolled in this study. The median level of MECOM expression relative to 
G6PD was 0.0002 (range, 4.43 × 10
-6
 – 5.46 x 10-2). This was significantly lower than 
that observed in 3 CML blast crisis (BC) patients with 3q26 rearrangements (median, 
0.00346; range, 0.00265 to 0.13; p=0.036). There was no significant association 
between expression of MECOM and any of the patient characteristics shown in (Table 
2.1). Interestingly, there was no significant association between detectable MECOM 
expression at the start of 2G-TKI therapy and characteristics commonly associated with 
progression to advanced phase such as clonal cytogenetic evolution (p=1.0), presence 
of KD mutations (p=0.67), Sokal score at diagnosis (p=0.4), haematological resistance 
to imatinib (p=0.43) and bone marrow blast cell count >5% (p=0.21). The CD34+ 
count in the bone trephine and the percentage of blast in the bone marrow were also 
comparable between patients with (0.8% and 3.9%) and without (1.4% and 3.5%) 
MECOM expression (p=0.9 and p=0.7, respectively). 
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Table ‎2-1 Patient characteristics at the time of starting 2G-TKI and 2.5-year probabilities of event-
free survival (EFS), progression-free survival (PFS) and overall survival (OS)* 
Variable N EFS (%) PFS (%) OS (%) 
Age,   p=0.84 p=0.86 p=0.77 
>55 years 40 84.5 87.6 91.8 
≤55 years 35 87.2 89.9 89.2 
Sex,   p=0.13 p=0.11 p=0.37 
Male  35 80.6 82.7 88.4 
Female 40 91.5 94.8 92.6 
Sokal risk group,   p=0.65 p=0.77 p=0.28 
Low 15 92.3 92.3 100 
Intermediate 29 82.2 85.9 83.2 
High  31 86.4 89.8 93.5 
Status at the onset of imatinib therapy,    p=0.80 p=0.94 p=0.48 
Newly diagnosed CP patients  28 85.1 89.1 86.1 
Late CP  47 86.7 89 93.2 
Additional cytogenetic abnormalities at start of 2G-TKI,    p=0.17 p=0.44 p=0.25 
No 63 88.3 90 92.5 
Yes 12 74.1 83.3 81.5 
Percentage of Ph-pos marrow metaphases at start of 
2G-TKI,  
  p=0.064 p=0.14 p=0.29 
<95% 28 96.4 95.2 96.4 
≥95% 47 79.9 84.5 87.9 
Time from imatinib failure to starting 2G-TKI    p=0.42 p=0.60 p=0.84 
≤6 months 15 93.3 93.3 90.9 
>6 months 60 84.2 87.8 90.5 
Best cytogenetic response on imatinib    p=0.002 p=0.043 p=0.017 
0-94% Ph-pos 42 63.7 76.5 75.3 
≥95% Ph-pos 33 92.6 92.6 96.4 
Hematologic resistance to imatinib,   p=0.29 p=0.44 p=0.78 
Yes 55 79.7 90.3 89.5 
No 20 88.3 85 91.4 
Maximal dose of imatinib,   p=0.55 p=0.68 p=0.82 
400 mg/day 16 93.8 93.8 93.8 
600 mg/day 29 81.5 85.4 87.9 
800 mg/day 30 86.2 89.8 92 
KD mutation at start of 2G-TKI,    p=0.51 p=0.31 p=0.11 
No  55 84.9 86.9 100 
Yes 20 90 95 86.7 
Transcript type   p=0.57 p=0.62 p=0.72 
e14a2 26 83.9 83.9 86.3 
e13a2 34 91.1 91.1 93.2 
e14a2 and e13 a2 15 78.3 93.3 93.3 
MECOM at start of 2G-TKI,   p=0.0001 p<0.0001 p=0.0003 
negative 67 90.6 93.8 95.2 
positive 8 43.7 43.7 47.5 
Percentage of blasts in bone marrow at start of 2G-TKI,    p=0.02 p=0.1 p=0.3 
≤5% 54 90.4 88.4 90.4 
>5% 21 66.7 77.1 83.8 
BCR-ABL1 transcript ratio at start of 2G-TKI,    p=0.01 p=0.06 p=0.04 
≥100% 17 95.2 95.2 97.1 
<100% 58 74.3 80.9 82.5 
N  Number of patients EFS event-free survival PFS progression-free survival OS overall survival 
* Other peripheral blood and bone marrow parameters are not included in the table, as they did not significantly 
predict for any of the outcomes. (p values were calculated using the log-rank method. Variables with a p value < 0.1 
were included in the multivariate analysis for each outcome) 
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Patients with positive MECOM expression at the onset of 2G-TKI therapy had a 
significantly lower 30 month EFS (43.7% vs. 90.6%, p=0.0001), PFS (43.7% vs. 
93.8%, p<0.0001), OS (47.5% vs. 95.2%, p=0.0003) and cumulative incidence of 
CCyR (12.0% vs. 59.7%, p=0.05) (Table  1-2  Definition of haematologic, cytogenetic 
and molecular response), than patients without MECOM expression (Figure  2.3, Figure 
2.4 and Figure  2.5). Multivariate analysis for overall survival, EFS and PFS was 
performed. Expression of MECOM (present or absent) and the achievement of at least a 
minor cytogenetic response (MiCyR) during the prior imatinib therapy were the only 
independent predictors for OS with relative risk (RR) of (RR=0.11, p=0.009 and 
RR=5.2, p=0.05), PFS (RR=0.07, p=0.0003 and RR=4.9, p=0.03) and EFS (RR=0.08, 
p=0.0004 and RR=8.1, p=0.002). 
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Figure ‎2.3 Overall survival of imatinib resistant patients according to presence of MECOM gene 
expression at the onset of second generation tyrosine kinase inhibitor (2G-TKI) therapy. The 
probability of survival at 30 months from the onset of 2G-TKI was 95.2% for IM resistant MECOM non-
expressors (blue line), vs. 47.5% for IM resistant MECOM expressors (red line); p=0.0003 
 
Figure ‎2.4 Eevent free survival (EFS) for imatinib resistant patients according to presence of 
MECOM gene expression at the onset of second generation tyrosine kinase inhibitor (2G-TKI) 
therapy. The probability of EFS at 30 months from the onset of 2G-TKI was 90.6% for IM resistant 
MECOM non-expressors (blue line), vs. 43.7% for IM resistant MECOM expressors (red line); p=0.0001 
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Figure ‎2.5 Progression free survival for imatinib resistant patients according to presence of 
MECOM gene expression at the onset of second generation tyrosine kinase inhibitor (2G-TKI) 
therapy. The probability of PFS at 30 months from the onset of 2G-TKI was 93.8% for IM resistant 
MECOM non-expressors (blue line), vs. 43.7% for IM resistant MECOM expressors (red line); p<0.0001 
2.3.2 Lack of early cytogenetic response to 2G-TKI and MECOM expression 
indentifies those patients with higher risk of progression  
At 3 months, 42 patients had achieved at least a MiCyR. These patients had a 
significantly better OS, PFS and EFS than the 33 non-responders, namely 100% vs. 
79.9% (p=0.005); 100% vs. 75.1% (p=0.001) and 97.4% vs. 71.9% (p=0.002) 
respectively. The multivariate analysis was repeated using the variables shown in 
(Table  1-2) and the level of cytogenetic response achieved at 3 months. Expression of 
MECOM and the achievement of MiCyR were the only independent predictors for OS 
(RR=0.09, p=0.004 and RR= 8.3, p=0.02), PFS (RR=0.09, p=0.001 and RR= 10, 
p=0.01) and EFS (RR=0.16, p=0.007 and RR= 11.1, p=0.025) (Figure  2.6) shows the 
results of combining both variables. 
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Figure ‎2.6 Overall survival of CML patients receiving second generation tyrosine kinase inhibitor 
(2G-TKI) therapy according to the presence of at least a minor cytogenetic response (MiCyR) at 
three months. MiCyR at 3 months (green line), absence of both MiCyR and MECOM expression at 3 
months (blue line) or absence of MiCyR with presence of MECOM expression (red line). The graph 
demonstrates that in patients lacking a MiCyR on 2G-TKI, MECOM expression is a strong predictor of 
poor outcome. 
Significantly, none of the patients in the cohort in whom MECOM expression 
was detected harboured a BCR-ABL1 KD mutation known to confer resistance to 2G-
TKIs; this observation should exclude this mechanism as an alternative explanation for 
their inferior outcome. Retrospective analysis of archived material revealed that 
MECOM expression was not present in diagnostic samples of patients who were later 
found to express the protein, but emerged at a median of 31 months after diagnosis 
(range 15-103 months). Diagnostic samples from a further 23 CML patients were also 
screened, 10 of whom responded to imatinib and 13 did not. None of these samples had 
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detectable MECOM expression, suggesting that MECOM expression is not commonly 
present in patients at diagnosis, regardless of subsequent response to imatinib. 
Interestingly, when analysis was limited to patients who failed to achieve 
MCyR on dasatinib, MECOM status remained the only significant predictive factor for 
probability of PFS (p=0.00017; Figure  2.7). 
 
Figure ‎2.7 Survival of CML patients receiving second generation thyrosine inhibitor dasatinib 
therapy according to the presence of at least a major cytogenetic response (MCyR) at 12 months. 
Absence of MECOM expression (n=17)(blue line), presence of MECOM expression (n=8)(green line). The 
graph demonstrates that in patients who fail to achieve an MCyR after 12 months of dasatinib, MECOM 
expression is a strong predictor of poor outcome (p=0.00017). 
A further validation using an independent patient cohort was essential to confirm 
the predictive value of MECOM expression at the point of imatinib failure. Such a 
sample group was provided by the Department of Haematology at the University of 
Liverpool in the form of an independent cohort of 28 patients who were treated in the 
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Liverpool Royal University Hospital with nilotinib (n=13) or dasatinib (n=15) after 
imatinib failure while still in CP. Importantly the results have validated the prognostic 
value of MECOM with patients with positive MECOM expression at the onset of 2G-
TKIs therapy showing a significantly lower 30-month EFS (0.0% vs. 84.2%, 
p=0.0001), PFS (0.0% vs. 88.6%, p<0.0001), and OS (50% vs. 95.7%, p=0.007) than 
patients without MECOM expression. 
2.3.3 MECOM expression and stem cell transplant in CML: Absence of adverse 
prognostic association  
Given the apparent adverse prognosis conferred by MECOM expression in 
patients receiving 2G-TKI, we also sought to determine whether MECOM expression 
was predictive of outcome in patients receiving stem cell transplantation after imatinib 
treatment for CML. Interestingly, an opposite association to that seen in 2G-TKI 
patients was observed, with MECOM expression predicting a favourable survival 
outcome (p=0.013). For this analysis the cohort was segregated into 2 groups using the 
median expression value as a threshold. This association remained in a multivariate 
analysis (p=0.025), and was independent of the Gratwohl score which is scoring system 
used for to predict outcome after allogeneic hematopoietic stem cell transplantation 
(allo-HSCT) for haematological disease in general (Figure  2.8).  
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Figure ‎2.8 Leukaemia free survival analysis (LFS) of imatinib resistant CML patients treated with 
allogeneic haematopoietic stem cell transplantation (allo-HSCT) according to MECOM expression 
level. High MECOM expression (n=23)(blue line), Low MECOM expression (n=25)(red line). In contrast to 
the findings from patients treated with 2GTKI, the graph demonstrates that in transplanted patients there 
is a trent towards an improved outcome in patients with higher MECOM expression with p=0.013. 
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2.4 Discussion 
The findings presented in this chapter demonstrate that detection of expression of 
the MECOM oncogene in imatinib resistant CP CML patients at the start of 2G-TKI 
therapy is a strong predictor for disease progression and shorter survival. Measurement 
of MECOM expression at the point of imatinib failure may therefore identify patients 
who would fare badly on a 2G-TKI regimen and might be better served by early referral 
for transplant. These findings also suggest that, in patients who fail to achieve MiCyR 
after 3 months of 2G-TKI therapy, MECOM expression status may help to distinguish 
those patients with poor disease outcome from those who have a significantly higher 
chance of long-term progression-free survival. 
The findings regarding the frequency of detection of MECOM expression in 
chronic phase CML patients are in keeping with those of Ogawa and colleagues, who 
reported that 1/14 patients showed detectable MECOM expression by Northern blot 
analysis (Ogawa et al. 1996a;Ogawa et al. 1996b). Also in keeping with previous 
reports, we found a higher frequency of MECOM expression in CML blast crisis 
samples, with 5/23 samples testing positive by real time PCR (data not shown). These 
findings, together with the observed lack of MECOM expression in CML patients at 
presentation suggest that MECOM expression may be a marker of extreme “late” 
chronic phase of CML, which may in turn explain the impact of detectable MECOM 
expression on patients’ risk of progression and survival. The higher MECOM 
expression detected in 3q26 rearrangement-positive samples compared to samples with 
expression but no 3q26 rearrangement is also of interest in this regard (Daghistani et al. 
2010). The latter observation may explain why patients may express MECOM in 
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absence of 3q26 rearrangement and remain in CP whereas 3q26-rearrangement-induced 
expression is exclusively associated with the advanced phases of CML. 
Significantly, none of the patients in our cohort in whom MECOM expression 
was detected harboured a BCR-ABL1 kinase domain mutation that was known to 
confer resistance to 2G-TKIs, thus excluding this mechanism as an alternative 
explanation for their inferior outcome. It is possible therefore, that up-regulation of the 
MECOM transcription factor, a known BCR-ABL1-independent mechanism of 
oncogenesis, is itself responsible for inferior response and outcome seen in these 
patients. However, further investigation is required to support this hypothesis.  
In acute myeloid leukaemia (AML) high levels of expression of MECOM are 
also associated with an unfavourable outcome (Haas et al. 2008;Lugthart et al. 2008). 
In keeping with this observation, down-regulation of MECOM has recently been 
reported to be associated with a good prognosis in patients with AML with epigenetic 
changes being implicated in the transcriptional regulation of MECOM (Vazquez et al. 
2011). 
Despite a high degree of association between MECOM expression and response 
to 2G-TKI, there was no such association between its expression and patients’ outcome 
after stem cell transplant. The latter finding is not entirely surprising considering the 
fundamental differences between the two treatment modalities. However, the positive 
correlation between MECOM expression and sustained leukaemia-free survival after 
transplantation was unexpected and, if genuine, a worthwhile area for future 
investigation. An association between high MECOM expression and prolonged 
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leukaemia-free survival in post-stem cell transplant patients is somewhat paradoxical, 
given the potent oncogenic role ascribed to MECOM. It is possible that leukaemic cells 
that express MECOM stimulate a more aggressive graft-versus-leukaemia effect than 
MECOM-negative leukaemic cells. One further explanation relates to the fact that 
MECOM expression is itself indispensable for normal HSC self-renewal in the foetal 
and adult haematopoietic system (Kataoka et al. 2012). It is plausible that MECOM 
expression in leukaemic cells is stimulated by subversion of inherent bone marrow 
stromal factors that in normal individuals regulate MECOM expression in stem cells. 
Patients whose leukaemic cells express MECOM may therefore also be those in whom 
stromal factors stimulate MECOM expression in normal haematopoiesis more 
effectively; thus MECOM-positive leukaemia may act as a surrogate marker of a bone 
marrow microenvironment that is more conducive to normal LSC maintenance and 
proliferation. Further work is required to explore these hypotheses.  
2.5 Further investigation 
It has previously been shown that MECOM directly represses PTEN transcription 
via interaction with several polycomb group proteins, which leads to activation of 
AKT/mTOR signalling on which MECOM-expressing leukaemic cells are dependant 
(Yoshimi et al. 2011). The PTEN/AKT/mTOR signalling pathway and the MECOM-
polycomb interaction therefore provide rational targets for therapy that suppress the 
leukemogenic activity of MECOM that require further investigation in TKI-resistant 
and advanced phase CML. 
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One further question raised by the work in this chapter is whether the precise 
level of MECOM expression is linked to a degree of resistance or risk of progression to 
BC. If MECOM expression can be located to a specific cellular compartment (e.g. 
CD34+) it may be possible to measure expression more precisely and to correlate this 
with risk of progression. It is currently unclear whether up-regulation of MECOM 
expression is caused by exposure to imatinib or is a marker of late chronic phase 
independent to imatinib exposure. Further screening for MECOM expression in patients 
treated with dasatinib as first line therapy may help to answer this question. 
Preliminary results suggest that up-regulation of MECOM expression is 
associated with prolonged leukaemia free survival after stem cell transplantation. If this 
finding can be confirmed, further work is required to investigate whether the effect is 
due to either (1) a more intense graft-versus-leukaemia effect, or (2) a bone marrow 
microenvironment that may more readily foster host donor cell haematopoiesis via 
extrinsic factors that more effectively stimulate normal stem cell maintenance and 
proliferation. 
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CHAPTER 3 : Self referenced high resolution oligo-
array CGH of chronic myeloid leukaemia  
3.1 Introduction 
The Philadelphia translocation in CML is assumed to occur in a pluripotential 
hematopoietic stem cell, but the mechanism by which an expanding BCR-ABL1 
positive clone exerts a proliferative advantage over residual normal stem cells is 
unknown, as is the precise mechanism in which the presence of the BCR-ABL1 fusion 
gene increases the risk of leukaemia progression. Different clinical outcomes of CML 
patients indicate heterogeneity of the disease that might be due to minor genetic 
changes in leukaemic clones. Heterogeneity of such mechanisms may contribute to the 
clinical variability of CML, as various different factors could influence the nature of the 
disease and subsequently its response to treatment. To attempt to shed some light on 
these pathways, and the clinical heterogeneity of CML, several groups have performed 
“global” analysis of CML cells, at either the genomic or transcriptomic level in order to 
identify additional genetic hits or deregulated pathways that may be a recurrent feature 
of CML pathogenesis.  
Direct investigation at the genomic level using conventional cytogenetic 
analysis (Giemsa stain), was the first method which helped in understanding CML 
pathogenesis by detecting chromosomal aberrations in addition to the Ph-chromosome, 
such as trisomy 8, isochromosome 17q, and an extra Ph chromosome, which are 
commonly associated with disease transformation to BC (Johansson et al. 2002).  
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However analysis of leukaemic cells at improved resolution was a necessity in 
order to detect cryptic genomic changes and overcome the inherent limitations of G-
banding. In the mid 1990s, classical comparative genomic hybridisation (CGH) was 
developed as global means of detecting genetic aberrations, including those that are 
cryptic at the level of G-banding or present in non dividing cells. The principle of 
classical CGH is to identify genomic copy number changes by competitively 
hybridising differentially fluorescently labelled DNA samples against a control 
metaphase chromosome spread (Kallioniemi et al. 1992). The CGH technique was 
improved with the introduction of the microarray platform, which allows higher-
resolution mapping of genomic copy number aberrations via competitive hybridisation 
of test and reference DNA on to a matrix of genomic segments spotted on a microarray, 
rather than a control metaphase cell of the classical CGH (Figure  3.1)(Maser et al. 
2007;Pinkel et al. 1998).  
Genomic targets on array studies were initially made from mapped BAC clones 
of approximately 200kb in length (Pinkel et al. 2005). Recently higher resolution has 
been achieved using array platforms composed of oligonucleotide targets of around 
60bp in length. Oligonucleotide CGH platforms with over 2 million targets offer a 
resolution of as high as 1000bp (Ylstra et al. 2006). Arrays designed to characterise 
global SNP genotypes have also been applied to investigate copy number changes at 
high resolution using allele-specific oligonucleotides in place of BACs or standard 
oligos (Mullighan et al. 2008). 
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Figure ‎3.1 Schematic diagram showing the pronciple of oligo-array comparative genomic 
hybridization. Normal and tumour DNA samples are differentially labelled and competitively co-
hybridised to a glass slide spotted with an array of mapped genomic segments (usually BACs or 
oligonucleotides)[(Modified from (Davies et al. 2005)]. 
 
  
72 
Consequently, the use of array CGH has enabled the detailed analysis of global 
copy number changes in cancer, and the association of these changes with different 
clinical and pathological features of disease. In malignant melanoma chromosomal 
aberrations detected by array CGH have been linked with a poor prognosis (Hirsch et 
al. 2012). Array CGH has also identified multiple changes in diseases including 
multiple myeloma (Keats et al. 2007) and breast cancer with the potential for predicting 
clinical outcome (Bonnet et al. 2012;van Beers et al. 2006). 
Recurrent leukaemic aberrations continue to be identified using this approach, 
providing a deeper understanding of disease pathogenesis. For example by using high 
resolution SNP array analysis, the IKFZ1 gene has been identified as deleted in more 
than 80% of BCR-ABL1-positive ALL cases, but not in chronic phase of CML 
(Mullighan et al. 2008). Similarly in T-ALL, the majority of patients were found to fall 
into 2 categories based on CGH analysis: 1) patients with aberrations that resulted in 
up-regulation of PI3K-AKT, and 2) patients with aberrations that caused down-
regulation of TGF- (Remke et al. 2009). Furthermore studies of BCR-ABL1-positive 
acute lymphoblastic leukaemia patients, found a high frequency of deletions of genes 
implicated in regulation of the cell cycle such as CDKN2A, BTG1, PAX5, and EBF1. 
(Iacobucci et al. 2009) 
Published findings of array CGH in CML are limited but offer some insight into 
the frequency of sub-microscopic changes. Brazma et al,(Brazma et al. 2007) used 
array CGH at a 1Mb resolution and discovered 14 common cryptic abnormalities in 
CML blast crisis samples that were rare in CP. In a comparison between Ph-positive 
ALL and CML, Mullighan et al, (Mullighan et al. 2008) used a higher resolution 250k 
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SNP array and observed up to 8 copy number aberrations (CNAs) per patient (range 0-
8) in a cohort of 23 chronic phase CML samples, but no recurrent aberrations were 
detected and the authors did not specify whether samples had been taken at diagnosis or 
late CP. Recurrent aberrations that may co-operate with BCR-ABL1 in disease 
pathogenesis, drug resistance or progression to blast crisis have not yet been identified 
using this approach. 
Despite the progress made in defining drivers of pathogenesis by CGH, 
researchers have long recognised that characterisation of global cellular changes that 
drive malignancy is not possible via interrogation of DNA alterations alone. Hence 
gene expression profiling and global assessments of epigenetic changes such as 
methylation have also played a role in increasing the understanding the pathogenesis 
and clinical outcome of many common cancers. In CML, expression profiling has been 
used to identify potentially significant genes that are differentially expressed in BC and 
extremely aggressive forms of the disease, such as WT-1 and PRAME (Radich et al. 
2006). In addition, Yong et al. found that high expression of proteinase 3 or eastase 
with low CD7 can predict the length of chronic phase (Yong et al. 2006), while 
McWeeney et al proposed a 75 gene classifier that predicted likelihood of response to 
imatinib (McWeeney et al. 2010). However, such techniques have yet to yield findings 
useful to CML therapeutics or clinical management. 
Other techniques, of genome wide scanning include methylome analysis. Down-
regulation, or occasionally up-regulation, of gene expression by hypermethylation is 
emerging as a recurrent mechanism driving human malignancy (Baylin et al. 
2006;Martin-Subero et al. 2009). Global studies of CML at the epigenetic level have 
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revealed aberrant patterns of DNA methylation associated with disease progression and 
resistance to imatinib. Dunwll et al. (2010) identified hypermethylation of TFAP2A and 
EBF2 in association with progression to BC. In addition, hypermethylation of the 
promoter of ATG16L2 in patients was associated with inferior response in achieving 
MMR (Dunwell et al. 2010). 
3.2 Aims and research plan 
Although the use of array CGH in CML has permitted a more thorough analysis 
of global copy number changes when compared to classical CGH studies or 
conventional cytogenetics, the majority of the studies used platforms that had a 
relatively low resolution and would not allow detection of copy number changes less 
than 1Mb in size. In addition, the study design of the latter reports was limited by use of 
non-patient reference material, thereby introducing the complicating effect of normal 
copy number variation. There is, therefore, a need to enhance genetic characterisation 
of CML focussing on specific biological and clinical queries. 
With this in mind, high density array CGH will be applied to diagnostic material 
from two cohorts of CML patients with distinct clinical outcomes: 
1. Patients who subsequently responded optimally to imatinib, achieving 
complete cytogenetic response (CCyR) within 18 months, and 
maintaining this response (CML-Resp). 
2. Patients who failed to achieve major cytogenetic response (MCyR) 
within 18 months (primary resistance)(CML-Non-Resp). 
The goal of this analysis was to identify recurrent lesions leading to aberrant 
gene expression that may cooperate with BCR-ABL1 in disease pathogenesis or 
  
75 
contribute to imatinib resistance. CGH-defined lesions will be validated and their effect 
on transcription will be investigated. The function and clinical impact of deregulation 
of candidate gene expression will be examined in subsequent chapters. 
3.3 Materials and methods 
3.3.1 Patients and Controls  
The CML cell samples in this study were all prepared from the stored cells in 
The John Goldman Cellular Therapy Centre, Hammersmith Hospital, and Imperial 
College Health Care NHS Trust. These cells were leukapheresed at the time of 
diagnosis and frozen in liquid nitrogen. Two groups of patient samples were used to 
accomplish two different component of the project; informed consent for these studies 
in accordance with requirements of the Hammersmith Hospital Research Ethics 
Committee was given by all involved patients. Control samples were obtained from 
peripheral blood of healthy BCR-ABL1 negative individuals (n=8), from which the 
relevant cell type was then separated. Samples from 32 patients with newly diagnosed 
BCR-ABL-positive CML in CP were collected, prior to treatment with imatinib. Their 
median leukocyte count was 183 x 10
9
/L. All patients then began imatinib treatment at 
a dose of 400mg/day. In 20 patients, termed the “responder” cohort, complete 
cytogenetic response was achieved in less than 18 months, as confirmed by metaphase 
karyotyping and a two to three log reduction in the BCR-ABL1 ratio by quantitative 
(RT-PCR). The remaining 12 patients showed minimal or no cytogenetic response after 
18 months (the “non-responder” cohort). Polymorphonuclear (PMN) cells, 
mononuclear cells (MNCs) as well as CD34+ cells were collected from all diagnostic 
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samples. Control samples were obtained from peripheral blood of healthy BCR-ABL1 
negative individuals, from which the relevant cell type was then separated.  
3.3.2 Cell Separation  
White blood cells were prepared from 10 to 20mL of blood collected into an 
EDTA tube. Peripheral PMN cells were separated from mononuclear cells (MNCs) in 
blood using Ficoll
™
 (GE Healthcare Bio-Sciences, Oslo, Norway) by density 
centrifugation. To the PMN cells, red cell lysis buffer (Qiagen, Hilden, Germany) was 
added to 50mL and stored on ice for ten minutes. The cells were then centrifuged and 
the supernatant removed. Subsequently, the cells were washed twice using phosphate 
buffered saline (PBS) (Invitrogen, Paisley, UK) and stored at -70°C. The number of 
MNCs was counted using a microscope and 2 x 10
8 – 5 x 108 cells were added to 1mL 
Robosep buffer (Stemcell Technologies, Grenoble, France).  
3.3.3 Purification of CD34+ cells 
CD34+ cells were isolated using the MiniMacs technology according to the 
manufacturer’s instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). Cells 
were suspended in 350μl of MACS buffer [phosphate buffered saline (PBS) (Gibco), 
0.5% bovine serum albumin (BSA) (PAA laboratories, Pasching, Austria) and 2mM 
EDTA (Sigma)] per 10 x 10
8 
cells, and centrifuged at 300×g for 10 minutes. The 
supernatant was completely aspirated, and the cell pellet resuspended in 300μl of buffer 
with 100μl FcR blocking reagent and 100μl of CD34+ microbeads. This was mixed 
well and incubated for 30 minutes at 4°C. The cells were then washed by adding 5-
10mL of buffer, centrifuged at 300×g for 10 minutes and resuspended in 500μl buffer. 
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Labelled cells were then passed through a pre-washed MiniMACS column mounted on 
a magnet. Following this, the column was washed 3 times with 500μl buffer.  The 
column was removed from the magnet and the cells eluted with 1mL MACS buffer.  
3.3.4 DNA Extraction 
DNA extraction from whole blood and cell lysates was carried out manually 
using the QIAamp
®
 DNA Mini Kit (Qiagen, Hilden, Germany). Using a spin column 
DNA was eluted by 200µL of buffer AE (Qiagen, Hilden, Germany).  
3.3.5 Comparative genomic hybridisation  
CGH was performed on a 2.1 million oligonucleotide array (NimbleGen, UK; 
‘HD2’ 070713_HG18_WG_CGH_HX1 design). The probes on this array were selected 
to achieve a uniform distribution throughout the genome, with median probe spacing 
every 1169bp each probe is a 60mer.  
In this study patient DNA was hybridised against a reference from the same 
patient's genetic material to limit the results to leukaemia-related acquired changes and 
to avoid detection of constitutional polymorphic copy number variants (CNVs; (Redon 
et al. 2006)). DNA was extracted from PMN cells (diagnostic samples) whole white 
blood cells (WBCs; reference remission samples) or, if the latter were unavailable, 
from patients’ purified Ph-negative, CD4+ve T-cells, taken from samples at diagnosis 
or during follow-up. Scanned array images were imported into NimbleScan 
(NimbleGen), to identify potential copy number aberrations (CNAs) from HD2 image 
and intensity data. Nexus Copy Number v6.0 software (BioDiscovery Inc, CA, USA) 
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was used to visualise the normalised-segmented data. To identify significant recurrent 
regions of potential copy number change, we used the Significance Testing for 
Aberrant Copy number (STAC) algorithm (Diskin et al. 2006), which provides 
permutation based concordance p-values for each location. Secondly, the (GISTIC) 
algorithm, which was designed for use on cancer samples (Beroukhim et al. 2007), was 
used to further refine the list of regions with a statistically high frequency of potential 
copy number aberration. This generated a “G score” which expresses the frequency of 
occurrence of the aberration and the magnitude of the copy number change (log ratio 
intensity) at each location for the aggregate of all samples in the data set; in addition to 
applying the false detection rate (FDR) correction for multiple testing and calculating 
the Q-boundary values. 
3.3.6 RNA Extraction and Complementary DNA (cDNA) Preparation 
RNA was extracted from PMN and CD34+ cell lysates through manual 
extraction using the RNeasy
®
 Mini Kit (Qiagen, Hilden, Germany). The “Animal Cells 
Spin” standard protocol was followed using 350µL of cell lysate. An optional step was 
performed in the extraction for DNase removal using DNase I. RNA concentration was 
measured prior to cDNA Synthesis. Reverse transcription of RNA was carried out using 
the Moloney murine leukaemia virus reverse transcriptase (MLV-RT) enzyme 
(Invitrogen, Carlsbad, USA) and the RNasin
®
 Ribonuclease Inhibitor (Promega, 
Madison, USA) to avoid RNA degradation. 2.4µL of MLV-RT (Invitrogen) and 1.2µL 
of RNasin (Promega) were added to 42µL of cDNA mix per reaction. The cDNA mix 
included 0.1M DTT (Biosynth, Staad, Switzerland), 25mM dNTPs (Bioline, London, 
UK), random primers at concentration 3ng/µL (Promega, Madison, USA), distilled 
water and a 5x buffer containing 0.25 mol/L Tris hydrochloric acid (HCL), 0.375 
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mmol/L potassium chloride (KCL) and 15 mmol/L magnesium chloride (MgCl2) 
(Invitrogen, Carlsbad, USA).  The freshly extracted RNA was incubated at 65°C for ten 
minutes prior to adding the enzymes and cDNA mix to linearise the molecules. 
Following addition of the enzymes and mixing, samples were incubated at 37°C for two 
hours. Lastly, the cDNA was placed at 65°C for ten minutes to inactivate the MLV-RT 
enzyme and cDNA was stored at -20°C. For the TLDA experiments, the High Capacity 
cDNA Archive Kit (Applied Biosystems, Foster City, USA) was used for cDNA 
synthesis, making sure enough total RNA was added, so that the final concentration of 
total RNA converted to cDNA was 10-100ng/µL in each well of RT-PCR reaction. 
Thermal cycle conditions were 10 minutes at 25°C, followed by 120 minutes at 37°C. 
All cDNA samples were stored at -15°C to -25°C. 
3.3.7 RNA and DNA Concentration Measurements  
RNA and DNA concentrations were determined using a NanoDrop 
spectrophotometer following the manufacturer’s standard protocol (NanoDrop, USA). 
The 260/280 ratio was used to assess the purity of the samples; for RNA a ratio of ~2.0 
was accepted, while a ratio of ~1.8 was accepted as “pure” for DNA. 
3.3.8 Gene Expression Assays 
Real-time qPCR (RT-qPCR) to measure levels of gene expression was carried out using 
a pre-designed primer and probe mix of TaqMan
®
 Gene Expression Assays (Applied 
Biosystems, Foster City, USA) for NAMPT and PSTPIP1 genes (Hs00237184_m1, 
Hs00182777_m1) respectively (Applied Biosystems, Foster City, USA).  The 
housekeeping gene GUSB was used as a control gene (Hs99999908_m1; Applied 
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Biosystems, Foster City, USA). Reactions were carried out in a volume of 20µL 
composed of 10µL 2x TaqMan
®
 Universal PCR Mastermix, 7µL distilled water, 1µL 
primer and probe mix and 2µL cDNA. All reactions were carried out in triplicate to 
increase the reliability of the result and included a non-template control (NTC). The 
cycling program used started with 50°C for two minutes, an initial denaturation step at 
95° C for 10 minutes and 40 cycles of denaturation at 95°C for 15 seconds and a 60°C 
combined annealing and elongation step for one minute. Results were recorded on the 
7500 system v1.4 software (Applied Biosystems) and analysed with a threshold of 0.05 
using an automatic baseline. The average level of expression of the target gene was 
calculated using the differences in cycle threshold (CT) values as (2
ΔCT
). The average 
expression for each gene was calculated using triplicates that were within one unit of 
each other. Statistical analysis was carried out using the GraphPad Prism
® 
software 
v5.0. One-way ANOVA was applied to detect significant difference, followed by the 
Bonferroni post-hoc test comparison. 
 
3.3.9 TaqMan® Low-Density Array (TLDA) design 
The TaqMan
®
 Low-Density Array (TLDA) platform was used to explore gene 
expression, for the multiple genes that appeared to be subject to recurrent copy number 
aberration based on CGH analysis. TLDA is a quantitative RT-PCR assay that 
measures the gene expression of each selected gene in triplicate. RNA-18S and GUSB 
genes were included in the design as reference genes based on their demonstrated role 
as housekeeping genes (Appendix 7.3). Each cDNA sample (30-50µL) was added to 
50µL of TaqMan
®
 Universal PCR Master Mix (No AmpErase UNG; Applied 
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Biosystems); the total was adjusted to 100µL with the RNase-free water. The mixture 
was then transferred into the loading port of the TLDA card. After centrifugation in a 
Sorvall Legend
™ centrifuge (Kendro Scientific, Asheville, USA) for 1 min x 2 at 
12,000 rpm the TLDA were card was sealed with a TaqMan
®
 low density array sealer 
(Applied Biosystems, Foster City, CA, USA). PCR amplification was done using 
Applied Biosystems Prism 7900HT Sequence Detection System under the following 
thermal cycler conditions: 2 min at 50˚C and 10 min at 94.5˚C for 40 cycles (30s at 
97˚C and 1 min at 59.7˚C).  
3.3.10 Data analysis of TLDA and Statistics 
The fluorescent measurements generated from the TLDA were analysed using 
the Applied Biosystems DataAssist v3.0. Gene expression was normalised to the GUSB 
gene. The stringency settings used consisted of detectable amplification at CT=32. 
Outliers were automatically removed using the Grubbs detection method to 0.1. 
Statistically, the significance of differential gene expression in the 2 groups (CML 
patients and Normal individuals) was determined using the GraphPad Prism
® 
5 
software The Mann-Whitney-U test was performed to compare the two independent 
groups and a p value of <0.05 was considered significant. 
3.3.11 Copy Number Measurement Assay 
RT-PCR TaqMan
®
 copy number assay kits (Applied Biosystems, Foster City, USA) 
were used for NAMPT (Hs03654469_cn) and PSTPIP1 (Hs03895362_cn) with FAM
™
 
dye labelled MGB probes. As a control gene the TaqMan
®
 copy number reference 
assay RNase P (Applied Biosystems) was used with VIC
®
 and TAMRA
™
 dye-labelled 
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probe. A duplex reaction was performed in which the reference gene assay was placed 
in the same well as the target gene assay. Experiments were carried out with four 
replicates and a non-template controls (NTC). The total reaction volume was 20µL with 
10µL 2x TaqMan
®
 Genotyping Master mix (Applied Biosystems), 1µL 20x copy 
number assay (Applied Biosystems), 1µL 20x copy number reference assay (RNase P) 
(Applied Biosystems), 4µL distilled water and 4µL of genomic DNA at a concentration 
of 5ng/µL. The standard cycling program was used: 50°C for two minutes, an initial 
denaturation step at 95°C for ten minutes and 40 cycles of denaturation at 95°C for 15 
seconds and a 60°C combined annealing and elongation step for one minute. Readings 
were recorded on the 7500 system v1.4 software (Applied Biosystems) and analysed 
with a threshold of 0.05 using an automatic baseline. CT values were imported as text 
files to the CopyCaller
™
 software v2.0 (Applied Biosystems), and analysed according 
to the defaults settings recommended for post PCR data analysis of copy number 
quantification experiments, accepting results with confidence score of ≥95%.  
3.3.12 Paralog Ratio Test 
The paralog ratio test (PRT), first described by Armour et al (Armour et al. 
2007), was carried out as an alternative means of substantiating the overrepresentation 
of NAMPT identified by CGH by simultaneously amplifying a region within NAMPT 
and a control pseudogene elsewhere in the genome.  The primers were designed to 
amplify the NAMPT gene itself (chromosome 7) to give a product of 225bp, and the 
chromosome 16 pseudogene, to give a product of 235bp (Supplementary Appendix 
7.6). NAMPT copy number can be assayed by separating these products using capillary 
electrophoresis and measuring the chromosome 7 to chromosome 16 ratio. The PCR 
reaction was carried out in a volume of 10 µL using 1µL 10x LD mix (Supplementary 
  
83 
Appendix 7.7), 0.5µL of genomic DNA, 1µM of each primer (Sigma-Aldrich) and 0.1 
units of Taq DNA polymerase (Invitrogen). Cycling conditions included an initial 
denaturation step at 95˚C for 2 minutes, 28 cycles of denaturation at 95˚C for 30 
seconds, annealing at 55˚C for 30 seconds and elongation at 68˚C for one minute, 
followed by a final elongation step at 72˚C for 20 minutes. 1µL of PCR reaction was 
mixed with 10µL of HiDi/ROX500 solution and run in duplicate on the ABI PRISM
® 
3100 Genetic Analyzer capillary electrophoresis instrument (Applied Biosystems). 
Results were recorded and analysed using the GeneMapper
® 
version 4.0 software 
(Applied Biosystems), statistical analysis was carried out using the GraphPad Prism
® 
5 
software, Wilcoxon signed ranks test was applied to detect significant difference. 
3.3.13 Allelic Imbalance PCR 
In order to further investigate putative amplification of the NAMPT gene, PCR 
reactions for two SNPs found within the region shown to be amplified by CGH 
(rs10808150 and rs4730153) as well as a 3bp insertion/deletion polymorphism 
(rs35301913) were performed (Primers shown in Supplementary Appendix 7.8 & 7.9).  
For the indel PCR, reactions were carried out in a volume of 10µL, using 10ng 
of genomic DNA, 1µM of each primer (Sigma-Aldrich, Haverhill, UK)  and 0.05 units 
of Taq DNA polymerase (Invitrogen, Carlsbad, USA). Cycling conditions included an 
initial denaturation step at 95˚C for two minutes, 24 cycles of denaturation at 95˚C, 
annealing at 60˚C and elongation at 70˚C (all for 30 seconds) and a final elongation 
step at 72˚C for 20 minutes. In order to distinguish and quantify the alleles by their 
difference in length, 1µL of PCR reaction was mixed with 10µL of HiDi/ROX500 
solution and run in duplicate on the ABI PRISM
®
 3100 Genetic Analyzer capillary 
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electrophoresis instrument (Applied Biosystems, Warrington, UK). Results were 
recorded and analysed using the GeneMapper® version 4.0 software (Applied Biosystems).  
 
For the two SNPs, PCR reactions were carried out in a volume of 50µL with 
1.8mM MgCl2 (Invitrogen), 0.5µM of each primer (Sigma-Aldrich) and 0.025 units of 
Taq DNA polymerase (Invitrogen). Thermal cycling was carried out at 94˚C for three 
minutes (initial denaturation), followed by 32 cycles of denaturation at 94˚C for 40 
seconds, annealing at 63˚C for 40 seconds and elongation at 72˚C for one minute. For 
SNP genotyping and allele quantification of the PCR reactions, pyrosequencing was 
used in accordance with the manufacturer’s standard protocol (Pyrosequencing AB, 
Uppsala, Sweden). The percentages each SNP allele were determined by the Allele 
Quantitation Algorithm using the PSQtMA software (Pyrosequencing AB). 
For both SNPs and the indel, an allelic ratio that did not differ significantly from 
one indicated a normal copy number of two, while a ratio that was significantly 
different to one would imply that an allelic imbalance was present due to a copy 
number change in the PCR-amplified region. Statistical analysis was carried out using 
the GraphPad Prism
® 
software v5.0, the paired t-test was applied to each matched 
sample to determine whether the ratio of alleles were significantly different between the 
groups. 
3.3.14 Nucleosome Density Assay 
A nucleosome density assay was used to detect evidence of differential 
chromatin condensation in the promotor regions of candidate genes in CML. The 
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chromatin is digested with a micrococcal nuclease to produce mononucleosomes, which 
have 147bp of DNA wrapped around them. Micrococcal nuclease digests DNA linkers 
that are not protected by nucleosomes leaving the nucleosome-bound DNA undigested. 
After protease treatments, the undigested fragments can be then quantified by qPCR. 
We used pre-designed primers that overlapped to produce products not larger than 
100bp, so that a significant region of a suspected condensed chromatin DNA sequence 
could be investigated. In this way one can compare the degree of chromatin 
condensation in patients compared with healthy individuals; a higher qPCR value 
equates to a higher degree of chromatin condensation around that area (Gevry et al. 
2009). 
Digesting chromatin. PMN cells were suspended in 1mL of cold buffer A 
(Appendix 7.4.1), and each sample was incubated for 15 minutes at 4˚C.  The contents 
of each tube were split into four 250µL samples, after which samples were centrifuged 
for 10 minutes at 4500 rpm at 4˚C.  The supernatant was removed carefully and then 
each tube resuspended in 225µL of MNase buffer (Appendix 7.4.2). 2µL of the enzyme 
was added and then incubated for 10, 15, 20, and 25 minutes at 37˚C. After the 
incubation, 25µL of MNase stop solution (Appendix 7.4.3) was added to the each tube 
followed by 250µL of digestion buffer (Appendix 7.4.4). The tubes were then 
incubated at 65˚ C for 4 hours to reverse the cross linkers. 
Purifying DNA. Proteinase K was added to each sample (50g/mL final 
concentration) and incubated for 30 minutes at 37˚C. After the incubation, 250µL of 
phenol:chloroform:isomylalcohol (25:24:1) was added. Each sample was centrifuged at 
13,000 rpm for 5 minutes, producing two liquid phases in the tube; the top phase was 
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carefully removed and kept.  2.5 volumes of 70% ethanol, 1/10th volume of sodium 
acetate and 1µL of glycogen were then added. Tubes were incubated at -80˚C for at 
least for 45 minutes and then centrifuged at 13000 rpm for 15 minutes at 4˚C. The 
supernatant was removed and then 500µL of 70% ethanol was added to the pellet. The 
samples were again centrifuged, the supernatant was removed and the pellets air-dried. 
500µL of DNase and RNase free water was added to the pellets. The isolated DNA was 
quantitated; a concentration between 10 and 20ng/µL was accepted for qPCR analysis. 
To confirm complete nucleosome isolation, products were run on 2% agarose gels 
(Ultrapure
™
 Agarose, Invitrogen) that were stained with SYBR
®
 Safe DNA gel stain 
(Invitrogen). Visualisation of bands around 147bp indicated true nucleosome isolation 
(Figure  3.2). 
 
Figure ‎3.2 Agarose gel electrophoresis showing amplification of complete nucleosomes (Bands of 
approximately 147bp) following differential exposure to nuclease. A similar degree of nuclease 
isolation was apparent after exposure at 15, 20 and 25 minutes. 
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Primer Design. Primer express v3.0 software (Applied Biosystems, Foster City, 
USA) was used to design 6 overlapping pairs of primers  for NAMPT (Appendix 7.4.5), 
while 5 overlapping pairs of primers for PSTPIP1 (Appendix 7.4.6), with similar 
annealing temperatures, providing full coverage of the target region (Figure  3.3). Target 
regions were 500bp around the promoter of the gene of interest. ABL1 was used as a 
reference gene (Appendix 7.4.7). The significance of the overlapping primers is to 
achieve as much coverage of the DNA sequence of interest as possible. Optimum 
annealing temperatures were confirmed using gradient PCR; products were run on 2% 
agarose gels (Ultrapure
™
 Agarose, Invitrogen) that were stained with SYBR
®
 Safe 
DNA gel stain (Invitrogen) to enable visualisation.  
 
Figure ‎3.3 Schematic diagram of primer coverage used in the nucleosome density assay. Primer 
pairs were designed to overlap so the entire promoter region could be covered. 
 
Quantitative PCR (qPCR) using the SYBR green system was used to measure 
the average DNA amplification of the promoter region of the NAMPT, PSTPIP1 and 
ABL1 (control) genes between CML and normal individuals. The Applied Biosystems 
7500 (Applied Biosystems, Foster City, USA), Quanti
®
 Tect SYBR
®
 Green PCR 
Kit (Qiagen, Hilden, Germany) master mix was used according to manufacturer’s 
instructions. The volume required of SYBR
®
 Green in each reaction well equal was 0.5 
x [Total reaction volume (μL)], with a final concentration of 0.3μM for forward and 
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reverse primer. For each primer pair the reaction was carried out in duplicate, as well as 
2 non-template controls (NTC). The cycling program began with 50°C for 2 minutes, 
10 minutes of denaturation at 95°C. 40 cycles of 15 seconds of denaturation at 95°C 
followed. The annealing and extension temperature was set at 62°C for the NAMPT 
primers and 60°C for the PSTPIP1 primers (both for 1 minute). Analysis was carried 
out using the 7500 system, SDS software v1.4 (Applied Biosystems, Foster City, USA). 
The standard curve was set to have a threshold of 0.02 with auto baseline. For each 
primer set the difference in average cycle threshold (ΔCT) compared to control, 
expressed as 2
ΔCT
, was calculated in Excel (Microsoft
®
, 2007).  
Optimal MNase exposure time of 20 minutes was established by treating a 
single CML sample for 10, 15, 20, and 25 minutes and performing qPCR for regions 
within the NAMPT promoter. The most significant increase in NAMPT PCR 
amplification compared to normal cells was observed at 20 minutes (Figure  3.4). All 
reactions were performed in triplicate. An exposure time of 20 minutes was henceforth 
used in all nucleosome density assays. 
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Figure ‎3.4 Relative increase in PCR amplification of 6 regions within the NAMPT promoter in a 
CML sample (blue bars) compared to cells from a normal individual (red bars) at different lengths 
of nucleae exposure. 20 mins of exposure produced significant evidence in support of nucleosome 
binding as evidenced by increased amplification (and hence nuclease protection) in regions 2 to 6. 
Statistical analysis was carried out using the GraphPad Prism
® 
software v5.0. 
One-way ANOVA was applied to detect significant difference, followed by the 
Bonferroni post-hoc test comparison. 
3.3.15 CD34+ Culture Media 
CD34+ stem cells were washed and cultured in 12 wells culture plate with 
CD34+ culture media consisting of a serum free media (SFM) (Iscove’s modified 
Dulbecco’s medium), 1% glutamine (100mM), 1% penicillin-streptomycin (100mM), 
0.1μM 2-mercaptoethanol supplemented with serum substitute BIT (StemCell 
technologies) and supplemented with a 5 growth factor cocktail comprising 100ng/mL 
Flt3-ligand (100ng/mL) stem cell factor (100ng/mL), 20ng/mL each of interleukin (IL)-
3, IL-6 and granulocyte colony-stimulating factor (all from PeproTech) for the first 24h 
following separation of CD34+ cells. 
3.3.16 Demethylating Azacitidine-5 Assay 
Three CML patient samples and one bone marrow sample from a normal 
healthy donor were used in these experiments; CD34+ cells were isolated and cultured 
as previously described (section  3.3.3 Purification of CD34+ cells and,section  3.3.15 
CD34+ Culture Media, respectively). 5-azacytidine (Sigma) at concentrations of 
0.5μM, 1.0μM and 2.5μM was added and incubated for 24 hours. Afterwards cells were 
washed, collected, and lysed prior to RNA extraction and cDNA synthesis.  
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Importantly, we observed no difference in cells apoptosis nor on expression of 
housekeeping gene GUSB after exposure to 0.5, 1.0 and 2.5uM of 5-AZA, indicating 
that the gene is fully unmethylated in CML and normal individuals and therefore 
represents a suitable reference gene to explore the activity of demethylating agents. 
Statistical analysis was carried out using the GraphPad Prism
® 
software v5.0. 
One-way ANOVA was applied to detect significant difference, followed by the 
Bonferroni post-hoc test comparison. 
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3.4 Results 
3.4.1 Frequency of CGH copy number “calls” in CML patients 
Comparative genomic hybridisation analysis was applied to a cohort of 32 CML 
patients. Positive control lesions in the form of genetic aberrations previously identified 
by cytogenetics or FISH (chromosomal aneuploidies and BCR-ABL1 deletions) were 
successfully detected, thus demonstrating that the technique was working optimally. In 
addition to these known aberrations, a total of 1116 sub-microscopic (<5MB) copy 
number calls were reported by the analysis software across all 32 patients. One hundred 
and two regions were detected as aberrant in three patients and more, of which 32 were 
seen in at least four patients and were confirmed as significant changes using the STAC 
algorithm (Diskin et al. 2006). Furthermore, 15 of these remained significant when 
applying the GISTIC algorithm (Beroukhim et al. 2007), which is specifically designed 
for analysis of cancer samples (Table  3-1). Aberrations that involving regions that 
recurred in 4 or more patients were of a similar appearance in that they appeared to be 
focussed on the coding regions of individual genes, involved little, if any, flanking 
material and predominantly suggested gain of genomic material (Figure  3.5 and Figure 
 3.6). The genes found to be aberrant in four or more patients are summarised in Table 
 3-1. Importantly, the majority of these genes would be plausible functional candidates 
for a role in CML pathogenesis if abrogation of transcription were to be confirmed. 
Pathways in which these genes are involved include apoptotic signalling (e.g. STK17B, 
MAPK8IP1 and FBLMI1), the MAPK pathway (e.g. MAPK8IP1 and DUSP1), 
destruction of CML-related transcription factors (e.g. C19ORF2 and LITAF), ABL1 
dephosphorylation (e.g. PSTPIP1) and myeloid proliferation (e.g. NAMPT and BMI1). 
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Figure ‎3.5 Extent of apparent recurrent enrichment at the NAMPT locus in relation to the boundaries of the gene itself observed by oligo array CGH. In the majority 
of patients the enrichment encompassed the majority of the gene and little, if any, flanking material. 
 
Figure ‎3.6 Extent of apparent recurrent enrichment at the PSTPIP1 locus in relation to the boundaries of the gene itself observed by oligo array CGH. In the 
majority of patients the enrichment encompassed the majority of the gene and little, if any, flanking material.
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Table ‎3-1: Summary of genes involved in recurrent copy number calls detected by CGH in 4 or more CML samples 
CNA Location Gene(s) Type Frequency, % Function** 
7 q22.2 NAMPT* Gain 65 NAD+ biosynthesis; G-CSF induced myeloid differentiation (Skokowa et al. 2009) 
15 q24.3 PSTPIP1* Gain 50 
Dephosphorylates ABL1; Involved in regulation of the actin cytoskeleton; catalyzes the rapid 
transport across the plasma membrane of many monocarboxylates (Cong et al. 2000;Wu et al. 
1998) 
2 q32.3 STK17B* Gain 33 Serine/threonine kinase; induces apoptosis (Sanjo et al. 1998) 
11 p11.2 MAPK8IP* Gain 33 
Decreases MAP kinase induced apoptosis; proven role in cell growth and cancer (Boutros et al. 
2008) 
10 p13 BMI1* Gain 33 
Regulates haematopoeitic stem cell renewal in normal and leukemic progenitor cells (Schuringa et 
al. 2010) 
5 q35.1 DUSP1* Gain 27 
Suppresses activation of MAP kinase (Pomerance et al. 1992); has known roles in cell growth, 
death, and cancer (Boutros et al. 2008). 
3 p25 HRH1* Gain 27 
Regulate sterol synthesis in human mononuclear leukocytes (Krone et al. 1988); mediates a variety 
of lymphocyte functions (Osband et al. 1981). 
11 q13.1 SCYL1* Gain 22 Activates transcription of telomerase reverse transcriptase and DNA polymerase (Tang et al. 2004) 
11 q13.1 MALAT1 Gain 22 Non-coding RNA with potential role in human cancer (Ji et al. 2003) 
17 q25.3 SLC16A3* Gain 22 
Encode monocarboxylate transporter MCT4, which is involved in tumour cells and drug transport 
(Halestrap 2013) 
19 p13.2 MBD3L2 Gain 22 Acts as a transcriptional repressor and transcriptional modulator (Jin et al. 2005) 
22 q11.23 CABIN1 Gain 22 Negative regulator of p53 activity (Jang et al. 2009) 
1 q21.2 ADAMTSL4 Gain 22 Cellular adhesion, angiogenesis (Neuhann et al. 2011) 
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CNA Location Gene(s) Type Frequency, % Function** 
1 p34.1 PLK3* Gain 20 
Serine/threonine kinase with roles in inhibiting cell proliferation and inducing apoptosis (Jiang et al. 
2006) 
1 q21.2 HIST2H2BE* Gain 20 
Histone H2B family member, Involved in cell proliferation and invasion-related genes, were identified 
as direct IRX1 target genes (Guo et al. 2010) 
10 q21.3 SRGN* Gain 20 Haematopoietic cell granule proteoglycan, mediates apoptosis (Kolset et al. 2008) 
17 q25.3 CSNK1D* Gain 20 
Proven role in DNA replication and repair (Okamura et al. 2004); phosphorylates  p53 
(Knippschild et al. 1997) 
10 q26.2 PTPRE* Gain 20 
Proven role in cell growth, differentiation and oncogenic transformation via down regulation of 
MAPK signalling pathway (Kraut-Cohen et al. 2008) 
16 q21 CDH11 Gain 20 Cadherin, cell adhesion, tumour suppressor (Carmona et al. 2012;Li et al. 2012) 
X q12 VSIG4 Gain 20 Macrophage complement receptor (Vogt et al. 2006) 
16 q23.1 BCAR1* Gain 17 
SRC kinase substrate, role in cell transformation, invasion & survival (Sawada et al. 2006) in lung 
and prostate cancer (Dai et al. 2011;Huang et al. 2012) 
10 q26.13 DMBT1 Loss 13 
Atypical tumour suppressor in several human cancers e.g. melanoma (Deichmann et al. 2002) & 
lung (Takeshita et al. 1999) 
9 p13.3 GLIPR2 Gain 13 Initiated activation of ERK1/2 signalling and cell migration(Huang et al. 2013) 
16 p13.3 LITAF Gain 13 
TNF factor with suggested role in leukemogenesis (Wang et al. 2007a); transcriptional regulator 
(Myokai et al. 1999) 
16 p13.11 MYH11 Gain 13 
Myosin heavy chain, involved in chromosomal  inv(16) in AML, causes hematopoietic defects 
leukaemia (Castilla et al. 1996;Kamikubo et al. 2013) 
19 q12 C19orf2  Gain 13 
central role in maintaining S6K1 signalling and BAD phosphorylation, acting as an oncogene 
amplified in ovarian cancer cell lines and human ovarian carcinomas (Theurillat et al. 2011) 
10 p12.2 COMMD3 Gain 13 Control  down regulate the activation of NF-kappa-B (Burstein et al. 2005) 
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CNA Location Gene(s) Type Frequency, % Function** 
1 p36.13 FBLIM1 Loss 13 
key regulator both at cell adhesion sites and nuclei and is implicated in the pathogenesis of 
several human diseases (Wu 2005) 
14 q13 FOXG1 Gain 13 
Forkhead transcription factor, encodes a brain-specific transcription factor, has an important role in 
the developing brain, which is associated with a Rett-like syndrome (Brunetti-Pierri et al. 2011) 
1 p36.2 PLEKHM2 Gain 13 Knockout mouse showed  increased leukocyte (GERDIN 2010) 
9 q22.3 PTCH1 Gain 13 
Component of Hedgehog pathway implicated in haematopoietic stem cell renewal (Naka et al. 
2010a) 
18 q23 SALL3 Gain 13 
Interacts with DNMT3A and shows the ability to inhibit CpG island methylation in hepatocellular 
carcinoma (Shikauchi et al. 2009) 
 
*Genes identified by GISTIC algorithm, in addition to STAC algorithm method with G score of more than 2. 
**Particularly, where relevant, in relation to human cancer or haematopoiesis. 
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3.4.2 Validation of recurrent copy number calls using targeted molecular assays   
Although intriguing at this stage, these putative copy number changes required 
confirmation with a complementary DNA assay as is customary with all CGH studies. 
As there were a large number of genes with apparent genomic aberrations, we decided 
to focus our confirmatory experiments on NAMPT and PSTPIP1 as they were the genes 
that appeared, according to the CGH data, to be subject to the most frequent copy 
number change. 
3.4.2.1 Copy number investigation 
Real-time DNA-based PCR using TaqMan
® 
probes optimised for copy number 
assessment was applied specific for NAMPT and PSTPIP1, in order to further 
investigate the integrity of these loci in CML samples (Figure  3.7 and Figure  3.8). In 
interpreting data generated from these assays, any deviation from an approximate 1:1 
ratio for the CT values of the gene of interest compared to the control gene, RNAse P 
would support a copy number change at that locus. Conversely a ratio close to 1:1 
would indicate a normal copy number of two.  
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Figure ‎3.7 Map‎showing‎the‎location‎of‎the‎common‎region‎of‎“amplification”‎compared‎to‎the‎
location (Chr.7:105905756) of the copy number assay for NAMPT gene. 
 
 
Figure ‎3.8 Map‎showing‎the‎location‎of‎the‎common‎region‎of‎“amplification”‎compared‎to‎the‎
location (Chr.15:77296626) of the copy number assay for PSTPIP1 gene. 
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The average ratio of the CT value for NAMPT to the CT value for RNAse P in 
the CML samples multiplied by 2 was found to be 2.11 (range 1.60–2.32). This value 
was slightly higher but not significantly different to the ratio observed in CML 
remission samples and non-CML individuals (1.92 and 2.0, respectively; ranges 1.62-
2.24 and 1.76-2.21, respectively; Figure  3.9). Similarly the average PSTPIP1 to RNAse 
P CT ratio multiplied by 2 was 1.98 (range 1.68-2.2), which again was not significantly 
different to the ratio observed in CML remission samples and non-CML individuals 
(2.15 and 1.96, respectively; ranges 1.95-2.27 and 1.81-2.35, respectively; Figure  3.10). 
In summary therefore, there was no evidence in support of copy number change at 
either of these loci that had been suggested by the CGH analysis. 
 
Figure ‎3.9 NAMPT Copy number analysis by DNA real-time PCR of CML diagnostic samples, CML 
remission samples and non-CML individuals. There was no evidence for aberrant copy number in the 
CML samples. 
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Figure ‎3.10 : PSTPIP1 Copy number analysis by DNA real-time PCR of CML diagnostic samples, 
CML remission samples and non-CML individuals. There was no evidence for aberrant copy number 
in the CML samples. 
Taken together these results argue against the results of the CGH that indicated 
highly recurrent copy number changes involving these genes. Further investigation of 
this discrepancy was therefore undertaken using alternative techniques.  
3.4.2.2 Paralog Ratio Test (PRT) 
The paralog ratio test (PRT), first described by Armour et al (Armour et al. 
2007), was performed as an alternative means of substantiating the overrepresentation 
of NAMPT identified by CGH. The assay works by simultaneously amplifying a region 
within NAMPT and a control pseudogene on chromosome 16 using a single primer pair 
(Figure  3.11a). The amount of product from the two loci, which differ in length by 
several base pairs, is then accurately compared. Genomic DNA from PMN cells from 
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diagnosis and remission (following treatment with imatinib after which complete 
cytogenetic response was reached) was used. We found that the average ratio for test 
versus reference loci was higher at diagnosis than at remission (1.20 vs. 1.0, 
respectively; range 1.00 to 1.33 vs. 0.93 to 1.12, respectively; p=0.001). In a paired 
analysis the PRT ratio in the diagnostic samples was significantly different from the 
ratio in the same patient’s remission samples (p=0.001, Wilcoxon signed ranks test; 
Figure  3.11b). Although significantly different to the remission samples, it should be 
noted that the PRT ratio at diagnosis was not as high as would be expected for a single 
copy gain (1.5). 
 
Figure ‎3.11 Paralog Ratio Test (PRT) to explore over-representation of the NAMPT locus. A) 
Principle of PRT showing visualisation PCR products from NAMPT test locus (225bp) and a NAMPT-
related pseudogene reference locus (235bp) by capillary gel electrophoresis in control sample and CML 
patient, a ratio of peak intensities is calculated for each sample. B) Paired comparison of PRT ratios in 
CML diagnostic and remission samples from the same patient. A significant increase in ratio is observed 
in the diagnostic samples (p=0.001, Wilcoxon signed ranks test), however this ratio is less than the 1.5 
ratio that would be expected for a 1-copy gain. 
3.4.2.3 Quantification of allelic ratio of heterozygous polymorphisms 
In a further attempt to confirm a putative amplification of the NAMPT gene, 
allelic ratio tests were performed using two SNPs found within the region shown to be 
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amplified by CGH (rs10808150 and rs4730153) as well as a 3bp deletion 
polymorphism (rs35301913) (Figure  3.12a). In the case of amplification, one would 
expect to see an imbalance of allelic ratio in individuals heterozygous for any of these 
polymorphisms, as the chromosome containing the amplification should harbour an 
extra copy of one allele. Thus, a ratio of other than 1:1 (eg 2:1), for a heterozygous 
SNP, would indicate a copy number change, whereas a ratio of approximately 1:1 
would indicate a lack of allelic imbalance and therefore argue against copy number 
change. Results were also compared to germ line samples, in which no acquired copy 
number change was expected. The allelic ratios for all three polymorphisms are shown 
in (Figure  3.12b). Importantly, no significant difference was observed between the 
ratios in the CML samples and the corresponding germline samples for all 
polymorphisms tested (p>0.05), consistent with absence of allelic imbalance, and thus 
absence of copy number change in the tumour samples.  
 
Figure ‎3.12 Investigation of allelic imbalance within the NAMPT gene at the site of two single 
nucleotide polymporphisms and an insertion/deletion polymorphism. A) Capillary sequencer trace 
showing an approximate 1:1 ratio for the NAMPT 3bp indel in CML and germline (remission) tissue. B) 
Summary of allelic ratio for indel and both SNPs in CML patients and non-CML germline samples, 
supporting absence of allelic imbalance and thus, absence of true copy number change. 
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The results of different methods of copy number analysis for the NAMPT gene 
can therefore be summarised as follows: 
1) CGH indicated copy number gain. 
2) Real time DNA-based PCR indicated a slight increase that was not 
significant. 
3) Paralog ratio test indicated a significant increase but less than a whole 
integer. 
4) Allelic ratio test indicated a 1:1 ratio for heterozygous polymporphisms; 
excludes copy number change. 
We hypothesised that the cause of this apparent discrepancy between CGH/PRT 
and RT-qPCR/allelic ratio could be the presence of differential chromatin condensation 
between the CML samples and the remission/germline reference DNA. Such alterations 
in chromatin structure might lead to a relative protection of these genes in the CML 
samples from nuclease activity associated with the cell lysis and DNA extraction 
process, thus resulting in a moderate enrichment of these regions compared to reference 
DNA derived from non-CML haematopoietic cells, while maintaining a 50:50 ratio for 
heterozygous polymorphisms.  
3.4.3  Expression analysis genes subject to recurrent copy number calls  
To further investigate the hypothesis that genes classified as aberrant by CGH 
may in fact harbour epigenetic, rather than genetic changes. The expression level of 
NAMPT and PSTPIP1 in the PMN cells of 12 CML patients who had been tested by 
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CGH array was compared to that of normal controls. Both genes were expressed at a 
significantly lower level in CML patients than normal counterparts (p<0.001; Figure 
 3.13). This finding therefore supports the theory that the recurrent focal copy number 
changes identified by self-referenced CGH may reflect the impact of chromatin 
condensation on the ability of genes in the CML samples to withstand mild nuclease 
exposure during cell lysis. 
 
 
Figure ‎3.13 Comparison of expression of NAMPT and PSTPIP1 in granulocytes from CML patients 
at presentation (n=12) and non-CML individuals. Significantly lower gene expression in CML. Both 
genes are expressed at a significantly lower level in CML samples. 
It was therefore of interest to measure gene expression in the remaining genes in 
which recurrent copy number calls had been observed. Since the majority of genes were 
plausible functional candidates this may reveal important information about key 
deregulated genes in CML, in spite of an absence of demonstrable copy number 
change. In addition it may provide further evidence in support of differential chromatin 
modification as a cause of false positive array CGH copy number calls. 
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Having demonstrated that NAMPT and PSTPIP1 showed significantly lower 
expression in CML, the expression of the remaining 30 genes classified as recurrently 
aberrant by CGH of CML diagnostic samples from the same 32 CML patients on which 
CGH had been performed was measured by real-time PCR using the TaqMan
®
 low 
density microarray (TLDA) platform.  
Interestingly we observed that twelve of the 30 genes were significantly under 
expressed in CML samples compared to PMN cells from normal donors (Figure 3.14A-
L). A further ten genes showed no significant change between the two sample types, 
while expression of the remaining eight genes was undetectable in both the CML 
samples and the normal controls. Our observation that the majority of these genes are 
under-expressed in CML samples is in keeping with the theory that these genes may 
play a role in CML pathogenesis. This observation also supports our theory that 
chromatin modification may play a role in generating artefactual CGH calls.  
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Figure ‎3.14 Of 30 genes that showed aberrant copy number calls by CGH, 12 showed significantly 
different expressions between CML (n=32) & Normal (n=8) samples. A)DUSP1, B)PTPRE, 
C)STK17B, D)ADAMTSL4, E)CABIN1, F)CSNK1D, G)HIST2H2BE, H)LITAF, I)PLK3, J)SCYL1, 
K)SLC16A3, L)SRGN. 
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3.4.4 Investigation of chromatin condensation in NAMPT and PSTPIP1 using a 
nuclease sensitivity assay  
Our finding of reduced expression of many of the genes that generated false 
copy number calls by CGH supports a theory that epigenetic modification leading to 
altered chromatin structure which may play a role in generating false copy number 
calls. 
Gross changes in chromatin condensation that result from epigenetic 
modification may be investigated using a “nuclease sensitivity” assay in which 
micrococcal nuclease (MNase) is used to preferentially digest any DNA that is not 
bound to a nucleosome. The nucleosome is the basic repeating unit of chromatin, and 
plays a critical role in transcription. The positioning of nucleosomes on a promoter 
determines its responsiveness to gene inducing signals, and thus is a means by which 
gene expression can be altered in cancer. In a nuclease sensitivity assay, regions of 
interest are interogated by real-time DNA-qPCR. A high amount of product from the 
locus, relative to a control sample, indicates a relative increase in nucleosome density 
and thus more condensed chromatin resulting in lower gene expression (Figure  3.15). 
 
  
107 
 
 
Figure ‎3.15 Schematic diagram showing Nucleosome Density Assay. Chromatin is digested via a 
nuclease to produce mononucleosomes, following deprotienization, The remaining DNA is amplified via 
qPCR. This amplification will be more efficient in regions that are bound in nucleosomes than in regions of 
open chromatin that may indicate active genes or promotors [modified from (Gevry et al. 2009)]. 
We therefore investigated the promoter regions of NAMPT and PSTPIP1 for 
evidence of disease specific chromatin condensation that may explain their reduced 
expression in CML and help to support the theory that false copy number calls had 
resulted from differential chromatin condensation at these loci. 
A nuclease sensitivity assay was designed that was specific for a region within 
the NAMPT promoter using six overlapping real time PCR assays. PMN cells from 6 
CML patients were treated with MNase prior to DNA extraction. PCR amplification 
data was compared to amplification in cells from a normal individual that had also been 
treated with MNase under the same conditions. A significant rise in the 2
CT
 was 
observed in regions P3, P4 and P5 of the NAMPT promoter in the CML samples 
(Figure  3.16). These findings support the hypothesis that the NAMPT promoter 
undergoes chromatin remodelling in CML in order to modulate gene expression. 
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Figure ‎3.16  Real time qPCR amplification at the NAMPT promoter following MNase treatment in 
CML PMN cells from 6 patients compared to amplification in MNase treated non-CML cells. A 
significant rise in relative amplification was observed at positions P3, P4 and P5, indicating more 
condensed chromatin in this region in CML cells. 
Chromatin condensation at the PSTPIP1 promoter was also investigated using 
the same nuclease sensitivity assay as described for NAMPT. Five pairs of overlapping 
real-time PCR assays were designed specific for the promoter region. A significant rise 
in 2
CT
 was seen in one of the regions within the PSTPIP1 promoter observed at 
position P4 for which a qPCR assay had been designed. As with NAMPT, this finding 
supports the theory that PSTPIP1 expression is modulated in CML via chromatin 
remodelling (Figure  3.17). 
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Figure ‎3.17 Real time qPCR amplification at the PSTPIP1 promoter following MNase treatment in 
CML PMN cells from 4 patients compared to amplification in MNase treated non-CML cells. A 
significant rise in relative amplification was observed at position P4, indicating more condensed chromatin 
in this region in CML cells. 
3.4.5 Use of 5-AZA to investigate the role of methylation in modulating the 
expression of candidate genes in CML CD34+ cells 
The results of the nuclease sensitivity assay were consistent with epigenetic 
modification of both NAMPT and PSTPIP1. Since methylation is a common and well-
characterised method of chromatin remodelling and gene silencing, we decided to 
investigate the role of methylation in control of expression in seven of our candidate 
genes (NAMPT, PSTPIP1, CSNK1D, LITAF, PLK3, SLC16A3 and STK17B), using the 
demethylating agent azacytidine (5-azacytidine; 5-AZA). 
Azacytidine is a chemical analogue of cytosine nucleoside found in DNA and 
RNA. It can remove methyl groups from DNA, thus if expression of a gene of interest 
is found to increase after 5-AZA exposure, one may conclude that the gene exhibits a 
degree of methylation. A similar experiment has been previously performed on known 
hypermethylated CpG islands of the genes JUN, MAFB, KLF11, SSIAH2, and ZNF516 
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in the CML cell line U937, all of which showed a significant increase in expression 
after treatment with decitabine (aka 5-aza-2′-deoxycytidine; (Gebhard et al. 2006)). 
We therefore similarly measured the expression of 7 genes previously found to 
be under-expressed in CML (NAMPT, PSTPIP1, CSNK1D, LITAF, PLK3, SLC16A3 
and STK17B) on CML CD34+ cells before and after exposure to 5-AZA, and compared 
to the results to those obtained from normal CD34+ untreated cells. In all genes tested 
there was a trend towards increased expression after 5-AZA exposure, that rose with 
increasing concentration of the drug, supporting a role for methylation in down-
regulating these genes expression in CML. Interestingly, at higher concentrations of the 
drug, the majority of genes showed higher expression than in normal untreated cells, 
suggesting that the genes are also methylated in hematopoietic tissue of normal 
individuals, albeit to a far lesser degree. The significance level for treatment with 
2.5M 5-AZA for STK17B was p<0.05 whilst those for SLC16A3, CSNK1D and PLK3 
were each p<0.001 (Figure  3.18). 
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Figure ‎3.18 Effect of 5-Azacytidine on expression of 7 genes previously shown to be down-regulated in CML Analysis was performed using the TLDA system on CML 
CD34+ cells (n=3) after different dose of 5-Azacytidine (5-AZA) expressed as a fold change compared to untreated normal CD34+ cells. Expression is shown as a fold change 
compared to non-CML cells. A trend of increased expression with increasing concentrations of 5-AZA was observed for all genes. At higher concentration expression was 
significantly different to that in non-CML cells for STK17B, SLC16A3, CSNK1D and PLK3. 
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Combined analysis of all 7 genes at different exposures also demonstrated a 
significant trend towards increased expression with increasing exposure to 2.5μM of 5-
AZA with p<0.001(Figure  3.19). 
 
Figure ‎3.19 Effect of 5-Azacytidine on combined expression of the same 7 genes shown in (Figure 
‎3.18). Transcription (expressed as a fold change compared to untreated normal CD34+ cells) was 
observed to rise with increasing concentrations of 5-AZA. 
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3.5 Discussion  
The BCR-ABL1 fusion oncoprotein is involved in the initiation of CML and 
drives several key features including genomic instability, loss of tumour suppressor 
function and differentiation arrest. However, the presence of BCR-ABL1 alone is 
inadequate to explain the substantial clinical heterogeneity found in CML patients 
throughout the course of the disease (Marmont et al. 1984), suggesting that other 
aberrations that affect transcription of key genes might be present that could be 
detectable using global screening methods such as array CGH. Array CGH studies in 
CML to date are limited in number and have focussed mainly on identifying lesions 
associated with disease progression (Brazma et al. 2007;Mullighan et al. 2008). In 
addition, normal copy number variation was not accounted for in the latter reports. We 
therefore performed a comparable study using a high-resolution array and a paired 
design meaning that polymorphic CNVs would not feature on the list of observed 
imbalances. This analysis revealed apparent copy number aberrations in all 32 CML-
CP patients. The aberrations were mostly amplifications but deletions were also noted. 
Some of the aberrations appeared to have occurred randomly, but in other cases they 
involved known genes with an apparent high degree of recurrence. The most common 
aberrations were focal amplification of the NAMPT, PSTPIP1, and STK17B detected in 
65%, 50%, and 33%, respectively, in all patients. The majority of genes for which such 
recurrent copy number calls were observed were strong candidates for a role in 
granulopoiesis or cancer propagation. Genes at the site of the two most commonly 
observed copy number calls, NAMPT and PSTPIP1 were selected as models for further 
confirmatory testing using tailored molecular assays.  
  
114 
Of the two confirmatory copy number assays, PRT and real-time PCR, the 
former was consistent with moderate enrichment at the NAMPT locus in CML samples, 
albeit in 100% of patients, not only those for which copy number aberration had been 
suggested by CGH. However, the level of enrichment, indicated by the PRT ratio, 
appeared to be less than a single integer, and therefore lower than would be expected 
for a single-copy gain in all Ph+ cells. While the TaqMan
®
 assay showed a trend 
towards higher amplification for NAMPT in CML samples, this was not significant.  
In view of the conflicting information provided by the copy number assays, we 
also applied an allelic ratio test, designed to provide an approximate enumeration of 
alleles of three known heterozygous polymorphisms within NAMPT. Importantly this 
provided no evidence of skewing of the normal allelic ratio, and ratios were not 
significantly different to those obtained from germline samples from the same patients. 
We hypothesised that the cause of this apparent discrepancy between 1) a 
suggestion of enrichment at these loci by CGH/PRT and 2) exclusion of true copy 
number change by measurement of allelic ratio could be the occurrence of differential 
degradation of these genes in CML samples and their non-CML counterparts. Changes 
in chromatin architecture represent a mechanism by which such differential degradation 
could take place, since in theory areas of condensed chromatin would be relatively 
protected from the nuclease exposure inherent to the cell lysis and DNA extraction 
process. If chromatin condensation occurred in CML but not normal samples, this could 
result in relative over-representation of protected regions in CML samples that would 
manifest as copy number change using methods such as CGH, while maintaining a 
50:50 ratio for heterozygous SNPs. It would be important to verify such a hypothesis, 
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not only to explain our discrepant results, but also to confirm disease-specific 
regulation of these genes that might be important in the investigation of CML 
pathogenesis. 
In keeping with our theory, 14 of 32 (58%) genes that appeared to harbour copy 
number aberrations in at least 4/32 patients by CGH showed significantly lower 
expression in diagnostic cDNA samples from the same 32 patients, including our model 
genes NAMPT and PSTPIP1. Furthermore, a nuclease sensitivity assay was consistent 
with disease specific chromatin condensation in the promoter region of the latter two 
genes. We also measured expression of seven of the 32 genes in 5-AZA-treated stem 
cells from CML patients, and all showed increased expression relative to normal 
CD34+ untreated cells consistent with disease-specific methylation at these loci.  
While the above data support our theory that chromatin modification may have 
produced aberrant CGH calls in the CML samples, it should be noted that confirmatory 
assays were only applied to two of the genes implicated by CGH, therefore it remains 
possible that true copy number change was present at one or more of the remaining loci 
in a proportion of the patients. However, since the pattern of apparent copy number 
change was universal for all 32 genes, i.e. focal change involving little flanking 
material, accompanied, in the majority of genes, by a paradoxical reduction in 
expression, we believe our hypothesis may cautiously be applied to all identified genes. 
It remains unclear whether CpG methylation is the mechanism governing chromatin 
condensation in all identified genes, since expression of only seven genes were 
measured after treatment with 5-AZA. However the results of this analysis were 
consistent with a role for methylation in modulating activity of these seven genes in 
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CML, as has been shown to be the case for many genes in cancer (Das et al. 2004). 
Interestingly an in-house screen of the promoter regions of NAMPT and PSTPIP1 
showed no evidence of CpG methylation by bisulphite sequencing (Khorashad JS, 
unpublished data), implicating either methylation in a critical site elsewhere within the 
structure of these genes, or an alternative method of control of expression.  
Notwithstanding the absence of verifiable genomic aberrations, this 
investigation has revealed disease specific down-regulation of 14 genes in 
haematopoietic tissue of patients with chronic myeloid leukaemia, namely NAMPT, 
PSRPIP1, DUSP1, PTPRE, STK17B, ADAMTSL4, CABIN1, CSNK1D, HIST2H2BE, 
LITAF, PLK3, SCYL1, SLC16A3 and SRGN. The majority of these genes either have a 
proven association with aspects of cancer pathogenesis, or have functions which, if 
abrogated, would be consistent with the deregulated haematopoiesis that is 
characteristic of CML.  
The key functions of these genes in relation to myeloid leukaemogenesis are 
summarised in Table  3-1 however, a few are of particular note. NAMPT (Nicotinamide 
phosphoribosyltransferase, EC 2.4.2.12) is the rate-limiting enzyme of the 
Nicotinamide adenine dinucleotide (NAD+) biosynthetic pathway catalyzing the 
transfer of a phosphoribosyl group from 5-phosphoribosyl-1-pyrophosphate to 
nicotinamide, forming nicotinamide mononucleotide (NMN) and pyrophosphate 
(Garten et al. 2009). The end product of this pathway, NAD+, Nicotinamide 
phosphoribosyltransferase (NAMPT), converts nicotinamide to nicotinamide 
mononucleotide (NAD+), an essential cofactor that has been implicated in a broad 
range of cellular functions such as immune response to inflammation, DNA repair 
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(Garten et al. 2011) and metabolism, the latter as an insulin-mimetic hormone also 
known as Visfatin (Revollo et al. 2007). NAD+ has been shown to regulate the activity 
of sirtuins, which are enzymes involved in various metabolic and stress pathways 
(Skokowa et al. 2009). NAMPT has been implicated in the immune response, beta-cell 
development, insulin signalling, myeloid differentiation and cancer (Garten et al. 2009). 
In particular, in vitro studies have shown that NAMPT-mediated catalysis of NAD+ 
induces granulocyte differentiation of CD34+ haematopoietic progenitor cells in a 
GCSF-dependent pathway that governs SIRT1 activity (Ho et al. 2009;Skokowa et al. 
2009).  
Increased SIRT1 activity in turn leads to upregulation of C/EBP-α and/or 
C/EBP-β dependent G-CSF and G-CSFR synthesis, with subsequent induction of 
granulopoiesis via an autoregulatory feedback loop which promotes neutrophil 
differentiation (Figure  3.20; (Khanna-Gupta et al. 2009). Thus, NAMPT is involved in 
myeloid differentiation pathways which are central to the pathogenesis of CML. 
 
Figure ‎3.20 Granulocyte colony-stimulating factor (G-CSF)-induced myeloid differentiation 
involves NAMPT. GCSF activation induces NAMPT expression, leading to increased NAD, in which 
effects SIRT1 activity and subsequently induces NAMPT via the up-regulation of G-CSF through a 
feedback loop [modified from (Khanna-Gupta et al. 2009)]. 
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In another study it was shown that NAMPT expression can induce activity of 
SIRT1 (Ho et al. 2009), therefore it is plausible that that a low level of NAMPT 
transcript in CML cells, as observed in the present study, might reduce the function of 
SIRT1 and consequently change the cell cycle pattern towards proliferation rather than 
differentiation. NAMPT is also involved in the maturation of B cell precursors, and 
hence was previously named PBEF1 (Pre-B-cell colony-enhancing factor1); (Skokowa 
et al. 2009).  
Proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1) has a role 
in regulation of the actin cytoskeleton (McWhirter et al. 1993) and importantly, has 
been implicated in the dephosphorylation of ABL1, causing down-regulation of ABL 
tyrosine kinase activity (Cong et al. 2000). The latter report described hyper-
phosphorylation and increased activity of ABL occurring in the presence of a dominant 
negative form of PSTPIP1. The observation of decreased PSTPIP1 expression in CML 
is intriguing since, according to the observations of Cong et al, this would cause 
decreased dephosphorylation of BCR-ABL1 resulting in higher BCR-ABL1 tyrosine 
kinase activity (Cong et al. 2000). It is thus plausible that down-regulation of this gene 
helps to mediate oncogenesis in BCR-ABL1-positive cells. Further studies on the effect 
of varying PSTPIP1 expression in a CML cell line model may be useful in confirming 
the involvement of this gene in the biology of CML.  
Serine/threonine kinase 17b (STK17B), also known as Death-associated protein-
related apoptotic kinase-2 (DRAK2), is a serine-tyrosine kinase that belongs to a novel 
family of serine/threonine kinases that triggers apoptosis (Sanjo et al. 1998). 
Interestingly, STK17B down-regulation is known to be dependent on high COX-2 
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expression (Doherty et al. 2009), which has itself previously been shown to be a feature 
of CML (Giles et al. 2002). Further work is therefore mandatory to 1) confirm a 
functional role for STK17B silencing in CML, and 2) investigate COX-2 inhibition as a 
potential means of reversing STK17B silencing and thereby inducing apoptosis in CML 
cells (see chapter 5). 
Interestingly, four genes (PLK3, CABIN1, CSNK1D and LITAF) were identified 
with a known association with the p53 tumour suppressor pathway, itself a key aspect 
of CML disease progression. Polo-like kinase 3 (PLK3) is one of the PLK family, and 
plays an important role in the regulation of mitosis, and DNA damage checkpoint 
activation. Overexpression of PLK3 causes significant cell cycle arrest and cytokines 
defects, leading to mitotic apoptosis, in part via the p53 pathway (Xie et al. 2001). The 
latter observation is consistent with our observation of lowered PLK3 expression in 
CML, suggesting that reduced expression may confer a proliferative advantage to CML 
cells. Interestingly we also identified silencing of another p53-related gene calcineurin 
binding protein 1 (CABIN1), in CML. In a recent study, Cabin1 was found to control 
the expression of a subset of p53 target genes, via physical interaction with p53 and 
subsequent regulation of chromatin structure of specific p53 target promoters (Jang et 
al. 2009). One might therefore expect to see upregulation of CABIN1 in CML, rather 
than the down-regulation we detected. The role of this gene in CML, if any, therefore 
requires further clarification. CSNK1D has been reported to phosphorylate p53, and a 
role in a regulatory feedback loop involving p53 and CK1delta has been proposed 
(Knippschild et al. 1997). Moreover, CSNK1D has been found to be highly expressed in 
haematopoietic cells and mature granulocytes and has a role in DNA replication and 
repair (Okamura et al. 2004). The fourth p53-related gene that showed transcriptional 
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downregualtion in our study was LITAF. Interestingly, LITAF transcription is induced 
by p53 expression (Matsumura et al. 2004). Silencing of LITAF may therefore be a 
surrogate marker of down-regulation of p53. 
Interestingly, two further noteworthy genes, PTPRE and DUSP1, have a known 
a role in the mitogen-activated protein (MAP) kinase pathway. The RAS-MAPK 
pathway is one of the major signalling pathways activated by BCR-ABL1 in CML, 
causing uncontrolled proliferative signalling (Goldman et al. 2003). The DUSP1 
protein has intrinsic phosphatase activity, and specifically inactivates mitogen-activated 
protein (MAP) kinase in vitro by the concomitant dephosphorylation of both its 
phosphothreonine and phosphotyrosine residues (Pomerance et al. 1992). DUSP1 also 
has known roles in cell growth, death, and cancer (Boutros et al. 2008). The second 
MAPK-related gene, protein tyrosine phosphatase, receptor type, E (PTPRE), is a 
member of the protein tyrosine phosphatase (PTP) family that have roles in a variety of 
cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic 
transformation through indirect down regulation of MAPK signalling (Kraut-Cohen et 
al. 2008). It is therefore tempting to speculate that silencing of both DUSP1 and PTPRE 
is required for MAPK pathway activation in CML. 
3.6 Summary 
In summary, recurrent putative gene copy number aberrations were observed by 
CGH analysis of diagnostic samples from CML patients. These changes without 
exception conformed to a universal pattern of focal copy number change, 
predominantly gain, involving single genes with little or no flanking material. The two 
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most commonly observed of these, involving the NAMPT and PSTPIP1 genes, were 
subsequently investigated further using a range of targeted molecular assays. While the 
findings of these targeted assays were consistent with moderate enrichment of the 
regions tested, allelic ratios were not skewed, arguing against true copy number 
aberration. Furthermore, genes within the majority of loci at which recurrent copy 
number gain had been observed by CGH analysis showed a paradoxical decrease in 
expression. Taken together these investigations suggest that these distinctive apparent 
aberrations were not true copy number changes. Furthermore they support a theory that 
the integrity of CGH data from highly purified tumour cell populations using tissue 
matched germline DNA as reference material may be susceptible to disease-specific 
differences in chromatin condensation. This theory was supported by a nuclease 
sensitivity assay, which revealed a more condensed chromatin structure in the promoter 
regions of NAMPT and PSTPIP1, and by treatment of CML CD34+ cells with the 
demethylating agent 5-AZA, which appeared to increase expression of all down-
regulated candidate genes tested. 
While these findings are intriguing from a methodological perspective, they are 
also in keeping with the broad aims of this chapter in that fourteen genes were 
identified, albeit serendipitously, that showed disease-specific down-regulation in 
CML. The majority of these genes were plausible functional candidates worthy of 
further investigation.  
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3.7 Future investigation  
This study has identified reduced expression in a number of genes with a 
plausible role in CML pathogenesis. All of these genes warrant functional analysis in 
an in vitro CML model. Functional analysis of one of these genes, STK17B will be the 
focus of chapter 5. In addition the potential importance of these genes in CML 
pathogenesis raises the question of whether the precise expression level of one or more 
of these genes may be of prognostic value in predicting response to TKI therapy or 
length or likelihood of progression to blast crisis, as was shown to be the case for 
MECOM in chapter 2. The predictive value of all 14 down-regulated genes will be the 
focus of the next chapter. 
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CHAPTER 4 : Validation of candidate prognostic 
factors from differentially expressed genes identified 
by CGH on CML samples  
4.1 Introduction 
Despite a consistent pathological lesion chronic myeloid leukaemia patients 
display a paradoxical clinical heterogeneity particularly in length of chronic phase and 
time to progression to blast crisis. This variability remains evident even in the TKI era. 
A long-standing goal of CML translational research has therefore been to identify 
robust factors that may predict clinical outcome. 
The Sokal score, and Hasford score (Hasford et al. 1998;Sokal et al. 1984) are 
the conventional prognostic scoring systems that allow some discrimination of risk 
groups with a different response rate, progression-free and overall survival, based on 
individuals age, platelet count, spleen size, and blood myeloblasts proportion (Table 
 4-1). The Sokal score is generally unable to distinguish well between the low and 
intermediate risk groups – a shortcoming that the Hasford score, which also takes into 
account the blood percentages of eosinophils and basophils, was designed to overcome.  
In addition, haematologic, cytogenetic, and molecular responses to treatment, the 
amount of CD34+ cells at diagnosis and cytogenetic evolution have also been shown to 
offer prognostic information (Assouline et al. 2011).  
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Table ‎4-1 Comparison of the Sokal and Hasford scoring systems, the main prognostic risk 
calculation systems for CML (Hernandez-Boluda et al. 2009). 
Variables Sokal score
a
 Hasford score
b
 
Age 0.0116 × (age − 43.4) 0.6666 [when age >50] 
Spleen, cm below 
costal margin 
+0.0345 × (spleen 
size − 7.51) 
+0.042 × spleen size 
Platelet count, × 109/L 
+0.188 × ([platelets/700]2 − 0
.563) 
+1.0956 [when platelets 
>1.500] 
Blood blasts, % +0.0887 × (blasts − 2.1) +0.0584 × blasts 
Blood basophils, % - 
+0.2039 [when 
basophils >3%] 
Blood eosinophils, %  +0.0413 × eosinophils 
Risk Sokal score
a
 Hasford score
b
 
Relative risk <0.8 <780 
Low risk 0.8–1.2 781–1.480 
Intermediate risk >1.2 >1.480 
a
Sokal risk is expressed as exponential of the total.  
b
Hasford risk is expressed as the total × 1.000.  
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Gene expression profiling in CML has identified aberrant gene expression in 
numerous cellular processes including signal transduction, cell cycling, apoptosis, cell 
adhesion, DNA repair, differentiation, metabolism and chromatin dynamics (Nowicki 
et al. 2003), raising the possibility that this approach may also reveal prognostic 
biomarkers. Several studies have been able to differentiate patients in a particular 
disease phase based on gene expression signatures, allowing a more defined diagnosis 
of disease phase than morphological criteria (McWeeney et al. 2010;Oehler et al. 
2009;Radich et al. 2006). Several groups were able to predict a patient’s likelihood of 
failure to achieve cytogenetic response (McWeeney et al. 2010) as well as 
distinguishing those with primary or secondary resistance (Zhang et al. 2009) by use of 
expression array profiling. The survival in patients treated with TKI has also been 
predicted based on their gene expression signature in diagnostic samples (de Lavallade 
et al. 2010;Yong et al. 2006). High expression of CD7 in CD34+ cells coupled with low 
expression of PR-3 or ELA2, for example, was shown to correlate with poor survival. 
Similarly, low expression of CD7 with high PR-3 or ELA2 levels were associated with 
longer survival (Yong et al. 2006). Nevertheless gene expression profiling has yet to 
demonstrate the discriminative power required for use in the routine management of 
patients and alternative methods of stratifying patients are needed.  
CRKL, a substrate and surrogate marker for BCR-ABL1 activity has recently 
been assessed for its ability to predict clinical response to imatinib, albeit with 
somewhat with contradictory findings. White et al (White et al. 2005); found in vitro 
inhibition of phosphorylated CRKL to be of predictive value, while Bazeos et al 
(Bazeos et al. 2010) did not. Failure to confirm the predictive power of CRKL 
phosphorylation in the latter study is thought to reflect the diverse effects of imatinib on 
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different cell populations; White et al studied mononuclear cells while Bazeos et al 
(Bazeos et al. 2010;Bazeos et al. 2009) focused on CD34+ cells.  
SLC22A1, the organic cation transporter enabling imatinib (IM) entry into the 
cell, has shown to be predictive of achieving MMR in patients treated with IM. High 
SLC22A1 activity was shown in one study to predict achievement of MMR by 24 
months. Less than half of those patients (45%) with a low SLC22A1 activity fail to 
achieve this goal (White et al. 2007). Analysis over 5-years comparing patients with 
high versus low SLC22A1 activity, suggests the activity level of SLC22A1 not only has 
predictive significance of an initial molecular response but may also predict long-term 
treatment outcomes (White et al. 2010).  
Finally, patients with an increased expression of JunB, a transcription factor 
important in haematopoiesis, are statistically more likely to achieve a major cytogenetic 
and molecular response than individuals with no increase in expression (Liu et al. 
2006). However, as with global gene expression profiling, no individual factor has yet 
been identified that provides a sufficiently robust discrimination for clinical use. 
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4.2 RQ-PCR identification of potential biomarkers 
In the previous chapter we identified 14 genes that were significantly under-
expressed in CML compared to tissue matched samples from normal individuals. 
Rationalising that these genes may be important in disease pathogenesis, we also 
hypothesised that the expression of a proportion of the genes may have prognostic 
significance. We therefore aimed to carry out the following sequential investigations: 
1) Preliminary investigation of level of candidate gene expression in 
patients who respond optimally to imatinib compared to those that 
fail to achieve cytogenetic response by 18 months (primary 
resistance) using the previous test cohort of 32 CML patients, 
segregated according to response, in order to obtain a list of 
potentially predictive genes for further analysis. 
2) The expression of any genes that show differential levels of 
transcription according to imatinib response status in the test cohort 
will be measured in a large unselected cohort of CML patients. 
Association of gene expression with imatinib response, survival, 
progression free survival and likelihood of achieving CCyR/MMR 
will be assessed. 
3) The prognostic value of any genes that appear to predict outcome in 
the first unselected cohort will be validated in a second unselected 
cohort. 
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4.3 Material and method 
4.3.1 Patients 
The clinical details of patients are described in an earlier chapter (section 3.3.1) 
4.3.2 RNA Concentration Measurements 
Measurement of RNA concentration was performed as described in (section  3.3.7). 
4.3.3 Complementary DNA (cDNA) Preparation 
cDNA was prepared as described in (sections  3.3.6). 
4.3.4 Gene Expression Assays for investigation of prognostic significance. 
Real-time qPCR (RQ-PCR) was performed to measure levels of gene 
expression and was carried out using TaqMan
®
 Gene Expression Assays (Applied 
Biosystems, Foster City, USA). For NAMPT, STK17B, SLC16A3, PSTPIP1, PTCH1 
and CSNK1D genes pre-designed primer and probe mixes were used (NAMPT, 
Hs00237184_m1- FAM
™
; STK17B, Hs00177790_m1- FAM
™
; SLC16A3,  
Hs00358829_m1-VIC
®
; PSTPIP1, Hs00182777_m1- VIC
®
, PTCH1, Hs00970980_m1- 
FAM
™
; CSNK1D, Hs01020332_m1- VIC
®
(Applied Biosystems, Foster City, USA)).  
The housekeeping gene GUSB was used as a control gene, for which externally 
designed primers and a probe were used (Appendix 7.5). The latter primer and probe 
sequences were taken from Beillard et al (Beillard et al. 2003); the probe dye was 
adapted to Cy5 to enable multiplexing. 
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Reactions were carried out in a volume of 20µL compromising of 10µL 2x AB 
Taqman
®
 Universal PCR Master mix (Applied Biosystems, Foster City, USA), 7µL 
distilled water, 0.3μM of each primer, 0.2μM probe and 2µL cDNA. The cycling 
conditions started with 50°C for two minutes, an initial hot start step at 95°C for 20 
seconds and 40 cycles of denaturation at 95°C for 3 seconds and a 60°C combined 
annealing and elongation step for 35 seconds. Results were recorded on the 7500 
system v1.4 software (Applied Biosystems). The average level of expression of the 
target genes was calculated using the differences in cycle threshold (CT) values (2
ΔCT
). 
4.3.5 Statistical analysis of the predictive value of expression level of candidate genes 
in unselected cohorts of CML patients 
Each gene was assessed for its ability to predict the following: survival, IM 
failure, achievement of cytogenetic remission and achievement of major molecular 
remission. For each of these categories, each gene’s expression was assessed for 
predictive power in 3 ways: 
1) As a continuous variable.  
2) After segregating the cohort into 2 groups (high vs. low) using the median 
expression of each gene as a threshold.  
3) After segregating the cohort using a threshold determined by the receiver 
operator characteristic (ROC) curve method.  
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While analysis based on ROC-curve threshold was considered to be the most 
statistically rigorous, the other two (analysis as a continuous variable and segregation 
by median) were included to provide further evidence that may be useful to support any 
apparent association between a genes expression and outcome.  
Any gene whose expression was found to be predictive after segregation by the 
ROC-determined threshold was analysed in a validation cohort. Statistical analysis of 
the validation cohort was as above. The prognostic value of genes that showed a 
significant association with any outcome measurement in both test and validation 
cohort was assessed by Kaplan-Meier analysis with significance of p 0.05. 
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4.4 Results 
4.4.1 Identification of candidate genes with potential prognostic value by re-analysis 
of expression data from chapter 3 according to patients’ response to imatinib 
The 32 patients used in chapter 3 comprised 20 patients who responded 
optimally to imatinib achieving CCyR before 18 months, and 12 patients whose 
response was sub-optimal and failed to achieve even a minor cytogenetic response after 
18 months. Using the expression data presented in chapter 3, we were therefore able to 
investigate the existence of any association between gene expression level and response 
at 18 months. This approach was of particular relevance for the 14 genes shown to be 
under-expressed in CML, but was also worthy of investigation for the remaining ten 
genes uncovered by CGH analysis that did not appear to be differentially expressed in 
CML.  
Having segregated patients into the two outcome groups, expression data for all 
32 genes listed in Table  3-1 was analysed in order to identify any genes that showed a 
significantly different expression in the two groups. Importantly, seven of the 14 genes 
found to be down-regulated in CML showed a significantly higher expression in 
optimal responding patients compared to patients who failed to achieve response 
(NAMPT, PSRPIP1, STK17B, CSNK1D, LITAF, PLK3, SLC16A3; Figure  4.1). 
Furthermore, two of the ten genes whose expression was not significantly different in 
CML as a whole compared to normal individuals (BMI1 and PTCH1) showed lower 
expression in the 12 imatinib insensitive patients than the 20 patients whose response 
was optimal (Figure  4.1). 
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Figure ‎4.1 Nine of the genes previously identified by CGH were found to be differentially 
expressed in patients who responded optimally to imatinib (CCyR in 18 months, n=20) compared 
to patients who showed primary resistance to imatinib (absence of CCyR in 18 months, n=12; 
NAMPT, PSRPIP1, STK17B, CSNK1D, LITAF, PLK3, SLC16A3, BMI1, PTCH1)  
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4.4.2 Investigation of predictive value of 9 genes of potential prognostic significance 
in a large unselected cohort of CML patients. 
In order to explore further these preliminary findings, the expression of the 9 
genes that showed significantly different expression between the selected responder and 
non-responder groups (NAMPT, PSTPIP1, STK17B, CSNK1D, LITAF, PLK3, SLC16A, 
BMI1 and PTCH1) was measured in diagnostic samples from an unselected cohort of 
45 CML patients. Expression was correlated with measures of clinical outcome 
including overall survival, IM failure and achievement of CCyR and MMR. 
Six genes were identified whose expression was significantly associated with 
one or more outcome measurement when the cohort was segregated into two groups 
using the ROC-determined threshold, namely NAMPT, PSTPIP1, STK17B, CSNK1D, 
SLC16A3 and PTCH1 (Table  4-2). 
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Table ‎4-2 Statistical analysis of the association of expression of 9 genes in CML diagnostic samples with key outcome measurements 
G
en
e
 
S
u
rv
iv
a
l 
b
y
 i
n
te
n
ti
o
n
 t
o
 t
re
a
t 
(I
T
T
) 
A
ss
o
ci
a
ti
o
n
 a
s 
a
 c
o
n
ti
n
u
o
u
s 
v
a
ri
a
b
le
 (
p
) 
A
ss
o
ci
a
ti
o
n
 w
h
en
 c
o
d
if
ie
d
 b
y
 
m
ed
ia
n
 (
p
) 
A
ss
o
ci
a
ti
o
n
 w
h
en
 c
o
d
if
ie
d
 b
y
 
R
O
C
 (
p
) 
IM
 f
a
il
u
re
 
A
ss
o
ci
a
ti
o
n
 a
s 
a
 c
o
n
ti
n
u
o
u
s 
v
a
ri
a
b
le
 (
p
) 
A
ss
o
ci
a
ti
o
n
 w
h
en
 c
o
d
if
ie
d
 b
y
 
m
ed
ia
n
 (
p
) 
A
ss
o
ci
a
ti
o
n
 w
h
en
 c
o
d
if
ie
d
 b
y
 
R
O
C
 (
p
) 
A
ch
ie
v
em
en
t 
o
f 
C
C
y
R
 
A
ss
o
ci
a
ti
o
n
 a
s 
a
 c
o
n
ti
n
u
o
u
s 
v
a
ri
a
b
le
 (
p
) 
A
ss
o
ci
a
ti
o
n
 w
h
en
 c
o
d
if
ie
d
 b
y
 
m
ed
ia
n
 (
p
) 
A
ss
o
ci
a
ti
o
n
 w
h
en
 c
o
d
if
ie
d
 b
y
 
R
O
C
 (
p
) 
A
ch
ie
v
em
en
t 
o
f 
M
M
R
 
A
ss
o
ci
a
ti
o
n
 a
s 
a
 c
o
n
ti
n
u
o
u
s 
v
a
ri
a
b
le
 (
p
) 
A
ss
o
ci
a
ti
o
n
 w
h
en
 c
o
d
if
ie
d
 b
y
 
m
ed
ia
n
 (
p
) 
A
ss
o
ci
a
ti
o
n
 w
h
en
 c
o
d
if
ie
d
 b
y
 
R
O
C
 (
p
) 
LITAF NS NS NS NS NS NS NS NS NS NS NS NS 
NAMPT NS NS NS NS NS 0.028 0.013 NS 0.015 0.049 NS 0.05 
PLK3 NS NS NS NS NS NS NS NS NS NS NS NS 
PSTPIP1 NS NS NS NS NS NS 0.001 0.04 0.003 0.001 NS NS 
PTCH1 NS NS 0.027 0.003 NS 0.016 0.045 NS NS 0.019 NS NS 
SLC16A3 0.011 NS 0.019 0.0007 0.028 NS NS NS NS NS NS 0.04 
STK17B NS NS NS NS NS NS NS NS 0.016 NS NS 0.05 
BMI1 NS NS NS NS NS NS NS NS NS NS NS NS 
CSNK1D NS NS NS NS NS NS NS NS 0.04 NS NS 0.048 
 
Note: gene expression was significantly associated with clinical outcome the p value is given (grey boxes) otherwise NS (not significant) is indicated. 
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4.4.3 Validation of the predictive value of 6 genes which were significantly associated 
with outcome using a second independent unselected cohort. 
In order to validate the potential prognostic significance of these six genes’ 
expression we obtained a second unselected cohort of 41 CML patients with available 
diagnostic samples. The expression of the six genes in MNC from diagnostic PB 
samples from these patients was compared to outcome measurements as was described 
for the first unselected cohort (Table  4-3). In this validation cohort expression of 4 of 
the six genes (NAMPT, PTCH1, STK17B and CSNK1D) were found to be associated 
with one or more outcome measurement when using the ROC curve-determined 
segregation threshold. 
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Table ‎4-3 Validation of potential prognostic markers in a second unselected cohort (n=41) 
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NAMPT NS NS NS NS 0.014 0.012 NS NS NS NS NS NS 
PSTPIP1 NS NS NS NS NS NS NS NS NS NS NS NS 
PTCH1 NS NS 0.01 NS 0.016 0.01 NS NS 0.001 NS NS NS 
SLC16A3 NS NS NS NS NS NS NS NS NS NS NS NS 
STK17B NS NS NS NS NS NS NS NS NS NS NS 0.03 
CSNK1D NS NS NS NS NS ND NS NS 0.05 NS NS 0.045 
 
Note: gene expression was significantly associated with clinical outcome the p value is given (grey boxes) otherwise NS (not significant) are indicated. 
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A comparison of the outcome analysis in the test and validation cohorts is 
shown in Table  4-4. In summary, four of the six genes whose expression was associated 
with outcome in the test cohort were also associated with outcome in the validation 
cohort. It should be noted however, that expression of only two of these four genes was 
associated with the same outcome measurement in both cohorts: IM failure for NAMPT 
and survival for PTCH1 (Table  4-4). Therefore, while it is plausible that expression of 
all four of these genes when measured at diagnosis may be associated with outcome in 
CML, it would appear that NAMPT and PTCH1 are the strongest predictors. Of these 
two, expression of PTCH1 is associated with multiple outcome measurements, whereas 
expression of NAMPT is associated with IM failure only. This is further evidence in 
support of both the biological importance and potential clinical value of PTCH1. 
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Table ‎4-4 Comparison of the outcome analysis for test and validation cohorts 
G
en
e
 
S
u
rv
iv
a
l 
b
y
 
in
te
n
ti
o
n
 t
o
 t
re
a
t 
(I
T
T
) 
A
ss
o
ci
a
ti
o
n
 w
h
en
 
co
d
if
ie
d
 b
y
 R
O
C
 
(p
) 
K
a
p
la
n
-M
ei
er
 (
p
) 
IM
 f
a
il
u
re
 
A
ss
o
ci
a
ti
o
n
 w
h
en
 
co
d
if
ie
d
 b
y
 R
O
C
 
(p
) 
K
a
p
la
n
-M
ei
er
 (
p
) 
A
ch
ie
v
em
en
t 
o
f 
C
C
y
R
 
A
ss
o
ci
a
ti
o
n
 w
h
en
 
co
d
if
ie
d
 b
y
 R
O
C
 
(p
) 
K
a
p
la
n
-M
ei
er
 (
p
) 
A
ch
ie
v
em
en
t 
o
f 
M
M
R
 
A
ss
o
ci
a
ti
o
n
 w
h
en
 
co
d
if
ie
d
 b
y
 R
O
C
 
(p
) 
K
a
p
la
n
-M
ei
er
 (
p
) 
NAMPT 
Test NS ND Test 0.028 ND Test 0.015 ND Test 0.05 ND 
Validation NS ND Validation 0.012 0.008 Validation NS ND Validation NS ND 
PSTPIP1 
Test NS ND Test NS ND Test 0.003 ND Test NS ND 
Validation NS ND Validation NS ND Validation NS ND Validation NS ND 
PTCH1 
Test 0.027 ND Test 0.016 ND Test NS ND Test NS ND 
Validation 0.01 0.017 Validation 0.01 0.001 Validation 0.001 0.005 Validation NS ND 
SLC16A3 
Test 0.019 ND Test NS NS Test NS ND Test 0.04 ND 
Validation NS ND Validation NS ND Validation NS ND Validation NS ND 
STK17B 
Test NS ND Test NS ND Test 0.016 ND Test 0.05 ND 
Validation NS ND Validation NS ND Validation NS ND Validation 0.03 0.028 
CSNK1D 
Test NS ND Test NS ND Test 0.04 ND Test 0.048 ND 
Validation NS ND Validation ND ND Validation 0.05 0.046 Validation 0.045 0.039 
 
Note: gene expression was significantly associated with clinical outcome the p value is given (grey boxes) otherwise NS (not significant) or ND (not done) are indicated. 
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4.4.4 Kaplan- Meier analysis of genes whose expression was associated with outcome 
when codified using ROC 
Kaplan-Meier analysis was performed to further confirm an association between 
expression of NAMPT, PTCH1, CSNK1D and STK17B with outcome in CML. For 
NAMPT, Kaplan-Meier analysis showed a significant association between gene 
expression and Imatinib failure. Low and high expression groups had a 5 year rates of 
(IFFS) of 42% vs. 72% (p=0.008)(Figure  4.2). Cox regression using NAMPT 
expression (categorised into high and low using the ROC), age and Sokal score 
demonstrated that NAMPT expression was significantly associated with Sokal risk 
score (p=0.004). 
For PTCH1, Kaplan-Meier analysis showed a significant association between 
gene expression and 3 outcome measurements: overall survival, Imatinib failure, and 
achievement of complete cytogenetic response. Low and high expression groups had a 
5 year rates of Imatinib Failure Free Survival (IFFS) of 18% vs. 94% (p=0.001)(Figure 
 4.3), CCyR of 46.1% vs. 100% (p=0.005) and OS CML 74% vs. 100% (p=0.017). Cox 
regression using PTCH1 expression (categorised into high and low using the ROC), age 
and Sokal score demonstrated that PTCH1 expression was an independent predictor of 
Imatinib Failure and CCyR.  
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Figure ‎4.2 Kaplan-Meier survival analysis of an unselected cohort of CML patients according to 
expression of NAMPT, segregated according to ROC analysis. Patients with low NAMPT expression 
(blue line, n=21) had a significantly worse outcome than those with high expression (red lione, n=19; 
p=0.008).  
 
 
Figure ‎4.3 Kaplan-Meier survival analysis of an unselected cohort of CML patients according to 
expression of PTCH1, segregated according to ROC analysis. Patients with low PTCH1 expression 
(blue line, n=19) had a significantly worse outcome than those with high expression (red line, n=16; 
p=0.001).  
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For CSNK1D, Kaplan-Meier analysis showed a significant association between 
gene expression and 2 outcome measurements: achievement of complete cytogenetic 
response and achievement of major molecular response. Low and high expression 
groups had a 5 year rates of CCyR of 76.2% vs. 100% (p=0.046) and MMR 78.7% vs. 
93.8% (p=0.039).  Cox regression using CSNK1D expression (categorised into high and 
low using the ROC), age and Sokal score demonstrated that CSNK1D expression was 
significantly associated with Sokal risk score (p=0.003).  
For STK17B, Kaplan-Meier analysis showed a significant association between 
gene expression and one outcome measurement, namely achievement of major 
molecular response. Low and high expression groups had a 5 year rates of MMR of 
77.1% vs. 94.1% (p=0.028; Figure  4.4). Cox regression using STK17B expression 
(categorised into high and low using the ROC), age and Sokal score demonstrated 
that STK17B expression was significantly associated with Sokal risk score (p=0.025). 
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Figure ‎4.4 Kaplan-Meier analysis of achievement of MMR in an unselected cohort of CML patients 
according to expression of STK17B, segregated according to ROC analysis. Patients with low 
STK17B expression (blue line, n=18) had a significantly worse outcome than those with high expression 
(red line, n=22; p=0.028).  
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4.5 Discussion  
Recognising CML patients who will fail to achieve an optimal response to TKI 
treatment prior to the start of therapy is an important research goal, particularly as there 
are now more potent agents available which could be administered upfront to those who 
are most likely to benefit whilst sparing ‘good-risk’ patients from avoidable toxicity. In 
this study, the expression levels of 9 genes were found to be associated with imatinib 
response in a selected cohort composed of imatinib-responsive and imatinib-resistant 
CML patients. Analysis of these 9 genes in an unselected cohort of patients revealed 6 
genes for which expression appeared to significantly correlate with outcome. The 
predictive value of four of these genes, NAMPT, PTCH1, CNSK1D and STK17B 
validated in a second unselected cohort of patients, suggesting that measuring the 
expression of these genes at diagnosis may be a useful prognostic indicator in the 
management of CML patients.  
As discussed in the previous chapter, a key function of the NAMPT protein is 
its role as a rate-limiting enzyme in the NAD+ pathway, which is critical for myeloid 
differentiation, via induction of C/EBP-α and C/EBP-β (Skokowa et al. 2009). Though 
under expressed in CML (chapter 3, section  3.4.3) the work in the present chapter 
suggests that a higher level of NAMPT transcript in PB mononuclear cells, relative to 
CML as a whole, is associated with imatinib failure (p=0.008). This finding is in 
keeping with the known leukaemia-promoting properties of C/EBP-α and C/EBP-β. 
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In contrast to our findings regarding its expression level in CML as a whole, 
NAMPT has been found to be over-expressed in several non-haematological cancers, 
including colorectal (Hufton et al. 1999;Van Beijnum et al. 2002), breast (Folgueira et 
al. 2005), pancreatic (Bauer et al. 2009), gastric (Nakajima et al. 2009), and prostate 
cancer (Patel et al. 2010). Importantly however, Wang et al found that over expression 
of NAMPT increases resistance to oxidative stress (Wang et al. 2011), a finding that is 
not inconsistent with our observations regarding the poor prognostic association of 
NAMPT over-expression in CML. Increased protection against stress and apoptosis is a 
frequently observed aspect of the cancer phenotype, probably to cope with increased 
metabolic demands. Interestingly Folgueira et al; showed NAMPT over-expression 
could predict the poor response of breast cancer patients to doxorubicin-based treatment 
(Folgueira et al. 2005). Alternatively therefore, it is possible that a high level of 
NAMPT contributes to an adverse outcome in CML by preventing apoptosis though the 
management of oxidative stress, rather than by up-regulation of C/EBP-α and C/EBP-β 
via the NAD+ pathway, although it should be noted that these two theories are not 
necessarily mutually exclusive. Future work is required to elucidate the precise role of 
aberrant NAMPT expression in CML. 
As briefly discussed in chapter 3, serine/threonine kinase 17B (STK17B, also 
known as Death-associated protein (DAP) kinase-related apoptosis-inducing protein 
kinase 2 (DRAK2)) belongs to the death-associated protein (DAP) kinase family, which 
include DAP, DRP-1, ZIP kinase, DAPK2, STK17A, and STK17B. The DAP kinase 
family are positive regulators of apoptosis, and members contain a closely related N-
terminal kinase domain. The non-catalytic C terminus, however, is structurally different 
with very little homology between family members, suggesting the C terminal mediates 
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substrate specificity (Sanjo et al. 1998). Studies have shown STK17B mediated cell 
death is cell type and context dependent (Kuwahara et al. 2006). There is increasing in 
vivo evidence from STK17B transgenic mice suggesting its role is directly associated 
with the management of cell survival (Mao et al. 2006). Introduction of STK17B into an 
assortment of cell types leads to apoptosis (Kuwahara et al. 2006;Mao et al. 2006;Sanjo 
et al. 1998). The exact pathway by which STK17B influences cell survival, particularly 
in cancer pathways, remains ambiguous but STK17B has been reported to prevent the 
expression of anti-apoptotic proteins Bcl-2, Bcl-xL, and c-FLIP (Mao et al. 2006).  
In chapter 3, STK17B was found to be down-regulated in CML compared to a 
healthy cohort; this down regulation may protect leukaemic cells from apoptosis. In 
keeping with the theory that apoptosis is more readily induced in cells with a higher 
expression of this protein, we found a high expression level of STK17B was predictive 
for achievement of MMR (p=0.028). Consistent with these findings, a global gene 
expression study based on samples from our centre and from Marseille University also 
detected STK17B expression at lower level in imatinib resistant patients compared to 
those who achieved an optimal response (de Lavallade et al. 2010).  
CSNK1D encodes the delta isoform of casein kinase protein type 1 (CK1δ). 
Casein kinase type 1 (CK1) is a family of monomeric serine/threonine protein kinases 
of which are constitutively active. At least seven mammalian CK1 isoforms (α, β, γ1, 
γ2, γ3, δ and ɛ) have been characterized; all isoforms are extremely conserved within 
the kinase domains, but differ significantly in length and the primary structure of their 
N-terminal (9–76 amino acids) and C-terminal non-catalytic domains (24 amino acids 
up to more than 200 amino acids; (Knippschild et al. 2005)). 
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CK1δ regulates a range of cellular growth and survival functions such as Wnt 
and Hedgehog (Hh) signalling, in which CK1δ predominantly phosphorylates β-catenin 
(at residue serine 45), allowing its progressive phosphorylation by GSK3β and 
ubiquitinization (Gao et al. 2002). CK1δ also phosphorylates the tumour suppressor 
protein p53 (at threonine 18) weakening the interaction with its counterpart the cellular 
oncogene MDM2, thereby stabilizing and activating p53 functions. CK1δ has been 
found to complex with MDM2 in unstressed cells to serve as a negative regulator of 
p53 (Huart et al. 2009), giving it a significant role in cell cycle control. Moreover, 
CK1δ has functions in chromosome segregation, microtubule dynamics, and 
kinetechore and centrosome specific functions (Zyss et al. 2011). Therefore CK1δ is an 
important player in maintaining the integrity of the genome. CK1δ has previously been 
implicated in colon, pancreatic and breast cancer progression via the suppression of 
apoptosis, regulation of mitotic function, and/or activation of β-catenin signalling 
(Brockschmidt et al. 2008;Cheong et al. 2011). 
Differential expression and/or activity of CK1δ has been detected in a diverse 
selection of tumours such as pancreatic (Brockschmidt et al. 2008) and colorectal 
tumours (Ortega et al. 2008). In the latter CSK1D was down-regulated in tumour types 
associated with poor prognosis when compared to tumours with favourable outcome 
(Ortega et al. 2008). In keeping with this we found a high expression of CSNK1D was 
associated with a higher likelihood of achieving CCyR and MMR (p=0.046 and 0.039 
respectively). The precise reason why altered levels of CSNK1D may associate with 
outcome is unclear, but may be related to its role as an activator of p53. 
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Three of the four genes whose expression was found to be associated with 
outcome in this chapter were also found in the previous chapter to be down-regulated in 
CML as a whole (NAMPT, STK17B and CSNK1D). The remaining gene, PTCH1, is an 
exception to this, having been found in the previous chapter to be expressed at a level 
not significantly different to that in cells from normal individuals. PTCH1 (aka BCNS; 
PTC1; PTCH) encodes a member of the patched gene family and is a tumour 
suppressor. Mutations in mouse and human patched group of genes are associated with 
birth defects and several cancers. PTCH1, a 12-pass transmembrane protein, is a 
receptor for Sonic hedgehog (SHH) signalling proteins. SHH proteins activate 
transcription of target genes, including PTCH1, via GLI transcription factors (Nagao et 
al. 2005). Alteration in PTCH1 at chromosomal 9q22.3 region has a pathological 
significance in breast cancer (Sinha et al. 2008). It has been proven that PTCH1 is 
epigenetically regulated in many solid tumour types (Cretnik et al. 2007;Diede et al. 
2010;Sinha et al. 2008). It was also suggested that Hedgehog (Hh) signalling pathway 
may play a role in the progression of colorectal tumours (Bian et al. 2007). Interestingly 
it has been shown that high expression of PTCH1 does not necessarily correlate with 
higher amount of functional protein, in fact the reverse may be the case, via a 
regulatory feedback loop (Dierks et al. 2008). In a recent review, it has been found that 
Hh signalling pathway plays an essential role to maintain CML stem cell function and 
selfrenewal. Therefore, methods of treatment to eradicate the CML stem cells through 
inhibiting the Hh signalling pathway, have been proposed (Naka et al. 2010a). Indeed 
agents that inhibit Smoothened (SMO) – a key component of the Hh pathway- are now 
in early-stage clinical trials in conjunction with TKIs.  
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Despite the known association between Hh activation and stem cell 
maintenance in CML, this is the first study to recognise a prognostic association 
between expression of one of the components of this pathway and outcome. In our 
study higher expression of PTCH1 was significantly associated with an increased 
likelihood of longer survival and sustained response to imatinib. This would be 
consistent with a model where elevated Hh pathway activity causes an increase of 
downstream reporter proteins including PTCH1 and GLI1. This model does not, 
however, take into account the role of the negative feedback component of the Hh 
pathway, in which excess PTCH1 binds to upstream SHH, preventing activation of 
Smoothened and thus blocking further downstream activity. Nevertheless, of all 4 
potential prognostic biomarkers identified in this study, PTCH1 expression was 
associated with the most outcome measurements and would appear to be the gene with 
the strongest prognostic value. 
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4.6 Summary 
Despite a consistent pathogenomic marker CML patients display a paradoxical 
clinical heterogeneity. One important aim of translational research in this disease is 
therefore to identify biomarkers that may predict subsequent response to TKI therapy. 
The aim of chapter was to identify and validate potential prognostic markers, from the 
panel of genes investigated in chapter 3. Importantly the expression of four of these 
genes, NAMPT, STK17B, CSNK1D and PTCH1, was significantly associated with 
outcome in both training and validation cohorts, underlining their potential value as 
prognostic indicators that may be useful in guiding patient management. Furthermore, 
with the exception of PTCH1 whose role in CML is relatively well established, these 
genes warrant further functional analysis to investigate a potential causal role in CML 
pathogenesis. 
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CHAPTER 5 : The importance of down-regulation of 
the STK17B gene in CML pathogenesis 
5.1 Introduction 
The development and use of Imatinib and other tyrosine kinase inhibitors 
(TKIs) to treat CML has been one of the great success stories of modern molecular 
medicine. However, TKIs are not curative because they fail to kill all leukemic cells 
and in particular they do not eradicate leukemic stem cells (Druker 2006). In vitro 
studies have identified a population of quiescent stem cells insensitive to imatinib that 
persist in patients despite durable cytogenetic remission (Milojkovic et al. 2008). 
Therefore, there is a need to understand the underlying mechanisms contributing to 
leukaemia stem cell maintenance and resistance against eradication by current TKIs. 
Fourteen genes were identified in chapter 3 whose expression was differentially 
regulated in CML; several of these are involved in pathways of direct relevance to the 
propagation of leukaemia. While all of these genes merit further investigation in CML, 
one gene, STK17B, is a particularly attractive candidate for further research, not only 
because its protein belongs to a family of key apoptosis regulators, but also because its 
expression can be readily increased by inhibiting the protein COX-2. COX-2 inhibition 
thereby provides a simple mechanism for in vitro studies of the importance of STK17B 
in leukaemic cell survival, as well as representing a potential therapeutic intervention 
should induction of STK17B transcription prove to facilitate CML cell death. 
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STK17B (DRAK2: DAP kinase-related apoptosis-inducing protein kinase) is a 
member of the Death-Associated Protein (DAP)-like family of serine/threonine kinases. 
Members of this family induce apoptosis in various cell types (McGargill et al. 2004). 
STK17B contains an open reading frame that encodes protein consisting of 372 amino 
acids with a molecular mass of 42.34kDa. The putative kinase domain is located at the 
N-terminus of protein and contains all 11 sub-domains conserved among all 
serine/threonine kinases. The Protein is specifically expressed in T cells and B cells, 
and it is differentially regulated during T cell development (McGargill et al. 2004). 
Indeed, STK17B plays a critical role in T cell apoptosis and memory T cell 
development as it is a negative regulator of T cell activation (Mao et al. 2006). STK17B 
(DRAK2), like DRAK1, is localized to both the nucleus and cytoplasm. Cell death-
inducing activity of DRAKs was dependent on their intact structures but not their 
intensity of the kinase activity. However, the kinase activity in addition to C-terminal 
domain is required for the induction of apoptosis, because the kinase-inactive DRAKs 
fail to induce apoptosis (Sanjo et al. 1998). STK17B mediates apoptosis induced by 
extracellular stimuli, including UV irradiation and interleukin-2, and also regulates T-
cell receptor sensitivity in developing thymocytes. During these events, the sub-cellular 
localization of STK17B changes between the nucleus and cytoplasm (Kuwahara et al. 
2006).  
STK17B has frequently been implicated in the progression of cancer. For 
example, retroviral insertion in mutagenesis experiments implicated STK17B in 
transformation of APC-mutated colon epithelial cell (Tanaka et al. 2008). Disease-
specific modulation of STK17B expression has frequently been reported in 
haematological malignancy. STK17B was one of several genes found to be consistently 
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deregulated in human and murine MLL rearrangement leukaemia (Li et al. 2009). In 
keeping with our findings in CML (chapter 3) reduced STK17B expression has been 
reported in T-cell lymphoma and AML with common translocations (Hartmann et al. 
2008;Lee et al. 2006). Furthermore, in keeping with the findings of the previous 
chapter, reduced expression of STK17B has been associated with an adverse outcome in 
DLBCL, follicular lymphoma and paediatric AML (Capra et al. 2006;Yagi et al. 2003).  
How might the importance of reduced STK17B expression to the survival and 
function of CML cells be investigated? Interestingly, using expression microarray 
experiments, STK17B was recently shown to be one of the downstream targets of COX-
2 (Doherty et al. 2009). In the latter paper the authors subsequently demonstrated that 
STK17B expression could be induced in colorectal cancer (CRC) cells in vivo via 
administration of the selective COX-2 inhibitor rofecoxib (Doherty et al. 2009). 
Furthermore, in the same study rofecoxib increased apoptosis of CRC cells,. In vitro 
silencing of STK17B by RNA inhibitor following rofecoxib treatment enhanced CRC 
cell survival supporting STK17B-induced cell death as the mechanism responsible for 
the effect of COX-2 inhibition on CRC cells. High COX-2 expression has been 
associated with poor prognosis in chronic lymphocytic leukaemia, Hodgkin's 
lymphoma, non-Hodgkin's lymphoma and multiple myeloma (Bernard et al. 2008). 
While STK17B was not the focus of these studies it might be presumed that patients 
with high COX-2 expression had reduced STK17B expression as a consequence. 
Importantly, COX-2 expression in CML as a whole has previously been found 
to be high (Giles et al. 2002). Furthermore COX-2 inhibition was shown to inhibit 
proliferation in the CML cell line K562 (Vural et al. 2005) and has also been shown to 
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reduce survival of cells from other leukaemias (Bernard et al. 2008). In the latter report 
the authors speculated that this effect might be via enhancement of the surrounding 
microenvironment, however the role of STK17B induction was not investigated.  
5.2 Aims of this chapter  
There is no published data about the role of STK17B in the pathogenesis of 
CML. The work in this chapter therefore aims to investigate the importance of reduced 
STK17B expression for the survival of CML stem cells. COX-2 inhibitor will be used to 
stimulate expression of STK17B in CML cell lines and patient CD34+ cells. The 
apoptosis rate of COX-2 inhibitor treated cells will be investigated. STK17B specific 
RNA interference will be used in conjunction with COX-2 inhibition to investigate 
whether any observed effects on rate of apoptosis are specific to increase in STK17B 
expression or due to an alternative downstream effect of inhibition of COX-2.  
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5.3 Material & Methods 
5.3.1 CD34+ Culture Media 
Refer to CD34+ Culture Media section ( 3.3.15) above. 
5.3.2 CML Cell lines Culture Media 
All CML cell lines (K562, KCL22, BV173 and LAMA84; Source: Department 
of Haematology, Imperial college London) were grown in incubator at 37°C in RPMI-
1640 medium supplemented with 10% heat inactivated foetal bovine serum (FBS), 
100IU/mL penicillin, 100mg/mL streptomycin and 2mM L-glutamine (Gibco).  
5.3.3 Measurement of Intracellular STK17B protein level using western blot  
Upon measuring the protein level through the western blot we could not 
quantify the difference of the drug treated cells vs. the control vehicle treated cells 
(Figure  5.1), therefore, an alternative way of measurement was proposed using the flow 
cytometer, which is less laborious and enables more accurate quantification   
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Figure ‎5.1 Western blot X-ray film showing the effect of 5µM SC-236 on STK17B and GAPDH 
(control) protein expression in K562 cells. The difference between treated and control (DMSO-treated) 
cells was not visually quantifiable, therefore we adopted a flow cytometric method. 
5.3.4 Measurement of Intracellular STK17B protein level using Flowcytometry  
At least 0.5 x 10
6
 cells K562 or CD34+ cells were treated with 5µM imatinib 
(IM) or with 5µM COX-2-Inhibitor (COX-2-I) SC-236 in each well for 24 hours. After 
24h exposure to the drugs, treated cells and the same amount of untreated control cells 
were transferred to 1.5mL micro-centrifuge tubes and washed with PBS/1%FBS/0.1% 
sodium azide by spinning them in a micro-centrifuge for 3 minutes at 5000 rpm. The 
cell pellets were then re-suspended in 100µL of Reagent A (fix medium), from the FIX 
& PERM
® 
kit (Invitrogen) and incubated at room temperature for 15 minutes. The cells 
were washed with 1mL PBS/5%FBS/0.1%sodium azide and centrifuged at 5000 rpm 
for 3min. The supernatant was discarded and 50µL of Reagent B (permeabilising 
medium) from the FIX & PERM
® 
kit (Invitrogen) was added to the cell pellets. Next 
3µL of Monoclonal Anti-STK17B antibody (WH0009262M1, Sigma-Aldrich) was 
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added, while 5µL IgG2b Isotype Control from murine myeloma (M5534, Sigma-
Aldrich) was added to the control tube. After incubation for 25 minutes at room 
temperature, cells were washed with 3mL PBS/5%FBS/0.1%sodium azide and 
centrifuged at 5000 rpm for 3 min. 1µL of the second anti body goat anti-mouse IgG 
(Fab specific) F(ab′)2 fragment–FITC (F2653, Sigma-Aldrich) was added along with 
100µL of Reagent B (permeabilising medium) from the FIX & PERM
®
 kit (Invitrogen) 
were added, and the mixture was incubated for 25 minutes at room temperature. The 
cells were washed by addition of 3mL PBS/5%BSA/0.1%sodium azide and centrifuged 
at 5000 rpm for 3 min. The cells were re-suspended in 500µL of PBS and analysed on 
flow cytometer. To measure the effect on the STK17B protein level, the results were 
expressed according to the following formula: (X-Z/Y-I) where X = Media Fluorescent 
Index (MFI) of Anti-STK17B and the secondary antibody in treated cells; Z = MFI of 
treated cells stained with ISO Antibody and the secondary antibody; Y = MFI of Anti-
STK17B and the secondary antibody in control cells; and I = MFI of the control cells 
stained with ISO Antibody and the secondary antibody as represented in Figure  5.2. 
Control cells treated with an equal volume of dimethyl sulfoxide (DMSO) without the 
drug. 
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Figure ‎5.2 Histogram of Media Fluorescent Index (MFI) showing increased STK17B protein 
expression in K562 with COX-2 inhibition. (Expressed as fold change compared to control). 
 
5.3.5 Determination of the best COX-2-I concentration in culture 
 K562 cells were incubated with 0.0µM, 5µM, 10µM, 20µM and 40µM of SC-
236, cells and incubated at 37°C for 24 hours. Apoptotic effect was checked by flow-
cytometer before RNA extraction. After RNA extraction and cDNA synthesis, STK17B 
expression was measured. The increase in expression compared to control (DMSO-
treated) cells was similar for all concentrations (p>0.05) therefore 5µM was used in all 
experiments. 
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5.3.6  Measurement of Apoptosis using Flowcytometry  
Cell culture suspensions were spun down for 5  minutes at 1500 rpm,  washed 2 
times with PBS then centrifuged at 5000 rpm for 3 min. Cells pellets were resuspended 
in 1µL of Fixable Viability Dye 660 eFluor
®
 (eBioscience; per 1mL of PBS) vortexed, 
then incubated for 30 minutes at 2-8°C, protected from light. Cells were washed cells 
by adding 3mL of PBS and centrifuged at 5000 rpm for 3 min. Cells were then washed 
twice with PBS/5% fetal bovine serum/0.1% sodium azide then centrifuged at 5000 
rpm for 3 min, followed by a final wash with  1X Binding Buffer prepared from 
Annexin V Apoptosis Detection Kit eFluor
®
 450 (eBioscience). Cells were resuspended 
in 1X Binding Buffer then treated with Annexin V (1μL to 50μl of cell suspension; 
eBioscience). Following incubation for 20 minutes at room temperature protected from 
light, cells were washed in 1X Binding Buffer and resuspended in 200μL of 1X 
Binding Buffer. Cells were stored at 2-8°C in the dark and run on a flow cytometer 
within 4 hours. 
5.3.7 Gene Expression Assays 
Refer to ( 4.3.4) above, Hs00177790_m1-FAM™ (Applied Biosystems, Foster 
city, USA) were used to measure STK17B gene expression. 
5.3.8 siRNA Electroporation Transfection 
Prior to electroporation, K562 cells were washed twice with serum-free Opti-
MEM and resuspend to a final concentration of 10 x10
6
 cell/mL in Opti-MEM (Gibco). 
Cells were then transfected with Silencer
®
 Select siRNA STK17B (s17709; Ambion
®
, 
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Life technologies
™
) and Silencer
®
 Select siRNA#2 as a negative control, using the 
electroporation technique as follows: 500μl of cell suspension was mixed with of 
Silencer
®
 Select siRNA with a final concentration of 200nM and then transferred to a 
0.4-cm electroporation cuvette. Electorporation used a Gene Pulser electroporation 
apparatus (Bio-Rad Laboratories, Hercules, CA) with a single-pulse protocol (voltage 
of 280V and capacitance 960µF). Following transfection, K562 cells were incubated 
for 24 hours in culture medium. A transfection efficiency of 60% or more without 
significant reduction of viability was achieved, verified by flow cytometry. 
5.3.9 Statistical analysis 
Statistical analysis was carried out using the GraphPad Prism
® 
software v5.0. 
The paired t-test was applied to each matched sample between the groups. One-way 
ANOVA was applied to detect significant difference, followed by the Bonferroni post-
hoc test comparison when comparison of multiple (more than two).  
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5.4 Results 
5.4.1 Identification of an appropriate cell line model for the investigation of drug-
induced upregulation of STK17B in CML  
In order to identify an appropriate cell line model for induction of STK17B 
expression by COX-2 inhibition, we treated four BCR-ABL1 positive CML cell lines 
(K562, KCL22, BV173 and LAMA84) with 5μM of the COX-2 inhibitor SC-236 for 
24h, and measured the subsequent change in STK17B expression (Figure  5.3). In 
keeping with previous observations in colorectal cancer (Doherty et al. 2009), three of 
the four lines showed increased STK17B expression after COX-2 inhibition. The 
increase in transcript level of STK17B after SC-236 exposure was most striking in K562 
(p=0.0296), therefore K562 was selected as the best model for further experiments.  
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Figure ‎5.3 STK17B gene expression in BCR-ABL1 positive cell lines following inhibition of COX-2 
by 5μM SC-236. A significantly higher level of expression was observed for K562. 
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We also compared expression of STK17B relative to GUSB in K562 to 
expression in primary CML cells and non-CML volunteers. We confirmed that STK17B 
expression is indeed reduced in K562 compared to non-CML PMN cells in keeping 
with our findings in primary CML cells (Figure  5.4). In K562, STK17B expression was 
marginally lower than in PMN cells of patients who subsequently fail to achieve a 
cytogenetic response to imatinib (chapter 3). 
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Figure ‎5.4 STK17B gene expression in polymorphic nucleic cells in CML and non-CML samples. 
Gene expression of STK17B in CML-Responders (n=20), CML-Non-Respondrers (n=12) and K562 (n=5) 
was significantly lower than in Normal PMN cells (n=8), (p<0.0001). 
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5.4.2 Investigation of the expression of STK17B protein in K562 after inhibition of 
SC-236 treatment 
We also measured the level of STK17B protein in K562 following inhibition of 
COX-2. Following treatment with 5μM of SC-236 for 24h the level of STK17B protein 
in K562 cells as measured by flow cytometry was significantly higher than in control 
(DMSO-treated) cells (p=0.0018; Figure  5.5). This confirmed that the previously 
observed increase in STK17B transcript following 5μM SC-236 exposure results in a 
significant increase in protein expression. 
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Figure ‎5.5 A significantly higher level of STK17B protein in was observed in K562 cells treated with 
5μM SC-236. Protein level is expressed as a fold change in relation to control (DMSO-treated) cells (n=4, 
p=0.0018). 
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5.4.3 Investigation of the effect of COX-2 inhibition with and without concomitant 
IM exposure on apoptosis in K562 
We then investigated the impact of COX-2 inhibition via SC-236 exposure on 
apoptosis in K562. We observed a significantly higher level of apoptosis in K562 
following treatment with 5μM of SC-236 for 24h, compared to control (DMSO-treated) 
cells (p=0.0004; Figure  5.6). As expected, apoptosis following treatment with imatinib 
was also increased in comparison to control cells, albeit to a lesser degree than 
observed with SC-236. Interestingly a combination of imatinib and SC-236 resulted in a 
marginally higher level of apoptosis than with SC-236 alone, although this difference 
was not significant. 
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Figure ‎5.6 Apoptotic effect of imatinib, 5μM SC-236 and these agents combined in K562 cells. The 
highest level of apoptosis was observed using these agents in combination (n=8, p<0.0001). 
 
  
  
164 
5.4.4 Investigation the effects of SC-236 treatment on CML CD34+ cells 
We next investigated whether the effects of COX-2 inhibition observed in K562 
cells were reproducible in primary CML CD34+ cells. Treatment of CML CD34+ cells 
with 5μM of SC-236 for 24h caused a significant increase in STK17B expression 
compared to control (DMSO-treated) cells (p=0.0272; Figure  5.7).  
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Figure ‎5.7 A significantly higher level of STK17B gene expression was observed in CML CD34+ 
cells treated with 5μM SC-236 (n=3; p=0.0272). 
As with K562 we also investigated the effect of exposure to SC-236 on 
apoptosis in primary CML CD34+ cells. Unlike in K562 however, SC-236 did not 
significantly increase the apoptotic rate of CML CD34+ cells. In addition there 
appeared to be no synergistic effect with imatinib, as had been observed for K562, with 
the level of apoptosis in CD34+ cells treated with both agents not significantly different 
than the rate of apoptosis seen with imatinib alone (Figure  5.8). The discrepancy 
between the effects of SC-236 in K562 and primary CD34+ cells requires further 
investigation. 
  
165 
CML CD34+   n=4
D
M
SO
D
M
SO
+I
M
   
S
C
-2
36
IM
+S
C
-2
36
   
0.0
0.5
1.0
1.5
2.0
F
o
ld
 c
h
a
n
g
e
 o
f
A
p
o
p
to
s
is
 /
 c
o
n
tr
o
l
 
Figure ‎5.8 Apoptosis of CD34+ cells following treatment with imatinib, 5μM SC-236 and these 
agents combined. There was no significant difference between apoptosis seen with imatinib, and 5μM 
SC-236 and imatinib combined, and no difference between apoptosis in SC-236-treated cells and control 
(DMSO-treated) cells (n=4). 
 
One explanation for a possible difference in the effect of SC-236 on apoptosis in 
K562 compared to primary CD34+ cells is that this agent may have an “off-target” 
effect on a pathway unrelated to STK17B that is key to the survival of K562 cells but 
not to the survival of primary CML cells. Primary chronic phase CML cells generally 
have a markedly less complex karyotype than that of K562 (an advanced blast crisis 
cell line) and are thus far from identical in a biological sense, despite the common 
presence of the Philadelphia chromosome (Naumann et al. 2001). 
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5.4.5 Confirmation of inhibition by siRNA induces apoptosis in K562 
In order to attempt to confirm that a rise in STK17B expression, rather than an 
off-target effect, is responsible for the increased apoptosis in K562 cells exposed to SC-
236, we designed an experiment using a small interfering RNA (siRNA) molecule 
specific for the STK17B transcript which, when administered along with SC-236 would 
counteract the SC-236-mediated increase in STK17B expression. If the rise in STK17B 
was directly responsible for the increase in apoptosis then K562 cells simultaneously 
exposed to SC-236 and the STK17B-specific siRNA should not show the same high 
degree of cell death observed with SC-236 with siRNA-Negative (a scrambled siRNA). 
Alternatively if the effect of SC-236 on cell death is unrelated to STK17B expression, 
the rate of apoptosis seen on combining these agents will be raised to a similar degree 
as observed with SC-236 with siRNA-Negative. 
Figure  5.9 illustrates the degree of apoptosis seen in K562 cells treated with 
siRNA-STK17B alone, (SC-236 and siRNA-Negative) and (SC-236 and siRNA-
STK17B). These data demonstrate that while the COX-2 inhibitor SC-236 and siRNA-
Negative increases apoptosis as seen previously, the simultaneous degradation of 
STK17B transcript via siRNA-STK17B reduces the apoptotic rate to that seen in the 
absence of SC-236. The latter observation supports the theory that COX-2 inhibition in 
K562 increases apoptosis via up-regulation of STK17B and is therefore further evidence 
that this pathway may be important for the pathogenesis of CML. The reason for the 
difference between levels of SC-236-mediated apoptosis in K562 versus primary 
CD34+ cells, however, remains unclear and will be the focus of future work. 
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Figure ‎5.9 Inhibition of STK17B transcript by RNA interference counteracts the apoptotic effect of 
COX-2 inhibition in K562. A significant increase of STK17B gene expression was observed in K562 cells 
treated with 5μM SC-236 alone (n=4, p=0.0005), but not in cells treated with SC-236+siRNA-STK17B. 
 
  
  
168 
5.5 Discussion  
Using mouse models, several pathways have been identified in recent years as 
important regulators that sustain stem cells and drive cancer progression in CML. These 
include developmental pathways such as Hedgehog and Wnt/beta-catenin (Seke Etet et 
al. 2012), as well as the multifunctional signalling scaffold protein b-arrestin (Fereshteh 
et al. 2012), the promyelocytic leukaemia protein (PML), transcriptional regulators of 
FoxO and HIF1a (Ito et al. 2008;Naka et al. 2010b;Zhang et al. 2012), the arachidonate 
5-lipoxygenase Alox5 (Chen et al. 2009), and RNA binding proteins including hnRNP 
E2 (Eiring et al. 2010). However, these discoveries have not yet provided a therapy that 
may, either alone or in combination with TKI, cure CML via the eradication of 
quiescent stem cells. Lifelong therapy with TKI, although only effective long-term in 
70-80% of patients, remains the gold standard treatment in CML. 
Work described earlier in this thesis identified several genes whose expression 
was significantly altered in CML. In addition, a proportion of these genes appeared to 
have potential utility as prognostic indicators at diagnosis. Of these, STK17B appeared 
an attractive candidate for further functional work because its expression can readily be 
induced using COX-2 inhibition. Work described in this chapter therefore focussed on 
investigation the importance of reduced STK17B expression on the survival of CML 
blast cells using the cell line K562, and chronic phase primary CD34+ cells. 
The work described in this chapter provides important preliminary data on the 
importance of suppression of STK17B expression to the survival of CML cells. In 
keeping with the role of STK17B as an apoptotic regulator (Sanjo et al. 1998), induction 
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of its expression resulted in increased apoptosis in the CML cell line K562. Using an 
STK17B specific siRNA molecule we were able to demonstrate that this increase in cell 
death was a direct result of enhanced STK17B expression, rather than an alternative 
downstream effect of inhibition of COX-2. 
Enhancement of STK17B expression in primary CML CD34+ cells did not 
induce the same effect on apoptosis as seen for K562. There are several possible 
reasons that may in part explain this observation. Firstly it is plausible that due to the 
inherent heterogeneity of CML patients (Goldman et al. 2012), the effects of COX-2 
inhibition on individual patients’ disease cells may vary. Primary material from three 
patients was used in this study, in addition to K562 which is derived from a single 
CML patient in blast crisis. It would be necessary to perform the same experiments on 
material from additional patients to exclude the possibility that enhancing STK17B 
expression induces apoptosis in only a proportion of patients.  
A second possibility for the absence of an effect on apoptosis in the three 
patients examined relates to the fact that rise in STK17B expression observed in the 
presence of SC-236 was marginally lower in patient material than seen in K562. 
Although this difference was not statistically significant, it may nevertheless explain 
the absence of an effect on apoptosis in the patient cells. A future strategy that may 
address this issue would be to investigate the use of alternative COX-2 inhibitors on 
increasing STK17B expression and apoptosis in CML cells. It is known that different 
COX-2 inhibitors have slightly different potency and biological effects  (Wang et al. 
2012) thus it is plausible that this variability may extend to the degree of induction of 
STK17B expression.  
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Finally, it should be noted that K562 is a cell line derived from blast cells of a 
patient with blast crisis CML, while the primary material used in these experiments was 
total CD34+ cells from patients in chronic phase of CML. This raises two related 
possibilities: firstly it is plausible that the importance of reduced STK17B expression to 
the survival of CML cells increases with disease progression. Secondly it is possible 
that the effect of induction of STK17B expression on apoptosis may only be seen in 
early-stage progenitor cells. Such primitive cell compartments only constitute a 
minority of the total CD34+ population in chronic phase; however this proportion is 
likely to be skewed at blast crisis with the expansion of early blast cells. To address this 
issue it will be necessary to repeat these experiments on primary material from patients 
in CML blast crisis and also on earlier progenitor cells (e.g. CD34+/CD38-) from 
patients in chronic phase. 
5.6 Summary 
In summary this chapter provides tentative evidence that inducing expression of 
the putative tumour suppressor gene STK17B using COX-2 inhibition may reduce the 
viability of CML progenitor cells. Further experiments are required using alternative 
COX-2 inhibitors, earlier patient progenitor cells, and an increased number of patients 
in different stages of disease to fully explore this possibility. 
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CHAPTER 6 : Discussion 
 TKI therapy has revolutionised the treatment of CML, however, a substantial 
minority of patients eventually experience disease progression, even on more potent 
second-generation drugs (Hochhaus et al. 2007;Kantarjian et al. 2007;Milojkovic et al. 
2009b). Very little is known about the mechanisms of resistance to TKI, or of disease 
progression and there are few, if any, reliable methods of predicting either. Research 
into identifying biomarkers for therapeutic outcome and targets for future drug 
discovery is therefore warranted and is a major focus of this thesis.  
In chapter 2, expression of the oncogene MECOM at the onset of 2G-TKI 
therapy was shown to be an independent predictor for OS, PFS and EFS in CML 
patients. With improvements in the sensitivity of gene expression assays facilitated by 
the advent of digital PCR (dPCR)(Wang et al. 2010) and novel applications of next 
generation sequencing (NGS); (Logan et al. 2013). It is likely that all CML samples 
will show a degree of MECOM expression (personal unpublished data). Key questions 
in future may therefore be what degree of expression should be considered indicative of 
a high risk of adverse outcome, and, to refine this assay further, from which cell type? 
In this regard it was relevant that patients with an overt 3q26 rearrangement (all of 
whom had AML or CML BC) were seen to express a higher level of MECOM than 
those that expressed the gene in the absence of overt 3q26 aberration. In the future it is 
possible to envisage an improved MECOM based prognostic assay that utilises more 
sensitive detection of transcription coupled with a targeted cell type specific approach 
in order to accurately predict duration of chronic phase or imminent disease 
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progression. Combination of this strategy with PTEN/AKT/mTOR or polycomb 
signalling pathway inhibitors should be the focus of future research. 
A strategy to identify novel markers of biological heterogeneity in CML was 
employed in chapter 3 via the use of high resolution CGH. While this approach did not 
identify verifiable recurrent copy number changes, it resulted in the identification of a 
number of genes whose expression proved to be significantly modulated in CML. 
Intriguingly; preliminary data suggested that false-positive copy-number calls at these 
loci were caused by disease-specific differences in chromatin condensation. Further 
work is required to investigate whether this is a widespread phenomenon associated 
with performing high-resolution CGH on highly purified tissue-specific malignant cell 
populations, or a factor of local conditions to which samples were exposed prior to or 
during the CGH process. It was interesting to note that those genes with the most 
“recurrent” artefactual copy number calls were those with the most striking difference 
in expression between CML and normal haematopoietic cells. This may be taken as 
further evidence, albeit circumstantial, that the mechanism of down-regulation of 
expression and the mechanism whereby false copy number calls were generated may be 
linked. 
While investigation of CGH copy number calls was not exhaustive, no recurrent 
aberrations were identified in this study that were novel and withstood independent 
verification via alternative molecular tests. In keeping with this, nothing has been 
published in the literature since this work was performed that reported novel genomic 
aberrations associated with CML. Considering that the last three years have witnessed 
an explosion of affordable genomic screening technologies, this paucity of novel 
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genomic findings is itself revealing, as it suggests that, perhaps, the genomic landscape 
of chronic phase CML is as homogeneous as G-banding data suggests. Of course, the 
publication of “negative” findings from comprehensive high-resolution CGH 
experiments, or, preferably, NGS-based analysis would be required in order to 
substantiate this conclusion. Certainly, recurrent aberrations in the form of single point 
mutations can be found in a subset of CML patients, although these have mainly been 
reported in BC; their existence and clinical impact in chronic phase has not been 
thoroughly investigated (Grossmann et al. 2011). Again, a comprehensive whole 
genome sequencing study is required to fully understand the aetiology of acquired point 
mutations in the pathogenesis of this disease. 
The work presented in chapter 4 demonstrated that four of the genes identified 
as differentially expressed in chapter 3, namely PTCH1, STK17B, NAMPT and 
CSNK1D, are of significant value in predicting patients’ long-term outcome. 
Conventionally, a prospective study should be performed as a final validation of the 
predictive value of these genes’ expression, prior to clinical use. If one or more of these 
factors remains predictive, then this should sufficient evidence for the genes expression 
to be used to inform treatment decisions at diagnosis. Favourable levels of gene 
expression would indicate that imatinib would be an appropriate first-line treatment, 
whereas unfavourable measurements would be evidence that a patient may benefit from 
a more potent TKI upfront. 
The latter observations reinforce the biological significance of genes identified 
via artefacts of the original CGH experiments, the majority of which are plausible 
functional candidates. The theory that these genes may include key players in CML 
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pathogenesis is further reinforced by the recent focus on the Hh pathway in CML, of 
which PTCH1 is a key component. Indeed inhibitors of SMO, another Hh component, 
are currently undergoing clinical trials (Katagiri et al. 2013).  
After PTCH1, whose functional relevance is well established, STK17B appeared 
an attractive candidate for further functional investigation, due in part to its proven role 
as a tumour suppressor (Capra et al. 2006), its prognostic value (chapter 4) and the ease 
by which expression can be induced using COX-2 inhibition. Convincing data was 
generated that demonstrated that inducing STK17B expression using COX-2 inhibition 
led to a significant increase in apoptosis in K562 and was consistent with a synergistic 
effect when used in conjunction with imatinib. Unfortunately this effect could not be 
replicated in primary CML CD34+ cells. The reasons for this are unclear but may be 
related to cell type used, drug potency or phase of disease. Further work in this area is 
warranted since a well-tolerated agent capable of eradicating CML cells in conjunction 
with imatinib would be of significant clinical benefit. 
6.1 Achievements  
The aim of the work described herein was to investigate the aetiology and 
clinical impact of both known and hitherto unknown forms of genetic and 
transcriptomic heterogeneity in CML, and to provide a framework to aid future clinical 
management and drug discovery. 
Expression of the MECOM gene was shown to be frequent in patients with late 
chronic phase CML with overt resistance to first-line imatinib, and predicted for an 
  
175 
adverse response to therapy. This provides a much-needed aid to clinical management 
of patients at a stage of disease in which second-line TKI therapy has a significantly 
lower degree of efficacy than at diagnosis.  
Array CGH applied to CML samples taken at diagnosis detected an absence of 
recurrent genomic changes, however the technique serendipitously revealed a group of 
genes whose expression is significantly modulated in chronic phase CML cells. The 
majority of these genes were involved in pathways central to granulopoiesis or 
tumourogenesis. Expression of four of these genes was significantly correlated with 
outcome, including, most notably, the Hh pathway component PTCH1, thus providing 
novel prognostic indicators of significant clinical utility at diagnosis. 
Finally, one of the four prognostically relevant genes, STK17B, was shown to be 
intrinsically linked to CML cell survival, with enforced expression causing a marked 
rise in apoptosis in the CML cell line K562. Although not reproducible in primary 
CD34+ cells from patients in chronic phase, this therapeutic strategy requires further 
investigation as a well tolerated co-therapy capable of eradicating TKI-insensitive CML 
stem cells would be of significant step towards a “functional cure” for CML. 
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Appendix 
7.1 MECOM plasmid primers insert 
Primer Name Sequence 
MECOM-Taq-F 5’- TTCCTGATAGAGACTTGAGATCGTT -3’ 
MECOM-Taq-R 5’- ACATAAGTGACACTTAAATGGCTTCTC -3’ 
7.2 MECOM and G6PD Primers and probes  
Primer Name Sequence 
MECOM-Taq-F 5’- ACCCACTCCTTTCTTTATGGACC -3’ 
MECOM-Taq-R 5’- TGATCAGGCAGTTGGAATGTG -3’ 
MECOM-Taq-Probe- FAM
™
- TAMRA
™
 5’ -TGAGGCCTTCTC CAGGAT TCT TGT TTCAC -3’ 
G6PD-Taq-F 5’- GGCGATGCCTTCCATCAG -3’ 
G6PD-Taq-R 5’- CCAGGTCACCCGATGCA -3’ 
G6PD-Taq-Probe- VIC
®
 5’- -CGGATACACACATATTC -3’ 
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7.3 TLDA gene assay list  
Assay Name all labelled with with FAM
™
 
NAMPT-Hs00237184_m1 HIST2H2BE-Hs00269023_s1 
PSTPIP1-Hs00182777_m1 HRH1-Hs00911670_s1 
18S-Hs99999901_s1 LITAF-Hs00191583_m1 
ADAMTSL4-Hs00296775_m1 MALAT1-Hs00273907_s1 
BCAR1-Hs00183953_m1 MAPK8IP1-Hs00271363_m1 
BMI1-Hs00180411_m1 MBD3L2-Hs00544743_m1 
C19orf2-Hs01026936_m1 MYH11-Hs00224610_m1 
CABIN1-Hs00899623_m1 PLEKHM2-Hs00392013_m1 
CDH11-Hs00901475_m1 PLK3-Hs00177725_m1 
COMMD3;BMI1-Hs00201350_m1 PTCH1-Hs00970980_m1 
CSNK1D-Hs01020332_m1 PTPRE-Hs00369944_m1 
DMBT1-Hs00244838_m1 SALL3-Hs00601116_m1 
DUSP1-Hs00610256_g1 SCYL1-Hs00418602_g1 
FBLIM1-Hs00378472_m1 SLC16A3-Hs00358829_m1 
FOXG1-Hs00702391_s1 SRGN-Hs01004159_m1 
GLIPR2-Hs01555479_m1 STK17B-Hs00177790_m1 
GUSB-Hs99999908_m1 VSIG4-Hs00200695_m1 
7.4 Nucleosome Digestion Assay 
7.4.1 Buffer A 
Solution Final concentration 
HEPES pH 7.4 25mM 
NaCl 150mM 
EDTA 0.1mM 
Triton X-100 0.1% 
Glycerol 10% 
*DTT 1mM 
*Add Roche Protease Inhibitor Cocktail (1 pill/10mL) 
  
  
207 
7.4.2 MNase Buffer 
Solution Final concentration 
KCl 25mM 
Glycerol 12.5% 
Tris pH 7.9 50mM 
CaCl2 10mM 
MgCl2 4mM 
PMSF 1mM 
7.4.3 MNase Stop Solution 
Solution Final concentration 
Tris pH 7.9 10mM 
EDTA 200mM 
7.4.4 Digestion Buffer 
Solution Final concentration 
Tris pH 7.9 20mM 
NaCl 200mM 
EDTA 50mM 
SDS 1% 
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7.4.5 NAMPT promoter region primers 
 
 
 
 
7.4.6 PSTPIP1 promoter region primers 
 
 
 
7.4.7 ABL1 primers as housekeeping gene 
 
 
Primer Name Primer Sequence TM 
Primer set 1-F 5’- CTCGTGGCACTGGCAAAGCTGGG-3’ Tm: 62 ˚C 
Primer set 1-R 5’- GGTAAGCGCCCGGGTCACGC-3’ Tm: 62 ˚C 
Primer set 2-F 5’- CCGCTGCCTCCAGCTTCCCAGA-3’ Tm: 62 ˚C 
Primer set 2-R 5’- TGCCGCGCCCCGCCCTTTCT-3’ Tm: 62 ˚C 
Primer set 3-F 5’- TCACGTCCTCCTCCCCGCCC-3’ Tm: 62 ˚C 
Primer set 3-R 5’- AGGCGGGGGAACCGAGGTGG-3’ Tm: 62 ˚C 
Primer set 4-F 5’- CTTTCTCGGCCCCCGGAGGG-3’ Tm: 62 ˚C 
Primer set 4-R 5’- AGCCGCCGCAGCCGTCACC-3’ Tm: 62 ˚C 
Primer set 5-F 5’- GAGTCCGCCAGAGCTCCCAG-3’ Tm: 62 ˚C 
Primer set 5-R 5’- GACCCCTCCCCTCTCTCCGT-3’ Tm: 62 ˚C 
Primer set 6-F 5’- GAGCCGCCGCAGCCGTCAC -3’ Tm: 62 ˚C 
Primer set 6-R 5’- CCTCCTCCGCCGACCGAGCA-3’ Tm: 62 ˚C 
Primer Name Primer Sequence Tm 
Primer set 1-F 5’- ACAAAAACTGGGCCTCAGAC-3’ Tm: 60 ˚C 
Primer set 1-R 5’- CATCCATTCCCATTCACTGA-3’ Tm: 60 ˚C 
Primer set 2-F 5’- TTCCAAAACACCCCACTCTGT-3’ Tm: 60 ˚C 
Primer set 2-R 5’- CAGAAGGGGGTTCTCTGC-3’ Tm: 60 ˚C 
Primer set 3-F 5’- TCCTGTTTCTCTCTCTCCATCCA-3’ Tm: 60 ˚C 
Primer set 3-R 5’- CCAAACAGCGTCTAATCTGGA-3’ Tm: 60 ˚C 
Primer set 4-F 5’- GCCCCAAACAGCGTCTAAT-3’ Tm: 60 ˚C 
Primer set 4-R 5’- GCTGTTCTCCCTCATCTTGC-3’ Tm: 60 ˚C 
Primer set 5-F 5’- TCAGGCTGTTCTCCCTCATC-3’ Tm: 60 ˚C 
Primer set 5-R 5’- GACTATGGGCTCCTTGAGGG-3’ Tm: 60 ˚C 
Primer Name Primer Sequence Tm 
Primer set 1-F 5’- TTAATGCTTGGCCTTTTTGG-3’ Tm: 60 ˚C 
Primer set 1-R 5’- TGAATGTCTTCCAGCACTGTG-3’ Tm: 60 ˚C 
Primer set 2-F 5’- GTGCAGTTCTCAGCCTCACA-3’ Tm: 62 ˚C 
Primer set 2-R 5’- CCTTCTTCTGCCTACCTCTGTG-3’ Tm: 62 ˚C 
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7.5 GUSB house keeping control gene Real-time PCR 
 
*The probe dye was adapted to Cy5-BHQ3 or VIC
®
 to enable multiplexing 
7.6 Paralog Ratio Test 
7.7 LD Mix 
Reagent  Concn.      Stock to add (µL)     Volume 10x mix     
  Concn. In final 
PCR 
Tris HCl pH8.8    2M 500 500mM 50mM 
Ammonium 
sulphate   1M 250 125mM 12.5mM 
MgCl2   1M 28 14mM 1.4mM 
2-mercaptoethanol
#
   100% 10.5 75mM 7.5mM 
dATP   100mM 40 2mM 200µM 
dCTP   100mM 40 2mM 200µM 
dGTP   100mM 40 2mM 200µM 
dTTP   100mM 40 2mM 200µM 
BSA*   10mg/mL 250 1.25mg/mL 125µg/mL 
H2O  800   
  
Primer Name Primer Sequence Tm 
GUSB- Forward 5’-  GAAAATATGTGGTTGGAGAGCTCATT -3’ Tm: 60 ˚C 
GUSB Reverse 5’-  CCGAGTGAAGATCCCCTTTTTA -3’ Tm: 60 ˚C 
GUSB Probe* 5’-  CCAGCACTCTCGTCGGTGACTGTTCA -3’ Tm: 60 ˚C 
Primer Name Primer Sequence Modifications 
NAMPT Forward 5’-   CTTAGTGACAGAAAGTCAGAATT-3’ 5‘ HEX 
NAMPT  Reverse 5’-   AGTTTTGATAATCACCCATAA-3’  
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7.8 NAMPT Allelic Imbalance SNP Assay 
7.9 NAMPT Allelic Imbalance Indel Assay 
 
Primer Name Primer Sequence Modifications 
NAMPT_rs10808150-F1 5’-  GGGAAACTTGAAGTGAGCAGAGA-3’ 5‘ Biotin 
NAMPT_rs10808150-R1 5’- GCAAGTCTGTTGGTGCTATTTTT-3’  
NAMPT_rs10808150-S1 5’- CCAGATAAGGCAGTGAAC-3’  
NAMPT_rs4730153-F1 5’- TAGGCAGACACTTGATCTATCCC-3’ 5' Biotin 
NAMPT_rs4730153-R1 5’- CCAGCTACTTCATTTGCCTTACG-3’  
NAMPT_rs4730153-S1 5’- AATCATATCTCATGTTTACT-3’  
Primer Name Primer Sequence Modifications 
NAMPT indel F  5’-TCTAGGCAAACTCGCAGGTAA-3’ 5‘  FAM
™
 
NAMPT indel R 5’-CTCTGCTTTAAAAACATTTTCC-3’  
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